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Vitro Evaluation, and Preclinical Profiling of β-Cyclodextrin Polyrotaxane Families for Use As
Potential Niemann-Pick Type C Therapeutics. Major Professor: David H. Thompson.
!
Niemann-Pick Disease Type C (NPC) is a rare, autosomal recessive genetic disorder
featuring a loss of proteins responsible for unesterified cholesterol (UC) trafficking through the
late endosomes/lysosomes (LE/LY) of every cell of the body. Disruption of this pathway leads to
abnormal accumulation and storage of UC and other lipids. A broad range of visceral and
neurological symptoms result from this accumulation exhibiting a variable age of onset and a
disease progression that is ultimately fatal. The disease has an incidence of approximately 1 in
120,000 live births and has no known effective treatment.
β-Cyclodextrin (β-CD) are natural small molecules macrocycles composed of glucose
units with a hydrophobic inner cavity and hydrophilic outer rims. β-CD derivatives have recently
been shown to be effective therapeutics for NPC in cellular and animal models. In the mouse
model of the disease, β-CD therapy increases overall lifetime by as much as 50% and slows the
progression of neurodegeneration. The progress has led to the initiation of a National Institutes of
Health phase I clinical trial.
A main drawback of β-CD administration is the poor pharmacokinetic profile
characterized by rapid renal clearance of the drug through the urine. Libraries of β-CD derivative
carrying high molecular weight polyrotaxane (PR) systems have been designed to prevent
glomerular filtration of the injected β-CD dose. An initial family of unmodified β-CD PRs was
synthesized, characterized, and their therapeutic efficacy was tested in NPC fibroblasts. This was
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followed by screening of PRs consisting of mixed β-CD derivative threading featuring charged
sulfobutylether β-CD.
Finally, we sought to define PR structure-property effects on in vivo pharmacokinetics,
biodistribution, toxicity, immunogenicity, and protein hard corona composition. This was
accomplished using a family of gadolinium carrying PRs composed of triblock Pluronic copolymers of varying molecular weights and hydrophilic/lipophilic ratios. The effect of varying
threaded β-CD derivative surface chemistry on PR mediated hemolysis and hard protein corona
was also studied. Knowing if structure-property relationships exist in the in vivo performances of
PR materials will help with building pre-clinical profile, selecting candidate materials for a given
application, and understanding therapeutic outcomes.
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CHAPTER ONE: NIEMANN-PICK TYPE C DISEASE, CYCLODEXTRIN, AND
POLYROTAXANES

1.1. Niemann-Pick Disease

1.1.1. Introduction
Niemann-Pick disease Type C (NPC) is just one of approximately 50 known lysosomal
storage disorders involving the absence or dysfunction of one or more proteins within the lipid
transport pathways of the cell.1 This autosomal recessive genetic disorder features a loss of
proteins responsible for unesterified cholesterol (UC) trafficking through the late
endosomes/lysosomes (LE/LY) of the cell. Disruption of this pathway leads to abnormal
accumulation and storage of UC and other lipids. A broad range of visceral and neurological
symptoms result from this accumulation, exhibiting a variable age of onset and a disease
progression that is ultimately fatal. Few potential treatments exist for NPC patients and those that
do are inadequate. There is no effective treatment currently approved by the United States Food
and Drug Administration (FDA) for clinical use.
The Niemann-Pick disease family is divided into four patient groups.2 Niemann-Pick
Types A and B are distinct from NPC in that they are characterized by a deficiency of acidic
sphingomyelinase (AS) and an abnormal accumulation of sphingomyelin.2-4 Type A is defined by
presentation of both neurological and visceral disease, while Type B usually exhibits visceral
disease only. Distinct from these genotypes are Niemann-Pick Types C and D. Both of these
classes are characterized by disrupted production of one of either Niemann-Pick C1 or NiemannPick C2 proteins. These defects lead to UC accumulation and involve both neurological and
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visceral symptoms. No AS deficiency as been reported in these phenotypes. Type D is distinct
from Type C in that all of the patients have a common Acadian ancestry.2, 4, 5

1.1.2. Natural History
Because of its genetic origin, UC sequestration in NPC patients occurs in every cell of the
body. This means that symptoms are not localized and can affect the visceral organs of the chest
and abdomen as well as the central nervous system (CNS). Visceral symptoms include
organomegally usually involving, but not limited to, the spleen and liver. Progressive organ
dysfunction occurs as accumulating UC does increasing damage. The severity of organ disease is
proportional to the amount of UC present in the tissue.18,72-73 Neurological symptoms are more
varied and numerous. Patients may display any combination of supranuclear gaze palsy, delayed
motor development, ataxia, dystonia, dysphagia, dysarithria, seizures and dementia.6 While
neurological symptoms are often the first to drive patients and their families to visit the clinic, the
initial presentation of the disease can be visceral, neurologic, or psychiatric.
It is now understood that NPC is not a homogenous affliction, but instead has a widely
varying potential age of onset (Figure 1.1). Although previously characterized by the onset of any
NPC related symptom,7 are now grouped based on the onset of neurological symptoms.8 Because
of low awareness, the age at which a diagnosis of NPC is definitively made can be even more
variable.7 NPC disease is roughly grouped into four forms, perinatal disease, infantile disease,
late infantile/juvenile disease, and adult onset disease. Perinatal disease presents at birth, usually
with liver disease, and is often fatal by six months of age.9, 10 Infantile disease presents within 1218 months of birth and is usually characterized by delayed motor development and
organomegally. Patients in this classification typically succumb to the disease by age five.
The most commonly studied form of NPC, representing 60-70% of documented cases, is
the late infantile/juvenile onset form.7 Altered gait and organomegally will often present within
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the first 3-5 years of life. If presenting later, at 6-12 years of age, patients tend to exhibit poor
academic performance as the initial symptom. Both situations have the potential for other
neurological symptoms and nearly ubiquitous supranuclear gaze palsy. Patients experience an
inevitable intellectual decline before death in their teenage years.7 The adult onset form of NPC
follows a similar, truncated, course. This often includes the symptoms of dementia, psychosis,
and movement disorders.11 The latest known diagnosis has been of a 66 year old patient with no
discernable neurological symptoms.12

A

B

1

Foetal
it / Liver
ascites/
hydrops

Neurological signs, dead

25

Neurological signs, alive

Pa
atients (n=
=97)

Systemic involvement
Neonatal
Cholestasis

N neurological
No
l i l signs
i

Neonatal
fatal

Birth

50

1

(hepato) Splenomegaly
•
•
•

(Hepato)
Splenomegaly

Absent in ~15% of cases
Age of onset is variable
– always before neurological signs
May regress with age

Age, years

2

3

6

10

20

30

40

50

60

(Early) Infantile

Late Infantile

Delay in
motor
milestones
Hypotonia

75

100

Juvenile
Adult
Gait problems
School problems
Clumsiness
Psychiatric
y
problems
p
Ataxia
Speech delay
Ataxia, Dystonia
(Seizures)
Cataplexy
(Dementia)
(Cataplexy)

Vertical supranuclear
p
g
gaze p
palsyy
0

10

20

30

40

50

60
Age, years

Neurological involvement

Figure 1.1: Age of NPC Neurological Disease Onset Correlated With Lifespan (A).1 Breakdown
of Onset Periods and the Most Likely Neurological and Systemic Symptoms (B).7
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NPC is a rare disease. It has an estimated incidence of 1:120,000-1:150,000 live births.7
This figure is likely under-representative of the actual extent of the patient population due to low
public awareness and ineffective diagnosis. There are no routine genetic, blood, or urine tests
capable of diagnosing NPC.7 Typically, when NPC is suspected, a biopsy is made and a culture is
generated from the patient’s cells. These samples are screened for abnormal lysosomal UC
accumulation by staining with a small molecule dye, Filipin, which fluoresces when it binds UC
deposits. Specific Filipin localization is a sensitive probe of UC sequestration. This test is often
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coupled with UC homeostasis assays measuring the rate of cholesterol ester (CE) formation.13
Occasionally, structural studies of skin and liver biopsies can provide support for an NPC
diagnosis, but these studies are prone to false negatives.10

1.1.3. Normal Cholesterol Trafficking and Homeostasis
Cholesterol is a ubiquitous and essential metabolite of the human body. It helps
strengthen cell membranes, modulate their behavior and maintain their structural integrity. UC is
a precursor compound to many steroid hormones, oxysterols, and vitamin D-- all of which are
vital components within the body. Finally, UC and CE are involved in many regulatory pathways
within the body such that misregulation or imbalance of UC and CE has wide ranging biological
effects. In NPC, a breakdown in normal UC processing gives rise to the disease phenotype
discussed above.
The acquisition of cholesterol for use by the cell occurs through two independent
mechanisms. Cholesterol can be exogenously acquired through diet by internalizing circulating
lipoproteins; particularly low density lipoproteins (LDL), which contain large numbers of both
UC and CE. LDL has the ability to undergo receptor-mediated uptake into clathrin-coated
vesicles via the LDL receptor, but may additionally undergo bulk phase endocytosis.14
Cholesterol taken up from circulation is typically used within the cell.15 Secondly, UC can by
synthesized de novo from precursor compounds in the endoplasmic reticulum (ER) through a
sequence of reactions involving multiple enzymes and intermediates. This UC pool is typically
utilized by the plasma membranes of the cell. The UC utilized by the CNS is almost exclusively
synthesized within the body, as LDL particles are unable to cross the blood-brain barrier (BBB)
that protect the brain from general circulation.16
Because of the importance of cholesterol homeostasis for normal cell function, the
synthesis, uptake, and export by the cell are tightly regulated. There are two main mechanisms by
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which these factors are controlled. The first involves sterol regulatory element binding protein 2
(SREBP2). This transcription factor regulates UC homeostasis by controlling the genes involved
in cholesterol de novo synthesis and LDL receptor activity.17 In a situation where the internal UC
pool is decreased, SREBP2 would be activated and trigger an increase in UC synthesis and LDL
surface receptors. The second mechanism is known as the liver X receptors (LXR). These are a
family of nuclear receptor transcription factors that control the genes involved in cholesterol
efflux from the cell.18 In a time of decreased internal UC, cholesterol efflux would be down
regulated by LXR to slow cholesterol loss from the cell. These mechanisms will work in tandem
to maintain UC homeostasis and are greatly affected by the trafficking blockages that are
characteristic of NPC.
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Figure 1.2: Normal Cholesterol Trafficking Through the Late Endosome/Lysosome Maintains
Homeostasis.
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In a normally functioning cellular environment, endosomes carrying internalized
cholesterol will fuse with acidic lysosomes.19 Here, CE borne by LDL particles will be
hydrolyzed by the action of lysosomal acid lipase (LAL) to yield free UC. From here it is
thought that the tandem action of two proteins, NPC1 and NPC2, mediate the transport of UC out
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of the LE/LY (Figure 1.2).20, 21 The exact process by which this occurs is unknown and is the
subject of continued interest and research effort. In the end, this process leads to UC being
transferred from the LE/LY to the metabolically active pool, the organelles, and the plasma
membrane.22 Loss-of-function mutations in either NPC1 or NPC2 are the drivers of NPC disease
presentation.

1.2. Niemann-Pick Proteins

1.2.1. Niemann-Pick C2
NPC2, previously known as HE1, is a soluble luminal protein composed of 132 amino
acids and weighing 14.5 kDa.20, 23 It has been shown to reside in multiple locations in the cell,
including in endosomes, the trans-golgi network, and other organelles.24 NPC2 exhibits a
hydrophobic binding pocket with a high affinity for UC as evidenced by site directed mutagenesis
and confirmed by crystal structures with and without a UC ligand.25-27!In these structures, the
isooctyl chain of UC faces into the binding pocket. Additionally, NPC2 has been shown to
transfer UC between lipid membranes in vitro.28 NPC2 mutations are found in ~5% of all NPC
cases and in nearly every case are nonsense or frameshift mutations.20

1.2.2. Niemann-Pick C1
NPC1 is a large integral membrane glycoprotein with a molecular weight of 170-190kDa.
The protein is 1278 amino acids in length with 13 transmembrane domains and four hydrophilic
loops, three of which are luminal and one cytoplasmic.29 NPC1 has been shown to localize in late
endosomes and lysosomes and to interact with lysosomes and the trans-golgi network.30, 31 The
protein structure exhibits three important domains including a sterol sensing domain (SSD), a
cysteine rich loop, and a luminal domain, which are vital to its function in UC mobilization.32
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Every function of the protein and the role of each domain have not yet been described
completely.7 NPC1 is thought to regulate transport of multiple kinds of lysosomal cargo,
including UC, glycolipids, and other fatty acids.31, 33-35!Approximately 95% of NPC disease cases
involve mutations in the NPC1 protein.19
At least, 133 NPC1 mutations have been reported to result in NPC disease (Figure 1.3).7
These mutations are scattered throughout the protein, but have been shown to concentrate in a
number of key areas. One-third of the disease causing mutations affect the cysteine-rich luminal
loop.7 Additionally, those mutations that fall within the protein SSD have profound effects on
protein function.32 Clinically, the most common mutations are I1061T, P1007A, and G992W
mutations. The I1061T mutation accounts for 20% and 15% of NPC cases in the UK and the US,
respectively.36, 37 P1007A mutations affect populations of European descent and the G992W
mutation is overrepresented in Nova Scotian patients.7 Less common mutations include R518Q
and P474L, which tend to affect Japanese and Italian patients, respectively.38, 39!In addition to
reflecting ethnic origins, certain mutations also correlate with disease onset and severity. For
instance, some mutations, including C63R, Q92R, C113R, and T137M, are over-represented in
the severe infantile onset disease, and some, including I1061T, are present in all forms except the
infantile form.24, 36, 37, 40, 41
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Figure 1.3: Known NPC1 Mutations7
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1.2.3. Cholesterol and the NPC Proteins
The exact mechanism by which NPC1 and NPC2 work to move UC through the LE/LY
system is not known. What is clear, however, is that the loss of either protein leads to an identical
NPC disease state intracellularly. Based on this observation, it has been proposed that NPC2 and
NPC1 work directly in sequence, with the former protein handing UC off directly to the latter
through protein-protein interactions.20, 21!Further evidence for this exchange mechanism comes
from the fact that NPC2 and the NPC1-N-terminal domain (NPC1-NTD) bind UC with opposite
orientations; the former with the UC isooctyl chain buried within its binding pocket and the later
with the UC hydroxyl group into the pocket.27, 42 Additionally, it has been shown that there are
surfaces on the NPC1 second luminal domain with which NPC2 can interact.43 Finally, in in vitro
assays, NPC2 has been shown to be able to transfer UC from model lipid membranes to NPC1NTD.44 The desired NPC1-NPC2 hand-off structure, however, has never been observed. So while
it is possible that there is a direct transfer between the proteins, it has also been proposed that
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NPC1 activity simply depends on NPC2’s ability to insert UC into the surrounding plasma
membrane.45, 46
Whatever the mechanism of action, loss of either NPC1 or NPC2 proteins leads to
extensive lipid storage within the cell. This includes UC, bis (monoacylglycerol) phosphate
(BMP), and other sphingolipids.47 The major component of visceral lipid storage is UC (Figure
1.4). Storage of both intracellularly synthesized and LDL-derived UC occurs in these sites.48, 49!In
the CNS, while UC storage is elevated, the main storage lipids are the gangliosides GM2 and
GM3, culminating in demyelination of axons and extensive death of Purkinje cells.50 This
accumulation has many deleterious effects on cellular function. A central outcome is the altering
of protein and lipid trafficking. All cellular mechanisms modulated by UC downstream will be
affected.47 In NPC deficient cells, NPC1 positive endosomal and lysosomal compartments move
around the cell at much slower rates than similar compartments in wild type cells.51, 52
Additionally, although large stores of UC exist within the cell, the metabolic pool of UC available
to the cell is depleted and the cell perceives a lack of cholesterol downstream. This leads to
activation of SREBP2, increasing LDL uptake, upregulated cholesterol synthesis, and a
downregulation of LXR, thereby decreasing cholesterol efflux.53 In this way, the cholesterol
storage problem compounds on itself until ultimately presenting as the NPC disease phenotype.
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Figure 1.4: Mutations in NPC1 or NPC2 Proteins Prevent Escape of Unesterified Cholesterol
From the Late Endosome/Lysosome.
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1.3. Current and Potential NPC Treatments
Initial treatments for NPC focused on attempting to reduce or slow the sequestration of
UC. Attempts at utilizing low cholesterol diets, UC synthesis inhibitors such as statins, and drugs
that prevent the absorption of UC from the intestines did not succeed in preventing
neurodegeneration (ND) or extending lifetimes.54, 55 They did, however, result in a reduction of
UC in the peripheral tissues.56 This result is likely because tissues of the CNS rely on
endogenously synthesized UC. Additionally, attempted inhibition of LAL reduced UC
accumulation while triggering an accumulation of CEs. A condition similar to that which arises
from impaired production of LAL known as Wolman’s disease.57
A treatment that has had some success clinically is Miglustat, an iminosugar that inhibits
the first enzyme in glycosphingolipid synthesis.58 In a study following NPC patients through 4-8
years of treatment, most showed stabilization in many neurological symptoms including the
ability to swallow.59 Unfortunately, There was no control group in the study and the side effects
included epistaxis, insomnia, tremors, weight loss, and diarrhea. Shorter-term studies have also
shown improvement and/or stabilization of neurological symptoms.60, 61!In mice, Miglustat
treatment increases animal longevity by 25% and delays onset of neurological dysfunction.62 The
exact mechanism by which it mediates these beneficial effects is unknown, but a reduction in
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glycosphingolipid accumulation may relieve congestion in the LE/LY and facilitate movement of
UC from sites of storage. In 2009, the European Agency of Medicines approved Miglustat for
treatment of NPC patients, but the long-tem efficacy of the treatment is still unknown.59
Histone Deacetylase Inhibitors (HDACis) are small molecule drugs that act to alter the
acetylation patterns of histones in the nucleus. In this way, they affect gene expression by altering
chromatin structure.63 HDACis have been extensively studied as treatments for a spectrum of
conditions, leading to two FDA approved drugs, Vorinostat and Istodax, for the treatment of
cutaneous T-cell lymphoma.64, 65 Upon incubation with NPC1 cells, a number of HDACis,
including Vorinostat, were found to reduce cholesterol accumulation and increase the quantity of
NPC1 produced.63 It is hypothesized that increased production of mutated, but still moderately
functional, NPC1 protein is able to increase the efficacy of cholesterol mobilization in the cell.
HDACis may also be increasing the levels of protein folding chaperones to produce a more
functional form of the mutant NPC1 protein.63 Although there is a significant amount of clinical
data available for Vorinostat in adult cancer patients, much less is known about its performance in
juveniles, leading to concerns about off-target effects (e.g. widely changing the expression and
regulation of proteins having no involvement in NPC).
The indication that NPC mice have dysfunctional production of neurosteroids led to the
suggestion that allogregnanolone (ALLO) may serve as an effective NPC treatment. ALLO
functions in the growth, survival, and differentiation of neurons. Cerebral concentrations of
ALLO are diminished in NPC disease.66 When NPC mice were treated with ALLO, solubilized
by 20% HP-β-CD, it resulted in marked delays in ND. Indeed lifespan of treated mice nearly
doubled from 67 to 124 days.66 Upon further investigation, ALLO administered without the
solubilizing excipient resulted in none of the beneficial effects previously shown.67 In fact, it was
late discovered that the solubilizing HP-β-CD excipient was the active agent in effectively
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treating the disease. Numerous studies since this discovery have shown that β-cyclodextrin (βCD) derivatives to be attractive potential treatments for NPC.67-69

1.4. β-Cyclodextrin and Derivatives

1.4.1. Introduction
Cyclodextrins (CDs) are macrocycles composed of glucose units tethered by α (1-4)
glucosidic linkages. They are naturally produced from the enzymatic degradation of starches and
have come to be industrially prepared for a wide variety of purposes. The majority of their
applications are based on their ability, as cage molecules, to include small hydrophobic
compounds within their central nonpolar cavities. The most common CD variants, α-CD, β-CD,
and γ-CD, are comprised of 6, 7, and 8 glucose units, respectively (Figure 1.5). These compounds
have unique properties and a long history of scientific investigation and continuing interest in
their great potential.

1.4.2. Discovery and History
The first documented description of cyclodextrin came from Antoine Villiers (18541932) in the late 1800s. As he studied the enzymatic degradation of starches upon treatment with
a particular species of bacteria, he noted the appearance of a crystalline, insoluble side product.70,
71

Franz Schardinger (1853-1920) later isolated the specific strain of bacteria responsible for the

byproducts and crudely isolated two compounds which he called Dextrin A and Dextrin B.72
Later, he was the first to describe their production, separation and purification, and was the first
to propose a cyclic structure for the compounds.73 Hans Pringshelm (1876-1940) showed that
CDs form complexes with small molecules, including hydrocarbons and halogens.74 He also
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made the first biological tests utilizing CD derivatives, injecting them into rabbits and pigs in an
attempt to treat diabetes.75, 76
Karl Freudenberg (1886-1983) experimentally demonstrated that the cyclic structure of
CDs were composed of glucose units.77 In the late 1930s, this was finally confirmed by X-ray
structure analysis.78, 79 Friedrich Cramer (1923-2003) coined the term “inclusion complex” in
1967 after some time studying complexes between CDs and amines, aliphatics, aromatics, and
gases.80, 81 CDs began to be extensively studied for a range of applications. Between the 1950s
and the 1980s, the first patents for CD based products appeared, the first company based on CD
technology, Cyclolab, opened, and Jozsef Szejtli (1933-2004) initiated the first International
Cyclodextrin Symposium. The first pharmaceutical product incorporating a CD, a prostaglandin
E2 formulation with native β-CD, was approved in Japan in 1976.

1.4.3. Cyclodextrin Properties and Uses
CDs are comprised of α-(1-4)-glucosidic bond linked glucose units with a hydrophobic
inner cavity and hydrophilic outer rims. The structure is not a perfect hollow cylinder, but rather
has a slight “V” shape. Alcohol moieties on the CD surface, 18-24 depending on the CD species
under consideration, are arranged such that there is a narrow rim containing only primary
hydroxyl groups and a broader rim containing only secondary hydroxyl groups. Free rotation of
the primary hydroxyls allow for at least partial blockage of the CD cavity on one end. β-CD, the
focus of NPC therapy, contains 21 hydroxyl groups and has an average core diameter of 0.78 nm
(Figure 1.5). Through alcohol modification, a vast array CD derivatives have been synthesized
and utilized.82, 83 Because of production costs and complicated syntheses, few CD derivatives are
manufactured on a large scale. The main derivatives sold and used industrially are HP-β-CD, sold
as Encapsin or Cavitron, and negatively charged sulfobutylether-β-CD, sold as Captisol.84, 85
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Figure 1.5: Cyclodextrin Dimensions71

The lipophilic environment of the CD core solubilizes hydrophobic molecules in aqueous
media by minimizing mismatching hydrophobic-hydrophobic contacts. Interactions between host
and guest occur largely through van der Waals interactions and, as such, a CD inclusion complex
is subject to equilibrium conditions.86 Size matching of the guest molecule in relation to the CD
internal diameter (i.e. the degree of van der waals contact), plays an important part in binding, as
molecules that are too large in size will not be able to enter the CD cavity, and molecules too
small in size will not have sufficient contact with the interior surfaces. This is largely governed
by the narrowing that occurs due to the internal H-3 and H-5 hydrogens.87
As CD research matured, it was understood that inclusion of hydrophobic guests had the
potential to greatly affect their properties. In pharmaceuticals, this was seized upon as a natural
way to increase the solubility of insoluble drugs, replacing the use of organic co-solvents and
surfactants with known toxicological properties.88, 89 Drug formulation with CD derivatives was
also found to affect drug stability, bioavailability, and pharmacokinetics in ways that improved
their efficacy.71 After their introduction in Japan in 1976, a complex of Piroxican and β-CD
became the first treatment available in the European market in 1988. Finally, the US FDA
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approved an oral solution of itraconazole and HP-β-CD in 1997. To date, β-CD derivatives are
contained in greater than 40 drug formulations internationally.71
Outside of pharmaceuticals, CDs have found application in the food, cosmetic, and
agricultural industries.71 A great deal of study has gone into studying CDs as effective chemical
reaction catalysts.90 Applications have been shown using CDs in a wide range of chromatographic
applications including use as stationary phases in chiral and achiral separations, in electrophoretic
separations, and in gas chromatography.91-94!Finally, completing a non-exhaustive list, CDs have
greatly impacted the fragrance, aroma and textile industries.95, 96

1.5. Cyclodextrins and Niemann-Pick Type C

!
1.5.1. Therapeutic Efficacy
After the serendipitous discovery of their efficacy, β-CD derivatives have been
increasingly explored as potential NPC therapeutics due to their opportunity for rapid translation
into a rare disease indication. In the mouse model of the disease, a one-time injection of 4,000
mg/kg HP-β-CD at seven days of age increased overall lifetime by as much as 50%.
Neurodegeneration, as evidenced by loss of Purkinje cells, was slowed but not completely
prevented (Figure 1.6).97 A significant decrease in the total UC sequestered in the livers of treated
mice was also observed, with a corresponding improvement in liver function as evidenced by
levels of aspartate aminotransferase and alanine aminotransferase enzymes in serum. Whole body
UC, while reduced from untreated NPC controls, was still elevated when compared to wild type
mice. Serial injection starting at 7 days showed even greater benefit, normalizing UC in many
organs, doubling lifespan and further slowing neurodegeneration.67-69 However, even with
repeated injections of these large doses, neurodegeneration could not be prevented fully and no

!

!

16

response was seen in the lungs of treated mice.69, 97, 98 The cat model of the disease showed a
similar response to treatment, with the exception of possible damage to animal hearing.99

A

B

Figure1.6: HP-β-CD Treatment A) Extends the Average Lifetime of NPC Mice55 and B) Prevents
Purkinje Cell Death That Can Lead to Neurodegeneration.100

!
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The observation that neurodegeneration could not be prevented may result from the
inability of HP-β-CD to cross the BBB. The beneficial effects on the brain were decreased when
treatment was commenced later than 7 days of age.101 When treatment started at 49 days of age,
treatment was completely ineffective (Figure 1.6).100 In young mice, HP-β-CD is able to access
the brain through a BBB that has not fully formed. This barrier closes as the mice age and more
effectively excludes treatment. When bypassing the BBB with continuous infusion directly into
the ventricles, death of Purkinje cells was prevented completely.102, 103 Thus, achieving access to
the brain will be critical in order for β-CD derivatives to be a truly meaningful therapy.

1.5.2. Mechanism of Action
Practically, treatment with β-CD mediates efflux of sequestered UC beyond trafficking
blockades in the LE/LY and into the cytosol (Figure 1.7). In essence, β-CD replaces the lost
function of the NPC1 and NPC2 proteins.104 It is known that β-CDs are able to enter cells by
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pinocytosis where they exhibit their effects.104, 105 Intracellular evidence of UC mobilization by βCD derivatives comes from a decrease in SREBP2 and UC synthesis rates, an increase in CE
formation, and the activation of LXR genes. The cell is no longer sensing a downstream lack of
UC and, thus, cholesterol uptake and efflux return to normal rates. β-CD treatment, then, is
bypassing a UC mobilization block and allowing movement beyond the LE/LY.
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Figure 1.7: HP-β-CD Treatment Overcomes the Transport Defect in NPC Through an Unknown
Mechanism.

The exact mechanism of action by which β-CD derivatives mediate beneficial changes in
NPC is still a subject of debate. The assertion has been made that β-CD is simply extracting UC
from exterior PMs and carrying it out through the urine, driving UC relocation from the LE/LY.
However, no significant increase in UC was found in the urine of wild type mice after β-CD
treatment.19 Additionally, depletion of UC from the exterior of cellular plasma membranes would
be expected to have corresponding effects on SREBP2, CE, and LXR. The effects are not seen in
normal mice, indicating that they only come about when large cholesterol stores are present
within the animal.55, 100 Finally, SBE-β-CD is still able to overcome NPC transport defects despite
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being unable to remove UC from PMs because of its highly negative charge.106 Thus, it appears
that β-CD derivatives are not mediating their therapeutic effects before internalization.
There are two intracellular efflux mechanisms generally proposed for β-CD mediated UC
release. The first involves vesicular transport of UC:β-CD complexes away from the site of
accumulation. In this situation, β-CD would break up and solubilize UC aggregates or crystals
before leaving the site together. A stoichiometric amount of β-CD would therefore be needed.
Contrary to this potential mechanism, β-CD-Dextran polymers have been reported to co-localize
with sites of UC accumulation and reduce storage. These polymer systems do this while
remaining in the LE/LY, lending support to a second potential mechanism in which β-CD acts as
a catalytic transfer agent.107 In this scenario, β-CD would shuttle UC from LAL or UC aggregates
and into the limiting membrane. This mechanism would also bypass NPC1 and NPC2, wherein
the UC could then flip from the inner to the outer membrane leaflet and be carried forward to
downstream locations. Regardless of the mechanism, the beneficial effects of treatment are clear
as shown in Figure 1.6.

1.5.3. HP-β-CD Pharmacokinetics
A main drawback of HP-β-CD treatment is the rapid clearance of the molecule from the
body. In 49-day old mice, the half-life (T1/2) of subcutaneous injection is 1.6 h with 90% of the
drug being cleared from the body by 6 h (Figure 1.8).100, 102!The vast majority of this dose was
found unmetabolized in the urine after clearance from the blood stream by glomerular filtration in
the kidneys.108 When administered directly into the brain, T1/2 rose to 6.5 h.102 This extension of
residence time is likely because of the inability of HP-β-CD to effectively move across the BBB.
In 7-day old mice, a much higher percentage of the dose, 40%, remained in the blood at 6 h,
translating to a three-fold increase in plasma concentration when compared to the 49-day old
group. This can be attributed to incomplete glomerular formation and, therefore, inadequate
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filtration. Thus, these developmental features may account for some of the increased efficacy of
early treatment.100 When considering administration of β-CD to human patients, however, this
poor pharmacokinetic profile must be considered. Quick clearance of the injected dose from the
blood is likely to limit its efficacy, thereby necessitating injections of large concentrations of drug
at frequent intervals to counteract rapid loss from renal filtration.

Figure 1.8: HP-β-CD Pharmacokinetics After Subcutaneous Injection.100

!
1.5.4. National Institutes of Health Trial
The positive results in animal models of NPC led to a Phase I clinical trial for HP-β-CD
at the National Institutes of Health (NIH). Because the most troubling effects of the disease are
often the neurological symptoms, the main focus of the trial was delivery of β-CD to the brain.
Enrolling two patients and beginning in January 2013, the trial utilized Ommaya reservoir
administration. These devices are deposited under the scalp and a catheter is inserted through the
brain into the cerebrospinal fluid. Drug can be infused regularly through this port without the
discomfort of spinal taps. Unfortunately, the study had to be halted later that year due to
infections secondary to device implantation. The study resumed in September 2013 with 12
patients undergoing more invasive CD administration through lumbar puncture. The trial is
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currently ongoing, but planning of a phase II/III benefit trial to determine clinical benefit is in the
planning stages.

1.6. Cyclodextrin Polyrotaxanes

1.6.1. Polyrotaxane Properties and Components
Polyrotaxanes (PRs) are a class of materials consisting of multiple macrocyclic host units
“threaded” onto a high molecular weight polymer guest. These materials are then “capped” at the
polymer termini by bulky blocking moieties that act to prevent macrocycle dethreading (Figure
1.9). PRs isolated without endcaps are known as pseudopolyrotaxanes (PPRs). The field of PR
chemistry was preceded by a long history of scientific investigation into physically interlocked
molecules including rotaxanes, catenanes, and knots.109-111 Many hosts have been studied
including, but not limited to, transition metal complexes, crown ethers, and cyclic amides.112-114 βCD as a PR host molecule has been extensively studied and is of great interest because of wide
availability, ease of functionalization, natural origins and biocompatibility.115-117
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Figure 1.9: Cyclodextrin Polyrotaxane Structure and Synthesis
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The first report of a CD carrying PR was comprised of α-CD and poly (ethylene glycol)
(PEG).115 Since then, subsequent reports have shown the incorporation of β-CD and γ-CD as
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well118-120. Polymer guests that have been internalized include poly(oxytrimethylene),
poly(oxytetramethylene), poly(propylene oxide)(PPG), poly(perfluoroalkyl ethers), polyesters,
polyamides, polycaprolactone and a wide variety of di- and tri-block copolymers.121-128 In
addition to linear polymers, a variety of branched, star, and side-group polymers have been
rotaxinated as well.120, 129-131!PR endcaps must be chosen depending on the CD derivative that is in
use. Disubstituted benzene termini are large enough to prevent dethreading of α-CD, whereas
larger entities must be used for β-CD and γ-CD, including polycyclic moieties, amino acid
endcaps, or branched stoppers.115, 118, 132, 133!Terminal stoppering is the most common
methodology, but stoppering of multiple pendant groups along a rotaxinated chain has also been
reported.116
The same forces, in large part, which govern small molecule CD inclusion control the
threading of the macrocycles onto a polymer backbone. Hydrophobic and van der Waals forces
are the main interactions between the CD cavity and the guest.71, 134 A polymer that is a better fit
for the specific CD cavity will show tighter binding. This is evident in the fact that PEG will form
PR complexes with α-CD, but not β-CD, as the larger β-CD cavity does not allow for proper
contact.134 In addition to this, CD PRs benefit from stabilization due to hydrogen bonding
between adjacently threaded CD monomers.134 Maximization of energetically favorable hydrogen
bonding leads to CD threading in either head-to-head or tail-to-tail orientations, as primary
alcohols rims are more complimentary to another primary alcohol rim and secondary alcohol rims
more complimentary to secondary. This H-bonding stabilization leads to substituted-CD PRs
being less stable than native.134

1.6.2. Cyclodextrin Polyrotaxane Applications
The unique physiochemical characteristics of PRs imbue them with great potential for
future applications. They can be synthesized from biocompatible and biodegradable materials,
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making them attractive for pharmaceutical and biological applications. Interesting and tunable
gelation properties make them candidates for use as hydrogels and tissue engineering scaffolds.
Flexibility, CD mobility, and facile functionalization give them potential as targeted drug carriers,
biorecognition scaffolds and gene transfection agents. Finally, the potential to build
biodegradability into endcap cleavage gives the promise of tunable release or breakdown through
the molecularly engineered dethreading of CDs by reactions that can be programmed
synthetically in advance.
Tendency of PRs and PPRs to form stable, injectable gels made them attractive for slow
release hydrogel applications.135, 136 Drugs, proteins, or DNA can be physically incorporated into
these gels for extended release profiles that would likely improve bioavailability.137 Release rates
have been shown to from days to months depending on the polymer properties and CD ratios
used.138 CD PR and PPR hydrogels have been studied which incorporate PEG, copolymers, and
polymer mixtures.135, 136, 139-141 An additional potential application has been reported in the
application of degradable PR gels for bone and tissue cartilage regeneration.142 This continues as
an active area of investigation.
The ability to tune the cleavage of PR endcaps to specific biological conditions opens the
door to targeted and specific drug release, biodegradability and enhanced endosomal escape. The
first reported biodegradable endcaps were comprised of phenylalanine moieties linked to the PR
through short cleavable peptides.143 These PRs were shown to exhibit rapid dethreading upon
exposure to the enzyme papain. Since then, additional PRs have been shown to undergo
proteolytic degradation.144 In addition, pH triggered and reduction labile endcaps have been
introduced to allow PR breakdown in endosomal and lysosomal conditions.145-147 These
conditions have the advantages of being triggered after internalization.
Cationic CDs threaded onto PRs have been utilized as efficient gene delivery vectors.
The main advantage of cationic PRs is the ability to exploit CD rotational and translational
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mobility to condense nucleic acids. Systems have been reported utilizing α-CD grafted with
ethyleneimine units of varying length, dimethylaminoethyl and other cations. Multiple forms of
CD and cores including block co-polymers and polymers with branched architectures have been
reported.145, 148-150 Coupling these technologies with biocleavable endcaps may have the additional
advantage of promoting endosomal escape through UC depletion from endosomal membranes.151
The advantages of modification, biocompatibility, and flexibility have made CD PRs
attractive for targeted drug delivery. This field aims to localize toxic drug molecules in only
specific and necessary sites in the body, maximizing therapeutic efficacy and diminishing toxic
side effects. PRs utilizing doxorubicin (DOX) as an endcap have been designed to form stable
micelles and reduce tumor burden to mice in vivo.152 PRs with DOX conjugated to the CD
alcohols have also been reported and assessed in vitro. These systems show extended drug release
as endcaps are cleaved to allow CD dethreading.153, 154 The flexibility of the systems has the
potential to enhance targeted cellular uptake as the CDs can slide and rotate to achieve maximum
binding to receptors of interest. This has been reported using a biotin conjugated PR where
multivalent recognition in the PR led to enhanced affinity for streptavidin that was five times
greater than a biotin CD monomer.155 Combining these two aspects could yield a biodegradable
drug release system that effectively targets diseased tissues and dethreads to release drug
payloads.

1.6.3. Cyclodextrin Polyrotaxanes and Niemann-Pick Type C
With all the potential applications of PRs in biomedical applications, a special
opportunity exists when the host β-CDs are themselves the drugs to be delivered. This is the case
the NPC disease. Knowing that a main drawback of β-CD therapy is a poor pharmacokinetic
profile and rapid renal clearance, building β-CD onto larger drug carriers systems has the
potential to avoid filtration by the glomerular membrane. PRs, with greater hydrodynamic radii,
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would also rise above the cutoff size necessary to remain in circulation. This would enhance
bioavailability, decrease dosages, extend time between treatments, and make the β-CDs more
viable as a potential therapy. HP-β-CD PRs have been shown to efficiently mobilize UC from
sites of accumulation in human NPC fibroblasts.133, 156 It remains to be seen whether β-CD PR
systems will achieve similar effects in vivo.!!
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CHAPTER TWO: SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF βCYCLODEXTRIN POLYROTAXANES FOR MOBILIZATION OF ACCUMULATED
CHOLESTEROL FROM NIEMANN-PICK TYPE C FIBROBLASTS

!

The majority of this work was published in the journal Biochemistry.1

2.1. Introduction

2.1.1. Niemann-Pick Type C Disease
Niemann-Pick Type C (NPC) disease is one of a large set of lysosomal storage disorders
that arise secondary to abnormal function within the late endosome/lysosome (LE/LY)
compartment. In this rare disease, the accumulation of cholesterol and other lipids within the
LE/LY compartment gives rise to various disease states in the patient.2-4 Often, the defect
manifests itself in the form of neurological and/or hepatic or pulmonary symptoms that increase
in intensity over time.5 These can include enlargement of organs, dysarthria, dysphagia, ataxia,
and other neurological symptoms including epilepsy and dementia.3 NPC typically manifests in
children and is ultimately fatal, even with current treatment regimens.6
The underlying causes of NPC are genetic mutations that disrupt the function or
localization of either the NPC1 (95% of cases) or NPC2 (5% of cases) proteins. These proteins
are ubiquitously expressed and are localized to the LE/LY compartment.2,

3

In a normally

functioning cell, NPC1 and NPC2 are responsible for the efflux of unesterified cholesterol (UC)
from the LE/LY compartment into the cytosol and are generally thought to function in a common
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UC efflux pathway.7 The dysfunction of either NPC protein causes a ubiquitous sequestration of
UC in the LE/LY compartments.6 The accumulation of the UC, in turn, causes lysosomal
swelling, upregulation of the genes controlling cholesterol synthesis and LDL uptake, elevation in
intrinsic total cholesterol synthesis and lipoprotein uptake, and neurological effects including
demylination of brain cell axons and the death of Purkinje cells.4, 8, 9 Additionally, onset of
macrophage activity in affected tissues results in the release of pro-inflammatory cytokines in
most organs.8, 10-12 The cumulative impact of these factors is cell death and presentation of the
NPC disease state.

2.1.2. β-Cyclodextrin as an NPC Therapeutic
Since its demonstration by Camargo et. al., an increasing body of evidence shows that
derivatives of β-cyclodextrin (β-CD), a cyclic heterocycle consisting of 7 glucose subunits, are
able to initiate the efflux of accumulated UC from the LE/LY compartment of npc1 and npc2
deficient cells.4,

5, 8-13

Dietschy and coworkers have recently reported several studies that

demonstrate the ability of β-CD derivatives, HP-β-CD in this case, to mobilize UC in the murine
model of NPC1 disease.4-6, 9, 10, 14 Upon treatment with HP-β-CD, a normalization of intracellular
UC levels, suppression of intrinsic cholesterol synthesis, activation of the target genes for the
LXR nuclear receptors, and suppression of target genes for SREBP were observed in several
organs. All of these factors contribute to rapid egress of sequestered UC from sites of abnormal
storage.9, 11, 12 When injected directly into the CNS, similar effects were seen in the brains of
npc1-/- mice,5, 8 and continuous infusion with β-CD derivatives was shown to prevent expected
neurodegeneration.7 β-CD has also been shown to have similar positive effects in npc2-/- mice.13
At the cellular level, addition of β-CD to either npc1-/- or npc2-/- patient fibroblasts has been
shown to rescue the cholesterol accumulation phenotype of these cells.13, 15
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While reversal of UC storage in mice was seen after administration of β-CD, evidence

indicated that the animals began re-accumulating cholesterol shortly after dosing was
terminated.9, 10, 12 β-CD derivatives, therefore, overcome cholesterol transport defects in NPC1
disease, but the alleviation is temporary such that repeated or continuous infusions are needed for
prolonged effects.8,

10

Increasing the efficiency of β-CD delivery, by improving the

pharmacokinetics and biodistribution of the dose, would make β-CD much more viable as a
possible NPC therapeutic. One potential method for achieving these goals would be to deliver CD
via a high molecular weight, long circulating vehicle. A β-CD formulation offering improved
circulation time and lower clearance rates could potentially deliver a more efficacious dose and
be beneficial in NPC treatment.

2.1.3. Polyrotaxanes as NPC Therapeutics
Polyrotaxanes (PR) are supramolecular assemblies that have been of considerable interest
in biomaterials applications such drug and gene delivery and hydrogel formation.16-20 These
complexes are typically prepared by threading macrocycles noncovalently onto a polymer core to
produce a pseudopolyrotaxane with subsequent addition of bulky endcaps onto the central
polymer termini to produce a polyrotaxane. The endcaps prevent macrocycle dethreading and can
be tuned to be bioresponsive toward changes in pH or toward enzyme activity, allowing for
control over when and how the PR degrades to release its macrocyclic cargo.21-24 Cyclodextrinbased PR derivatives have been synthesized using many polymer cores including polyesters,25
polyamides,26 poly(ethylene glycol) (PEG),27-29 polypropylene glycol (PPG),30 and many di- and
tri- block copolymers.31
In this study, a library of PR derivatives has been synthesized using Pluronic block
copolymers and β-cyclodextrin as building blocks. Pluronic polymers have a PEG-PPG-PEG
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triblock copolymer architecture that differ in the relative lengths of the PEG and PPG blocks.
Molecular weights of the Pluronics used range from 1900-12600 g⋅mol-1. These polymers were
chosen because of their previous uses in pharmaceutical applications and their known
biocompatibility.32 Our aim was to increase the efficiency of β-CD delivery into NPC cells using
biocompatible Pluronic-derived β-CD PR.
The PR library was subsequently characterized by solubility tests NMR, NOESY, GPC,
AUC, AFM, MALDI. Analyses of free β-CD contamination levels in the compounds were made
by RPLC and HILIC. Dethreading kinetics were studied by RPLC, 1H NMR, and UV/Vis
analysis. Finally, the capacity of these compounds to mobilize UC in npc1-/- and npc2-/- fibroblasts
was evaluated by filipin staining and PR localization to LE/LY compartments was studied by
fluorescent PR co-localization with Lysotracker Blue.
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2.2. β-Cyclodextrin Polyrotaxane Synthesis

2.2.1. Synthesis of Modified Pluronic Copolymers
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Scheme 2.1: Synthesis of β-CD:Pluronic PR. Values of m and n Depend on the Pluronic Base
Under Investigation.

The synthesis of F127 Pluronic-based β-CD polyrotaxane will be described in detail
below (Scheme 2.1). All other β-CD:Pluronic PR were synthesized and purified in the same
manner, except where noted. The Pluronic precursor was added to a dry round bottom flask under
a dry N2 atmosphere and then dissolved in benzene before solvent evaporation. This azeotropic
drying procedure was repeated three times before finally the drying polymer under vacuum at 80
°C overnight.
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Pluronic F127 (4.0 g) was dissolved in 20 mL DCM and added to CDI (9.5 mmol, 30 eq.,

dissolved in 20 mL DCM) by syringe over the course of 6 h. The solution was stirred for 18 h at
20 °C before concentration by evaporation and addition to TREN (6.4 mmol, 20 eq., dissolved in
20 mL DCM) over 3 h. After stirring at 20 °C for 24 h, the solution was concentrated by rotary
evaporation and the residue precipitated in ether (3 x 350 mL), before collection by centrifugation
and drying overnight under vacuum. The TREN derivatives of L35 and L64 were isolated as
viscous yellow liquids, whereas the F127 and F68 derivatves were isolated as white solids.
TREN-polymers proved difficult to purify completely and, as such, were used with some
impurity. Extensive purification and dialysis of the final PR compounds would serve to remove
any impurity retained after these steps.

2.2.2. Polyrotaxane Threading, Endcapping and Purification
TREN-F127 (2.5 g) was added to a saturated aqueous solution of β-CD (5.9 mmol β-CD
in 361 mL H2O). After dissolution of the polymer, the solution was bath sonicated for 10 min at
65 °C to ensure complete mixing. Finally, the solution was probe sonicated using a ½ inch tip for
3 min and agitated on a rocker plate for 14 d to promote threading. For liquid polymers L35 and
L64, a white precipitate formed in the flask almost immediately and increased over time. The
threading progressed much more slowly for the solid polymers (F127 and F68), with precipitate
appearing usually after 24 h and increasing thereafter. After completion of the threading reaction,
TNBS (4 eq, 1.5 mmol, 5.1 mL in a 10% solution) was added to the reaction mixture and left on
the rocker plate overnight to effect the endcapping reaction.
The L35-, L64-, and F68-based PR were collected and washed by centrifugation 3-5
times with 30 mL of H2O for 3 min at 7000 rpm. After this, the products were dialyzed against
water in MWCO tubing appropriate for the expected molecular weight of the product. The
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products were dialyzed for 3 d with an average of six water changes, or until water remained clear
for two consecutive water changes.

2.3. β-CD:Pluronic PR Characterization

!
2.3.1. Confirmation of Endcapping and Threaded Architecture
Multiple techniques were used to characterize the β-CD:Pluronic PR products, including
verification of successful endcapping reactions, characterization of β-CD threading efficiencies,
determination of PR product molecular weights, and analysis of their purity with respect to free
β-CD content.
All β-CD:Pluronic PR products were poorly soluble in all solvents tested, except DMSO.
Poor solubility is a well-known property of PEG-based PR compounds.33 Poor solvent access to
the threaded polymer core, combined with high molecular weights, produce limited solubility of
these products.20, 24 Pluronic-based β-CD PR were expected to have similar properties.
This characteristic was exploited to purify the PR from the β-CD and Pluronic precursors
that are both quite water-soluble. Free Pluronic polymers, TREN-terminated Pluronic
intermediates, and free β-CD were removed by repeated aqueous washing of the relatively waterinsoluble PR product. Unsuccessfully- and partially-endcapped PR are also expected to dethread
upon repeated suspension in water since there is nothing obstructing diffusion of β-CD off the
unreacted polymer core, eventually rendering these byproducts water soluble and removable by
the washing and dialysis processes.
Multiple lines of 1H NMR evidence suggest that PR formation was successful. Endcap
peaks were observed indicating successful reaction of TNBS with the terminal amines of the
TREN-pseudorotaxane intermediate. These peaks were present in NMR spectra of each β-
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CD:Pluronic PR species. There was also evidence of broadening in the β-CD O2H, O3H, H1 and
O6H protons as well as in the signal corresponding to the Pluronic PPG methyl group (Figure
2.1). These characteristic changes, previously reported for β-CD PR, is a result of restricted β-CD
mobility upon threading onto the Pluronic core.33
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Figure 2.1: 1H NMR Spectra of Free β-CD and PR-F127 Product in DMSO-d6. Peak Broadening
Shows Inclusions of Polymer Inside β-CD Core.

Finally, 2D NOESY NMR was performed as an additional confirmation of PR formation.
Signals corresponding to the inward facing protons (H-3 and H-5) of the β-CD cavity (Figure 2.2)
and the proton resonances of the Pluronic PPG methyl groups are found to be cross-correlated.
The close proximity of these substituents suggests that the cyclodextrin molecules are threaded
onto the Pluronic core.34
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Hydrogens H3/H5 and the PPG Methyl Group is Shown.

2.3.2. Characterization of β-CD Content
Initial characterization of the threading efficiency was done using 1H NMR integration
with subsequent correction for the free β-CD contamination levels present in the sample as
determined by chromatographic analysis. Since β-CD has seven identical H1 protons at the acetal
position of each glucose subunit that appear at ~4.8 ppm, the intensity of this signal can be
directly related to the signal intensity of the Pluronic PPG block methyl group. This method
indicated that the PR threading efficiencies typically ranged between 62-100%.
Initial attempts to produce highly threaded Pluronic PR were less than satisfactory, with
threading efficiencies often in the range of 20-30%. We attributed these failed attempts to
aggregation of the Pluronic precursors. Since the critical aggregation concentration for the
Pluronic precursors used is quite low (0.004-1 wt%), we attempted to disperse the micelles into
Pluronic unimers in the threading mixture.31 Decreasing the Pluronic feed concentration and
addition of a probe sonication step into the threading procedure increased the threading
efficiencies for each of the Pluronic PR cores (Table 1). It is hypothesized that probe sonication of
solutions at the initiation of the threading reaction disrupts micelle formation allowing for the
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initial threading of β-CD molecules onto the Pluronic unimer which, in turn, prevents the
immediate reformation of micelles and allows for further threading (Figure 2.3).

Probe
Sonication

!

Increased
Threading

Figure 2.3: Hypothesized Mechanism of Increased β-CD Threading Upon Probe Sonication.

!
Quantification of the free β-CD content in a given PR sample is an important parameter
to measure so that the performance of these compounds can be properly evaluated during in vitro
and in vivo testing of cholesterol mobilization in NPC models. By having PR compounds
relatively free of unthreaded β-CD, it can be safely assumed that any observed increases in
cholesterol efflux or decreases in cholesterol synthesis are a product of β-CD initially entering the
cell as a PR complex where it is then dethreaded into the active monomeric form. A goal of ≤ 5%
free CD was selected as an acceptable level of contamination. PR that did not meet this criterion
were further purified as described. One round of further purification was usually enough to bring
the PR samples below the 5% free β-CD threshold as determined by RPLC and/or HILIC.

Table 2.1: Average Number of CDs per PR, Threading Efficiencies, Yields, and Free CD
Content.

!
β"CD%PR Base%MW%(kDa) PEG:PPG #%CDs %%Threading
F127
12.5
200:65
15
71.40%
F68
8.35
151:29
14
100%
L64
2.9
26:30
12
92%
L35
1.9
22:16
5
63%

!

%%Yield
32.90%
13.30%
29.10%
19.10%

%%Free%CD
4.40%
3.60%
2.40%
1.20%
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2.3.3. Characterization of Polyrotaxane Molecular Weight
GPC analysis of PR compounds produced molecular weight estimates that were in

agreement with the masses determined by NMR (after correction for free β-CD). The β-CD:F127
PR molecular weight for was 30,800 g/mol. GPC analysis indicated a mass of 33,300 g/mol, with
evidence of free β-CD noted in all samples analyzed. A mass of 30,000 g/mol was determined by
both sedimentation velocity and sedimentation equilibrium experiments (Figure 2.4). Taken
together, this data suggests that the average molecular weight of β-CD:F127 PR is ~31kD.
Molecular weights for each member of the β-CD:Pluronic PR library corresponded well in both
GPC and NMR analysis (Table 2).

Table 2.2: Average Polyrotaxane Molecular Weights

PR

!

NMR (kDa) NMR (kDa) NMR (kDa)

F127

30.8

33.3

30.0

F68

25.5

28.5

27.0

L64

17.7

17.1

21.0

L35

11.0

13.2

12.0
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Figure 2.4: Sedimentation Equilibrium (SE) Profile of β-CD:F127 PR.

MALDI-MS analysis gave additional confirmation of the β-CD:F127 PR molecular
weights as well as information about the heterogeneity of the system. The spectrum contains a
mass peak at ~30 kDa representing a threading of 15 CDs as found by other measures. Other
peaks in the spectrum correspond to members of the β-CD:F127 PR population with greater and
lesser degrees of threading. Most abundantly, additional m/z peaks corresponding to 18, 8, 7, 6,
and 1 threaded CD appear (Figure 2.5). As expected, there is some heterogeneity in the amount of
threading on any given PR monomer. Additionally, MALDI spectra of lower molecular weight
PR showed evidence of dimer formation. This fits well with the aggregation behavior noted in
AFM analysis (see below).
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Figure 2.5: MALDI-MS Spectrum of β-CD:F127 PR at Laser Power 6500.

2.3.4. Polyrotaxane Morphology
AFM analysis of the β-CD:F127 PR material produced evidence of PR aggregation. To
try and image non-aggregated particles, PR samples were probe sonicated before being fixed onto
mica plates. Sonication did not prevent aggregation, but did decrease the size and height of
imaged particles. It is hypothesized that β-CD:Pluronic PR are forming hollow micelles in
solution as previously reported in a similar β-CD:Pluronic PR system.34 Consistent with this
expectation, we found that higher PR concentrations produced larger aggregates. Samples at a
concentration of 10-5 mg/mL obtained an average diameter of 45.1 nm after probe sonication.
Samples at 10-7 mg/mL averaged 41.0 nm and concentrations of 10-9 mg/mL gave particles with
an average diameter of 32.1 nm (Figure 2.6). Thus, higher β-CD:F127 PR concentrations promote
aggregation and micellization into particles whose diameter depends on PR concentration in
solution.
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Figure 2.6: AFM Images of β-CD:F127 PR at 10-5 mg/mL (A), 10-7 mg/mL (B) and 10-9 mg/mL
(C) With Probe Sonication. Scale Bar Represents 500 nm. Size Distributions are Shown Below
Images.

Diffusion ordered spectroscopy measurements were able to confirm rotaxination and
provide some insight into how the β-CD:Pluronic PR constructs behave in solution.

The

diffusion constants (D) for β-CD:L35, β-CD:L64, and β-CD:F68 PR were 5.84 x 10-11 m2/s, 5.30
x 10-11 m2/s, and 3.38 x 10-11 m2/s respectively. These diffusion constants scale with molecular
weight and are in reasonable agreement with the diffusion behavior of similar systems.33,

35

Additionally, the least squares fit of a log(D) vs Log(MW) plot gave a scaling constant of -0.63.
Scaling constants < -0.6 are indicative of semiflexible wormlike systems,36 showing that the PR
system has more rigidity in solution than would a solvated linear random coil.37
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2.3.5. Polyrotaxane Dethreading Behavior
Experiments were performed to characterize the dethreading behavior of the β-

CD:Pluronic PR under acidic and reducing conditions in an attempt to mimic the LE/LY
environment (Figure 2.7). Experiments in which β-CD:Pluronic PR were suspended in solutions
at either pH 7.4 or 5.5 and sampled at intervals showed no increase in free β-CD levels by RPLC
analysis up to 24 hr after dissolution. This was in agreement with the design of the PR, which
were intended to be stable under acidic conditions.
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Figure 2.7: Hypothesized and Experimentally Tested Mechanisms for PR dethreading. A)
Glutathione Incubation with PR at Acidic and Neutral pH and (B) Acid Catalyzed Dethreading at
37 °C Showed No Signs of Dethreading. Hypothesized Dethreading (C) By Enzymatic Cleavage
of Carbamate Linkages Yields Free β-CD In Vitro.
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Additionally, 1H NMR and UV/Vis studies were conducted to monitor changes in endcap
morphology upon exposure to acidic pH and 10 mM glutathione. 1H NMR of a short bis-amine
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PEG-NH-TNB analog showed no changes in the characteristic TNB peaks even after 48 hr
incubation with glutathione at 37 °C, indicating that the TNB nitro groups had not been reduced.
Similarly, the UV/Vis spectra of the F68-TNB endcaps remained unchanged even after 48 h of
incubation in glutathione at both acidic and neutral pH. As expected, dethreading of βCD:Pluronic PR is not triggered by acid-mediated endcap cleavage or glutathione reduction of the
TNB endcap.
Finally, the possibility that β-CD:Pluronic PR were dethreading upon solubilization in
DMSO and/or incubation with media was investigated. 1H NMR analysis of PR samples showed
that neither incubation with DMSO/MEM nor DMSO/PBS buffer resulted in any changes in the
integrated threading efficiency of the samples when compared to PR controls. β-CD:Pluronic PR
should, therefore, be stable in culture before cellular internalization.

2.4. Niemann-Pick Type C Fibroblast Studies

2.4.1. Polyrotaxane Cholesterol Mobilization
Npc2-/- fibroblasts were incubated with each β-CD:Pluronic PR derivative and reductions
in cellular cholesterol accumulation were monitored over time to evaluate their impact on a
cellular model of NPC disease. Initially it was hypothesized that this library of PR constructs,
which was not designed to be either acid sensitive or reductively labile, would stimulate little or
no reduction in npc2-/- cholesterol accumulation. Figure 2.8, however, shows that a single dose of
any β-CD:Pluronic PR, yielding 25 µM β-CD, results in a reduction of approximately 60 to 75%
in accumulated cholesterol levels by 6 hr, relative to untreated controls. Results were
quantitatively similar to monomeric β-CD, which decreased cholesterol levels to ~30% of the
level of untreated cells over the same time period. Similar, although diminished, results are seen
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in npc1-/- cells (Figure 2.9). Differences in treatment based on protein mutation may be indicative
of varying sequestration severities.
It is worth noting that the levels of CD monomers used in the present studies are within
the range of effective concentrations shown by Peake and Vance to clear cholesterol from murine
npc1-/-neurons and glial cells,38 as well as by the data herein to clear cholesterol from human
npc2-/- fibroblasts.13 Levels that were demonstrated to cause neuronal cell toxicity, e.g. 10 mM
were not used in the present studies.38 In addition, although the fibroblasts were exposed to
potentially cytotoxic TNB upon endcap release, no alterations in cell density or viability were
observed in any of the cell samples.

A.

B.
0.5,hr

1,hr

3,hr

6,hr

,Control

DMSO

β&CD

C.
β&CD/L35

βCD/F127

βCD/L64

βCD/F68

βCD/L35

Control

β&CD/L64

Figure 2.8: Filipin Accumulation in NPC2 Deficient Fibroblasts Treated With β-CD:Pluronic PR.
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While each of the compounds induces rapid efflux of cholesterol, similar to monomeric
CD, slight differences in the efficacy of the PRs are apparent. For example L35, carrying 5 βCDs, stimulates the lowest degree of cholesterol efflux from npc2-/- cells while L64, with 12 β-
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CD monomers, is the most effective (p < 0.05). These differences in relative cholesterol clearance
by the PRs suggest that endcap cleavage and dethreading of CD is occurring within the LE/LY,
following bulk phase endocytosis of the intact compounds (Figure 2.8B). If dethreading were
occurring in the media prior to cellular uptake, approximately equal degrees of cholesterol
clearance would instead be expected for all the β-CD:Pluronic PR compounds, since each
treatment would yield 25 µM monomeric β-CD.

Figure 2.9: Cholesterol Mobilization from NPC1 Deficient Fibroblasts.

2.4.2. Polyrotaxane Subcellular Localization
In order to determine whether the β-CD:Pluronic PR compounds were in fact entering the
LE/LY compartment, a fluorescein labeled β-CD:F127 PR was synthesized. Thirty minutes after
addition of the compound to npc2-/- fibroblasts, fluorescein was observed to overlap entirely with
Lysotracker Blue staining, indicating localization of the compound to the LE/LY (Figure 2.10).
Therefore, it is likely that the carbamate linkages used to attach the PR endcaps are being cleaved
by enzymatic activation within the LE/LY. Hydrolysis of carbamate linkages has been previously
reported and, indeed, has been used as a method for activating prodrugs.39-41 Thus, carbamate
cleavage would allow for dethreading of β-CD monomers at high concentration within the LE/LY
and subsequent efflux of cholesterol from this compartment.
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Figure 2.10: Fluorescein Labeled β-CD:F127 PR Localizes to the LE/LY In npc2-/- Fibroblasts.
A) Fluorescein Localization B) Lysotracker Blue Staining C) Fluorescence Overlay D) Intensity
Plot.

2.5. Conclusions
We have synthesized a family of β-CD:Pluronic PR compounds as potential therapeutics
for treating Niemann-Pick Type C disease. The threading efficiency, molecular weight, and free
β-CD contamination in these analogs have been characterized. Each of the compounds has been
shown the capacity to trigger the efflux of cholesterol from npc1-/- and npc2-/- fibroblasts in vitro
via filipin staining studies. The rate and efficacy of β-CD:Pluronic PR mediated cholesterol
removal has been shown to be comparable to monomeric β-CD treatment alone. Based on these
findings, β-CD:Pluronic polyrotaxanes warrant further investigation with regard to their safety,
pharmacokinetics, biodistribution, and durability of response toward cholesterol efflux and/or
synthesis suppression in an in vivo model of Niemann-Pick C disease.
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2.6. Materials and Methods

2.6.1. Materials
(1,1)-Carbonyldiimidazole (CDI) and 2,4,6-trinitrobenzenesulfonic acid (TNBS) were
purchased from Research Organics. Tris(2-aminoethyl)amine (TREN), β-cyclodextrin, Pluronic
polymers and 2,2’-(ethylenedioxy)bis(ethylamine) were purchased from Sigma Aldrich. The four
Pluronics used in this study were F127, F68, L64, and L35. All solvents were dried and distilled
from an appropriate dessicant prior to use unless otherwise noted. Human fibroblasts cells from
an apparently healthy donor (GM03652) and from an NPC2 patient (GM18455) were from
Coriell Institute of Medical Research (Camden, NJ). Filipin and fluorescein were purchased from
Sigma and Lysotracker Blue from Molecular Probes.

2.6.2. Synthesis and Purification of β-CD:Pluronic Polyrotaxanes
PR synthesis is described in detail in the text above. The L35-, L64-, and F68-based PR
were first collected from the reaction mixture by centrifugation for 3 min at 7000 rpm. They
were then diluted with 30 mL of H2O, vortexed, and re-centrifuged under identical conditions.
Water washes were continued in this manner until the washes ran nearly clear; usually 3-5
repetitions.

The F127-based PR was not able to be collected by centrifugation due to the

formation of viscous suspensions. Therefore, this product was purified by extensive dialysis
described below.
The products were again suspended in 30 mL H2O and dialyzed against H2O using
dialysis tubing correlating to the estimated MW of the final product. L35- and L64-based PR
were dialyzed with MWCO 3500 and 6-8000 tubing, respectively. F68 and F127-based PR were
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dialyzed against water in MWCO 12-15k tubing. The products were dialyzed for 3 d with an
average of six water changes, or until water remained clear for two consecutive water changes.
Upon completion of dialysis, the purified products were frozen and lyophilized to yield
yellow-orange powders. β-CD:F127 PR was obtained in 32.9% yield (1.883 g). β-CD:F68 PR, βCD:L64 PR, and β-CD:L35 PR gave 13.29% (0.502 g), 29.1% (4.773 g), and 19.1% (1.12 g) of
solid, respectively. F127 1H NMR: (400MHz, DMSO-d6, 22°C) δ 8.94-8.76 (br s., 8H, TNB),
5.73-5.65 (m, 266H, O2H, O3H of CD), 4.8 (s, 133H, H1 of CD), 4.45 (t, 133H, O6H of CD), 3.673.59 (m, 532H, H3, H6, H5, H4 of CD), 3.51-3.48 (m, 995H, PPO and PPG -CH2-), 1.04-1.01 (d,
195H, PPG -CH3).
After the initial purification processes, the PR were analyzed by both RPLC and HILIC,
with the two methods consistently agreeing within 8%. Initial free CD measurements for βCD:F127 PR were 19.87% by HILIC and 26.88% by RPLC. Samples containing > 5% free β-CD
by RPLC were suspended in 15 mL H2O, vortexed for 2 min, and gathered by centrifugation as
previously described. After three repetitions, the samples were reanalyzed for free β-CD content.
This process was repeated until the HILIC and/or RPLC analyses indicated that the free β-CD
content was ≤ 5% free β-CD.
The inability to wash and collect β-CD:F127 PR by centrifugation made them more
difficult to purify of free, or entrained β-CD contamination. Samples containing > 5% free β-CD
contamination after initial purification were re-suspended in H2O, vortexed for 3 min, and again
left to dialyze against either MWCO 12-14k dialysis tubing or a 20K dialysis cassette for 2 d and
re-tested. This process was repeated until the HILIC and/or RPLC analyses indicated that the free
β-CD content was ≤ 5% free β-CD.
Fluorescein modified β-CD:F127 PR was synthesized by dissolution of 400 mg βCD:F127 PR in dry DMSO before activation with CDI (6.1 mmol) and coupling to ethylene
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diamine (7.4 mmol). A second activation with CDI (6.1 mmol), fluorescein coupling (6.1 mmol)
and precipitation twice in MeOH yielded the fluorescent PR derivative. The fluorescent PR
derivative was used without further purification.

2.6.3. Determination of Threading Efficiency by 1H NMR
Determination of PR threading efficiencies were initially performed by 1H NMR spectral
integration. The characteristic β-CD H1 proton at ~4.8 ppm was directly compared to the PPG
methyl protons of the polymer at 1.0 ppm. The PPG resonance was normalized to the average
number of hydrogens expected for that specific Pluronic’s methyl group. Given that each β-CD
monomer has seven acetal protons, the corresponding integration for the number of β-CD H1
protons present in the sample was divided by seven. This yielded an average number of β-CDs
per PR. This estimate of threading efficiency was then recalculated once the amount of free,
unthreaded β-CD in the sample was determined by chromatographic analysis. 1H NMR spectra
were acquired on a 400 MHz Bruker ARX400 spectrometer, using the solvent peak as the
reference standard and the chemical shift given in parts per million. NOESY spectra were taken
on a 500 MHz Bruker DRX500 spectrometer with a 5 mm TBI probe. DMSO-d6 was used as
NMR solvent unless otherwise noted.

2.6.4. Determination of Free β-CD in β-CD:Pluronic PR
Determinations of free β-CD in PR samples were done in two ways. First, PR solutions
of ~1 mg/mL were prepared in H2O for analysis on a custom made HILIC silica packed column
with 700 nm nonporous silica nanoparticles that were surface-modified with amide groups.42
Before analysis, PR were subjected to 2 rounds of vortexing for 2 minutes and bath sonication at
50 °C for 10 minutes. The temperature of the column oven was maintained at 25 °C. All runs
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were performed under the gradient conditions of 90-70% ACN with 0.1% formic acid.
Determinations were made on a Thermo Accela UPLC system (Thermo Fischer Scientific, MA,
USA) and LTQ Velos LC-MS. Mobile phases A and B were acetonitrile with 0.5% (v/v) formic
acid and water with 0.5% (v/v) formic acid. Chromatographic separation started at an initial
mobile phase of 95% A, held for 1 min, then followed by a linear gradient from 80 to 60% mobile
phase A in 15 min. The solvent composition then changed to 50% A over 0.1 min and was
maintained for 5 min before being re-equilibrated to 95% A. The flow rate was 150 µL/min.
Mass spectrometric data were acquired in the positive ion mode. The ESI conditions were
as follows: ESI spray voltage, 4 kV; temperature setting, 300°C; sheath gas flow, 30 U (arbitrary
units); auxiliary gas flow, 8 U.
Additionally, PR solutions in H2O (~1mg/ml) were analyzed by RPLC using an
H2O:ACN gradient elution as described by Agueros, Campanero and Irache.43 Analyses were
performed using an Agilent Technologies 1200 Series HPLC equipped with an ESA Corona
Detector and an Agilent Zorbax Eclipse XDB-Phenyl column (2.1 x 1250 mm, 5 µm particles).
Known concentrations of β-CD were used for both HILIC and RPLC measurements to construct
standard curves for fitting PR sample data.

2.6.5. Gel Permeation Chromatography
Corroboration of NMR molecular weight measurements and threading efficiencies were
made by gel permeation chromatography (GPC) analysis. PR samples (~30 mg/mL in DMSO)
were prepared and analyzed as described by Beirne, Truchan, and Rao.44 GPC measurements
were made using an Agilent Technologies GPC system equipped with an OHpak SB-803HQ
column (8 mm x 300mm), Dawn Helios II multi-angle light scattering detector (Wyatt
Technology Corporation), and Optirex RI detector (Wyatt Technology Corporation) using DMSO
as the mobile phase. The detectors were normalized using 25 kD pullulan and calibrated using
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11.6 kD and 48.6kD dextran standards. Flow rate was 0.16 mg/mL with a 100 µL injection
volume. 44

2.6.6. Analytical Ultracentrifugation
Analytical ultracentrifugation was done in the Purdue Bindley Bioscience Center on a
Beckman Coulter XLI (Beckman-Coulter, CA) ultracentrifuge using absorbance optics at 346 nm
and 422 nm and interference optics at 675 nm. PR were characterized in PBS buffer at pH 7.4 at
concentrations of 0.1, 0.2, and 0.4 OD. Sedimentation equilibrium (SE) experiments were done at
speeds of 25,000, 35,000 and 40,000 rpm for a total of 67.8 h and analyzed by the species
analysis model in SEDPHAT (v. 9.4).45 The system was standardized by running unmodified
F127 Pluronic (found to be 12,500 g/mol as expected). Sedimentation velocity experiments were
conducted at 50,000 rpm using a 2 channel charcoal centerpiece for 15 h and analyzed using
SEDFIT (v. 12.43).46 All experiments were carried out at 20 °C using an Anton 60 Ti rotor. Buffer
density and viscosity were calculated using SEDNTERP.47 The partial specific volume of
polyrotaxane without a PEG derivative was calculated to be 0.62 mL/g.48 The partial specific
volume of the polyrotaxanes with PEG derivatives was 0.85 mL/g, which agrees well with
published values.49

2.6.7. Atomic Force Microscopy
AFM images were taken by depositing and drying 1 µL of probe sonicated PR-DMSO
solution onto a mica plate. All samples were fixed ~5 min after probe sonication. Images were
obtained using a Dimension 3100 AFM from Veeco Instruments (USA). Images were obtained in
tapping mode using an NSC15/AIBS 325 kHz cantilever with a 46 N/m force constant and an
amplitude set point of 1 V.
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2.6.8. Mass Spectrometry Analysis
An ionic liquid matrix (ILM) was made for analyzing the PR by MALDI. The ILM was

made

as

follows:

2',4',6'-trihydroxyacetophenone

monohydrate

(THAP)

and

1,1,3,3-

tetramethylguanidine (TMG) were mixed at a molar ratio of 1:2 in methanol. The solution was
then sonicated for 15 min at 40 °C. After removal of methanol by centrifugal evaporation in a
SpeedVac for 3 h at 20 °C, ILMs were left under vacuum overnight. Final solutions were then
prepared at a concentration of 90 mg/mL in DMF for use as a matrix. The polyrotaxanes samples
were prepared at 3 mg/mL in DMF. The samples for MALDI-MS analysis were prepared by
mixing the PR sample and ILM in a 1:80 ratio. Then, 0.6 µL of the mixture was deposited on a
mirror polished stainless steel MALDI target and allowed to dry at 20 °C and atmospheric
pressure overnight. The spectra were acquired at a laser power of 6500 using 600 laser shots in
linear mode on an AB4800 MALDI TOF/TOF Analyzer. Peak assignments were made by
addition of modified polymer MW and 1,135n, where n is the potential number of bound CDs.
Lesser peaks flanking assigned masses can be attributed to variations in MW inherent in the base
polymer.
ESI mass spectrometry of the TNB terminated 2,2’-(ethylenedioxy)bis(ethylamine) was
performed on a Waters ZQ electrospray mass spectrometer in negative ion mode.

2.6.9. Dethreading Analysis
Bulk dethreading experiments of β-CD:Pluronic PR were performed by suspending each
PR in H2O, adjusted to pH 7.4 or 5.5, at concentrations of 1 mg/mL. Samples were placed in a
constant temperature bath at 37 °C and sampled at 1, 2, 4, 8, 16, and 24 h. Aliquots were analyzed
by RPLC as described above to monitor the increase in free β-CD in each sample. 1H NMR
analysis of similarly incubated PR was also conducted to reveal any changes in carbamate peaks
characteristic of successful endcapping.
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A short, unthreaded TNB endcapped PEG-bis-amine (MW 570.4 g/mol), was synthesized

to better visualize any possible changes in the encap. 0.1 g 2,2’-(ethylenedioxy)bis(ethylamine)
was dissolved in THF. TNBS (4.2 mL, 2.5 eq) was activated with 1 mL 5% NaHCO3 and added
to the THF solution. Reaction was allowed to stir for 24 h with a yellow/orange precipitate
forming within 1 h. Precipitate was collected by vacuum filtration and washed with THF (3x 25
mL). Product was isolated as an orange powder (158 mg, 40.8% yield). ESI-MS: Found 569.39
m/z. 1H NMR spectrum in the presence of glutathione. This compound was subjected to a D2O
solution of 10 mM glutathione at pH 7.4, incubated at 37 °C, and monitored at intervals for 48 hr.
The PEG-TNB concentration was 1 mg/mL.
TREN-terminated F68 polymer was synthesized as described. 0.26 mL (4 eq) of TNBS
(10% solution in H2O) was added to an aqueous solution of 0.2 g F68-TREN terminated polymer.
Reaction mixture was stirred for 18 h, precipitated in ether and collected by centrifugation.
Product was then dissolved and re-precipitated into ether (2 x 150 mL). Product was collected by
centrifugation and dried on Hi-vac. Product was collected as a yellow/orange solid (0.198g,
90.4% yield).
UV/VIS analyses of TNB endcaps were made using an Agilent HP 8453 UV/Vis
spectrophotometer (Agilent Technologies, Inc., Santa Clara, CA, USA). PBS solutions of an
unthreaded F68-TNB polymer were dissolved at 1 mg/mL with 10mM glutathione at either pH
7.4 or 5.5. Emission spectra were taken at 1, 2, 4, 8, 16, 24, and 48 h, with monitoring at 346 nm
and 420 nm wavelengths.

!

!

64
2.6.10. Polyrotaxane Media Stability
Two solutions of ~ 12 mg β-CD:F127 PR were prepared in 0.2 mL DMSO. The PR

solutions were then diluted to 10 mL with either PBS buffer or Minimum Essential Medium at
pH 7.4 before incubation for 1 hr at 37 °C. After incubation, the samples were dialyzed against
for 3 d with water changes approximately every 12 h. Samples were then frozen, lyophilized, and
collected as yellow-orange powders. Analyzed as described in the manuscript, integration of the
H1 protons for each sample showed 20.9, 21.1 and 20.5 protons for DMSO/media incubated,
DMSO/buffer incubated and control PR respectively. This corresponds to ~3 CDs for each
sample and no apparent degradation of the samples in DMSO or media

2.6.11. Diffusion-Ordered Spectroscopy
Experiments were performed on a Bruker AVIII300WB spectrometer using a diff50
diffusion probe with a maximum gradient strength of 30 T/m. The pulse sequence used was a
stimulated echo diffusion sequence (PGSTE)50 with an additional spoiler gradient in the diffusion
period. Signal attenuation was achieved by varying the gradient strength while all the timings in
the pulse sequence were kept constant. The main experimental parameters were as follows. The
effective gradient pulse duration δ was 1 ms using a sinusoidal gradient shape, the diffusion time
(Δ) was 20 ms, and the repetition time was 2 s. The gradient amplitude was varied in, 64 steps
linearly between 9 and 572 Gauss/cm (90 to 5720 mT/m). For each gradient step 64 scans were
performed for a total experiment time of about 2 h 15 m. The experimental parameters were not
optimized for speed; the experimental time could be cut down to less than half an hour. The
temperature was kept constant at 25°C. Data was processed using the Bruker Dynamics Center
program.
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2.6.12. Cell Studies
Human fibroblasts from npc1-/-, npc2-/-, or unaffected patients were seeded on 8-well

tissue culture slides at a density of 6x103 cells, in Eagle’s Minimum Essential Medium with
Earle’s salts and non-essential amino acids + 15% FBS at 37°C with 5% CO2. Sterile βCD:Pluronic PR samples were solubilized in DMSO and diluted in culture media to a
concentration that would yield 25 µM β-CD. The final DMSO concentration in all preparations
was ≤ 0.001%. Treatments were administered to cells 36 - 48 h after plating. Following varying
incubation periods, as indicated, cells were rinsed with PBS and fixed in situ with 10% buffered
formalin. Cell density and viability, determined by trypan blue exclusion, were determined using
cells collected immediately prior to fixation. No changes in cell numbers or viability (> 95%)
were found, indicating an absence of toxicity under the range of conditions used in the present
studies. Fixed cells were washed with PBS and stained with 50 µg/mL filipin in PBS for 1 hr.
Images were acquired using a DAPI filter set on a Nikon Eclipse E800 epifluorescence
microscope (Nikon Inc.), equipped with NIS-Elements BR 3.2 software (Nikon Inc.). Anti-fade
mounting agents and microscope light settings ensured the absence of photobleaching. Filipin
accumulation in cells was determined using NIS-Elements selection tools and calculated as a ratio
of filipin area to cell area.

The results in β-CD:Pluronic PR and β-CD treated cells were

normalized to filipin accumulation in untreated npc2-/- fibroblasts and are expressed as mean ±
SE.
Fluorescein labeled β-CD:F127 PR was prepared as described above and administered to
npc2-/- fibroblasts approximately 24 h after plating. Cells were rinsed with PBS 0.5 h or 1 h after
addition of the compound and incubated with 50 nM Lysotracker Blue (Life Technologies) in
PBS for 10 min. Cells were rinsed again and fixed in situ with buffered formalin. Images were
obtained using DAPI and B-2A filter sets for the fluorescent PR and Lysotracker, respectively.
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CHAPTER THREE: IN VITRO EFFICACY OF MIXED β-CYCLODEXTRIN
POLYROTAXANES AND PENDANT POLYMER SYSTEMS IN NIEMANN-PICK TYPE C
DISEASE

!
3.1. Introduction

3.1.1. Mixed β -CD Polyrotaxanes as NPC Therapeutics
Polyrotaxanes (PRs) are non-covalent self-assemblies obtained from macrocyclic
molecules, such as cyclodextrins, being threaded onto polymer axles. Macrocycles are retained
through bulky stoppers that prevent dethreading. These non-covalent constructs have attracted
wide interest in supramolecular and polymer chemistry, with particular attention focused on their
potential applications as sliding ring gels,1, 2 molecular machines,3 and as carriers for drug and
gene delivery.4, 5 Since the first PRs constructed from α-cyclodextrin (α-CD) and PEG were
reported by Harada et al.,6, 7 many research efforts have been dedicated to the design of various
Pluronic®-based PRs using β-cyclodextrin (β-CD) and its derivatives.8-14 Some of these studies
have been devoted to understanding the formation of cyclodextrin inclusion compounds, but the
forces that drive the complexation, especially for CD-polymer inclusion complex formation, have
yet to be fully elucidated.15-19 In addition, many reports have described the influence of
cyclodextrin modifications on the stability and solubility of the numerous drug:β-CD
complexes;20, 21 however, none of these contributions have methodically focused on their impact
on linear polymer complexes. Tonelli and coworkers have shown, while trying to interchange αCD between PCL chains and PLLA chains in solution, that the guest-host steric compatibility
plays an important role in polymer-CD complex formation.22
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Thompson and coworkers have previously reported the synthesis of 2-hydroxypropyl-β-

cyclodextrin (HP-β-CD):Pluronic® copolymer based PRs under heterogeneous conditions as part
of an effort to develop substrate reduction agents as potential Niemann-Pick Type C
therapeutics.23 This is an attractive and effective synthetic method for threading reactions
involving highly water-soluble CDs. Since the previously reported β-CD derivative based PRs
displayed limited solubility in saline solutions at concentrations necessary for practical clinical
translation, we sought to improve PR solubility by developing a library of PRs from mixtures of
β-CD derivatives with 4-sulfobutylether-β-cyclodextrin (SBE-β-CD). SBE-β-CD has been widely
utilized to improve the toxicity profile and water solubility of a variety of molecules in drug
formulations.24, 25
In addition, cholesterol has been incorporated into the PR design for a variety of reasons.
First, cholesterol is a biocompatible organic compound which the body produces indogenously, is
non-toxic, and has predictable and well-known metabolic pathways. This is in contrast to TNB
endcaps of the previously chapter which are potentially toxic foreign compounds. In addition, it
was hypothesized that utilizing cholesterol as an endcap may provide beneficial improvements in
uptake, targeting, and/or pharmacokinetics. Cholesterol mediated association with cell
membranes, which are rich in cholesterol, may drive adsorptive endocytosis. Serum protein
components known to circulate for extended periods, including serum albumins and low density
lipoproteins (LDL), have been shown to carry large amounts of cholesterol. Association with
these proteins may promote extended residence time in the body. Finally, cholesterol mediated
association with LDL could help with PR uptake, through LDL surface receptors, and trafficking
to the LE/LY, the ultimate destination of this pathway.
To understand the effect of macrocycle substituents on therapeutic efficacy, we used PRs
synthesized from mixtures of SBE-β-CD and HP-β-CD derivatives. Solubility studies with these
compounds demonstrate that PR water solubility can be significantly improved by incorporation
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of SBE-β-CD. It is also shown that PRs of a mixed β-CD threading population are therapeutically
active in an in vitro model of Niemann-Pick Type C disease.

3.1.2. Pendant Polymer Systems as NPC Therapeutics
Thompson and coworkers have previously published work describing the use of pendant
polymer systems to deliver pDNA and siRNA.26,

27

In these systems, a polymeric backbone

consisting of PEG-poly(vinyl alcohol) (PVA), is modified with acetal-linked pendants. These
backbone grafted pendants included adamantane (Ad), noradamantane (NAd), cyclohexane
(Cyc), and octane (Oct) modifications. These pendants exhibit variable affinity for CD cavities
and would, therefore, be expected to release CD at different rates. It has been shown that, as gene
delivery vectors, these materials form complexes of varying stability and deliver gene cargo in an
efficient and non-toxic manner. Re-purposing these systems as a CD-carrying therapeutic for
NPC disease may be attractive if they can effectively achieve cellular uptake and cholesterol
mobilization.
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Figure 3.1: Pendant Polymer and Cyclodextrin Derivative Structures.

In addition to the PVA-containing systems, pendant polymers were synthesized using
Hyaluronic acid (HA) as a backbone. HA is a natural glycosaminoglycan that makes up a large
portion of the extracellular matrix. It is often used in nanoparticle formulations because it is water
soluble, modifiable, and provides active receptor mediated endocytosis through CD44.28 These
features of increased solubility and targeted delivery make this system very attractive as an NPC
therapeutic. The scaffold is also biodegradable, as the body is well versed in the natural
breakdown of HA. Covalent modification with adamantane pendants would allow for HA to
become an effective carrier of a number of CD derivatives after non-covalent complexation. The
opportunity exists that utilizing a targeted approach would provide a boost in cholesterol
mobilization performance.
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3.2. Results and Discussion

3.2.1. Mixed β-CD Polyrotaxane Solubility and Cholesterol Mobilization
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Figure 3.2: General Representation of Polyrotaxane with Mixed Threading. Values of X and Y
Vary With β-CD Derivative Feed Ratio.
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The long-term goal of this work was to generate HP-β-CD PRs of sufficient water
solubilities to enable Niemann Pick Type C therapeutic studies. We anticipated that the negative
charges introduced by the SBE-β-CD units in the PR complexes would reduce their aggregation
and improve their water solubility (Figure 3.2). To test this assumption, the samples obtained
from HP-β-CD/SBE-β-CD mixtures were dissolved at 50 mg/mL in nanopure water and the
appearance of the solutions was monitored (Figure 3.3). Our findings show that increasing the
amount of SBE-β-CD in the PR structure leads to a significant improvement in their water
solubility, particularly for the samples with SBE-β-CD molar ratios of ≥ 25%. It is well known
that CD-based PRs are generally insoluble in water due to the aggregation of their rod-like
structures.29, 30 The incorporation of SBE-β-CD, a highly negatively charged material, leads to
weaker intermolecular interactions and improved water solubilities of the mixed PR products.
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Figure 3.3: Increased Solubility of Mixed Polyrotaxanes. Screening by Yawo Mondjinou.

Given that incorporation of SBE-β-CD is able to increase the solubility of PR constructs,
we sought to determine whether PRs of mixed threading were therapeutically active in an in vitro
model of Niemann-Pick type C disease. PRs carrying an increasing percentage of SBE-β-CD
were administered to Niemann-Pick C1 (NPC1) deficient fibroblasts to examine their ability to
mobilize cholesterol from sites of aberrant accumulation. Each PR family member, generated
with a 0%, 30%, 50%, 60%, or 100% SBE-β-CD feed ratio, was administered at 25 µM total βCD concentration and compared to administration of 25 µM SBE-β-CD or HP-β-CD monomers
alone. Comparisons were made at equivalent β-CD concentrations meaning that, because each PR
carries greater than 10 copies of β-CD, PR compounds were administered at molar concentrations
over an order of magnitude lower than for β-CD monomers.
Probing cholesterol mobilization 6 h after treatment revealed that these PR family
members perform roughly equivalently to their respective monomers in cholesterol mobilization
assays (Figure 3.4). Both HP-β-CD and SBE-β-CD decreased the average Filipin staining in
npc1-/- fibroblasts to approximately 75% of the untreated control in 6 hours. PRs carrying 100%
HP-β-CD and 100% SBE-β-CD performed equivalently, each decreasing Filipin staining to
~78% of control. PRs carrying 30:70 SBE-β-CD:HP-β-CD decreased fluorescence more
significantly to ~65% of the untreated group. PRs carrying a 50:50 and 60:40 SBE-β-CD:HP-β-
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CD performed slightly worse than controls, decreasing fluorescence to 86% and 83%,
respectively. A broader screen of PR concentrations would be necessary to determine if an
incorporation of low amounts of charged CD, e.g. 30%, truly enables PRs to mobilize cholesterol
more effectively than PRs with a greater percentage of SBE-β-CD. DMSO control experiments
showed no effect of DMSO treatment on Filipin staining. These experiments show that PRs
generated from mixed threading reactions retain therapeutic activity in vitro.

Control

HP-β-CD

30% SBE-β-CD

50% SBE-β-CD

SBE-β-CD

100% HP-β-CD

60% SBE-β-CD

100% SBE-β-CD

FIlipin Stained Area (% Control)!

1!

0.8!

0.6!

0.4!

0.2!

0!
Control!

HP-β-CD! SBE-β-CD! 100% HP!

30% SBE!

50% SBE!

60% SBE! 100% SBE!

Figure 3.4: Therapeutic Efficacy in npc1-/- Fibroblasts of Mixed Threading Polyrotaxanes
Carrying Varying Percentages of SBE-β-CD.

3.2.2. Cholesterol Mobilization by β-CD Carrying Pendant Polymers
PVA:HP-β-CD screens focused on differences in activity as a function of binding affinity
of the pendant group. Monomeric HP-β-CD control decreased Filipin staining by approximately
40%. This was identical to the reduction mediated by PVA grafted with Cyc and Oct pendants
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with weaker binding affinity for β-CD. Pendants with stronger binding affinity, such as Ad and
NAd, performed less effectively than the positive control, with reductions of approximately 20%
and 30%, respectively (Figure 3.5). Results seemed to map with binding affinity, possibly due to
delayed loss of CD from pendent groups with higher affinity. Insolubility and concerns about the
potential for bioaccumulation led us to abandon these compounds from further consideration. A
statistically significant number of biological replicates would be necessary to begin to draw firm
conclusions. The screens did, however, validate the pendant polymer system as a potential β-CD
delivery scaffold and led toward the probing of the water soluble and biodegradable HA
materials.

Control

Control

HP-β-CD

PVA-Ad:
HP-β-CD

PVA-NAd:
HP-β-CD

PVA-Cyc:
HP-β-CD

PVA-Oct:
HP-β-CD

HP-β-CD PVA-Ad: PVA-NAd: PVA-Cyc: PVA-Oct:
HP-β-CD HP-β-CD HP-β-CD HP-β-CD

Figure 3.5: Cholesterol Mobilization by HP-β-CD Carrying Pendant Polymers.
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In the HA-pendant polymer studies, incubation with free HA caused little change in the
Filipin staining profile of the fibroblasts (Figure 3.6). Monomeric β-CD caused a modest, but
typical, reduction in Filipin staining to about 82% of control. This reduction was increased to
about 70% of control upon non-covalent association of the CD to the HA-Ad. This may be due to
an increase in uptake and cholesterol mobilization of the CD by receptor mediated endocytosis,

!

!

79

although this has not ben confirmed. Conversely, while the β-CD therapeutic effect appeared to
be boosted from complexation with HA-Ad, the other two CD derivatives showed no noticeable
increase in efficacy. HP-β-CD and HA:HP complex performed similarly in cholesterol removal.
The same can be said for SBE-β-CD and HA:SBE-β-CD. In other words, treatment with
complexes of these CD derivatives does not perform any better than treatment with the monomer.
Complexes perform equivalently at equivalent concentrations, but the hypothesized boost in
performance from increased uptake was not seen. It is possible that the alcohol modifications are
interfering with effective complexation of HP-β-CD and SBE-β-CD. It remains to be seen
whether smaller, less strongly binding pendants would mediate a boost in performance similar to
that seen in the PVA materials.

Control
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1"
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Figure 3.6: Therapeutic Activity of Hyaluronic Acid:β-CD Pendant Polymers in NPC1
Fibroblasts.
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3.3. Conclusions
Interestingly, the water solubilities of the PRs were significantly improved due to the

presence of SBE-β-CD units in the PR product. Varying the ratio of SBE-β-CD carried by PR
family members, however, does not greatly affect their therapeutic activity in NPC disease. The
ability to achieve saline solubility, while retaining the ability to mobilize abnormally stored
cholesterol, make this generation of mixed threading PRs more therapeutically attractive that
those reported in Chapter 2. This removes the need for the use of DMSO in solubilization and has
the potential to increase the effective PR concentration that can be administered per injection. The
use of SBE-β-CD co-threading enhances the potential for PRs to become an easily administered
delivery vehicle to make β-CD derivatives more attractive NPC therapeutics.
In addition, proof of principle has been demonstrated in the use of pendant polymer
systems as NPC therapeutic vehicles. When using unmodified β-CD, pendant polymers
outperform their monomeric counterparts at equivalent concentrations. This is not the case when
CDs are modified. Interestingly, weakly binding pendants may mediate better performance than
the tightly binding Ad. It remains to be seen if the performance lost by CD modification can be
regained through the use of weaker binding guests. It is also unclear if the additional efficacy
exhibited by unmodified β-CD when in complex with HA is due to receptor mediated uptake.
These findings need more focused investigation with endocytosis inhibitors and flow cytometery
analysis of PR uptake. Despite the need for further investigation, pendant polymers have been
shown to be viable β-CD carriers in vitro.
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3.4. Materials and Methods

3.4.1. Materials
Pluronic® triblock copolymer L81 (PEG 6, PPG 43) was purchased from Sigma-Aldrich
and dried by azeotropic distillation from benzene under vacuum before use. β-Cyclodextrin and
2- hydroxypropyl-β-cyclodextrin (HP-β-CD, 0.8 molar substitution) were also purchased from
Sigma-Aldrich and were used as received. Sulfobutylether-β-cyclodextrin (SBE-β-CD or
Captisol®) was generously supplied by Cydex Pharmaceuticals with an average degree of SBE
substitution of 6.0-7.1 and was also used without further purification. Ultra-pure water (resistivity
≈ 18.0 MW/cm-1) was generated from a NANOpure Ultrapure water system.
NPC1 primary fibroblasts were obtained from Coriell Cell Repository (GM18453). Cells
were cultured in Eagles minimum essential medium (Sigma) with 15% fetal bovine serum and
5% Penicillin/Streptomycin. Cells were plated on 8-chamber Falcon culture slides (Fischer
Scientific) for analysis. Filipin complex was purchased from Sigma-Aldrich. Prolong Gold was
purchased from Life Technologies.

3.4.2. Mixed Polyrotaxanes Study Methods
Yawo Mondjinou synthesized mixed threading PRs. Cells were plated at 6,000 cells/well
and allowed to adhere for 36 h before incubation with an equivalent dose of 25 µM β-CD
regardless of whether it was free, in the control groups, or rotaxanated, in the PR groups. PRs
with 0% and 30% SBE-β-CD were first solubilized in DMSO before dilution to 25 µM CD. Final
DMSO concentration was ≤0.001% (v/v). After 6 h incubation, cells were washed 4 times with
500 µL PBS and fixed with 4% paraformaldehyde for 45 minutes. Cells were then stained with
150 µL of freshly prepared Filipin (50 µg/mL) for 45 minutes. Stained cells were washed 4 times
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with 500 µL PBS before addition of Prolong Gold antifade reagent and mounting. Fluorescent
imaging was done on a Nikon 90i microscope with a DAPI filter set. Results were plotted as an
average Filipin stained area per cell as a percent of the untreated control group. Reported values
are the average of 3 separate experiments ± SEM.

3.4.3. Pendant Polymers Study Methods
NPC1 primary fibroblasts were obtained from Corriell Cell Repository (GM18453). Cells
were cultured in Eagle’s minimum essential medium with 15% fetal bovine serum and 5%
Penicllin/Streptomycin. Filipin was from Sigma-Aldrich. Hyaluronic acid (357 kDa) was
obtained from Sigma before modification with adamantylamine by Aditya Kulkarni through EDC
coupling.
PVA pendant polymer materials were synthesized as described previously.26 Stock
solutions of HA and PVA pendant polymers were dissolved in PBS or 10% DMSO/PBS,
respectively. Stock β-CD, HP-β-CD, and SBE-β-CD solutions were prepared in PBS and mixed
such that the pendant: β-CD derivative ratio was 1:1. Each solution was diluted to 1 mL and
allowed to incubate for 1 h at RT to allow β-CD inclusion. Finally, each pendant polymer: β-CD
complex was diluted to 25 µM β-CD in media before addition to cell culture. Treatments and
controls were all done in triplicate for the HA-Ad materials.
Cells were plated at 6,000 cells/well and allowed to adhere for 36 h before incubation
with a 25 µM β-CD equivalent treatment. After the specified amount of time, cells were washed 4
times with PBS and fixed with 4% paraformaldehyde for 45 minutes. Finally, the cells were
stained with 50 µg/mL Filipin for 45 minutes. Fluorescent imaging was performed using a Nikon
90i microscope with a DAPI filter set. Results were plotted as an average Filipin stained area per
cell as a percent of the untreated control group.
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CHAPTER FOUR: NANOMATERIALS FOR IN VIVO USE

4.1. Introduction

4.1.1. Nanomaterials and Pharmaceuticals
Since the inception of the field, there has been great excitement and effort to exploit the
potential impacts of nanomaterials (NMs) in the fields of health and medicine. An immense
amount of research has been conducted into the use of NMs for a broad range of applications.
There are aspirations for NM translation into drug delivery applications, medical imaging, disease
diagnostics, and vaccine administration. There exists in the fields of nanomaterials and
nanomedicine the potential to revolutionize the way we diagnose and treat human disease.
A main driver of interest in NMs in medical fields is their ability to encapsulate and
otherwise alter the way traditional small molecule therapeutics behave within the body. Typically,
upon entrance into the biological milieu, hydrophilic small molecule drugs will be easily filtered
from the blood and/or metabolized because of their small size. This limits the applicability of
these molecules because of their shortened residence time and bioavailability. Hydrophobic
drugs, on the other hand, have the tendency to associate with serum proteins and circulate for
longer periods in blood. However, these drugs are easily captured and degraded by the
mononuclear phagocyte system (MPS) before being excreted by the body through bile or urine.1
This necessitates delivery of a correspondingly larger drug dose to exhibit the desired clinical
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effect. Increasing the administered dose of a drug increases the risk of off-site toxicity and
adverse side effects, as small molecule drugs often permeate the body non-specifically.
Lipinski’s rule of five is generally used as a rule of thumb when considering the clinical
potential of drug leads. By providing a simple set of guidelines to summarize the chemical
characteristics most likely to generate a favorable pharmacokinetic profile and survive oral
administration, drug candidates that adhere to these characteristics are more likely to achieve
clinical translation and market acceptance.2, 3!Drug leads with unfavorable chemical signatures
often go unpursued regardless of effective in vitro performance. Given that the odds of a drug
candidate identified by high-throughput screening (HTS) ultimately leading to clinical use are 1
in 100,00. The ability to alter the pharmacokinetic profile of a drug candidate would mean that a
greater number of HTS hits could be pursued and potentially reach therapeutic use.4 On top of
this, having this ability would give new life to previously shelved candidate compounds.
NMs potential comes from their ability to alter the physiochemical properties of their
cargo. Drugs that are too hydrophobic could be made more soluble by encapsulation or
attachment to nanoparticle (NP) platforms. This would make them much easier to administer and
increase drug concentrations at the delivery site. Additionally, packaging of a drug into a NP
formulation has the ability to prevent rapid clearance from the body, through renal or hepatic
filtration, and to protect them from destruction through metabolism. This will greatly increase the
bioavailability of the drug, improving circulation and mean residence times, and making them
efficacious at lower doses. Treatment costs and off-target side effects could also be reduced.5 In
addition to controlling side effects by lowering necessary dosages, NPs would likely not freely
diffuse through the tissues of the body, limiting the build up of drug at off-target sites by
improving tissue specificity.6 While not a definite solution to the problems of rapid clearance,
off-site accumulation and toxic side effects (there is certainly concern about the toxicity of the
NMs themselves), the potential to positively impact these areas is real. In fact, in 2006, more than
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250 nanotechnology products were in the pharmaceutical pipeline, with some already being used
in the clinic.5, 7
Along with a diverse set of potential applications is an even more diverse set of materials
from which NMs can be generated. These include (in a non-exhaustive list) carbon based
materials like nanotubes (CNTs) and fullerenes, lipid based materials including micelles,
liposomes and solid lipid nanoparticles (SLNPs), polymeric NMs like polymerosomes,
filomicelles and dendrimers, and metal containing NMs including gold nanoparticles (AuNPs),
quantum dots (QDs) and iron oxide containing NPs (Figure 4.1). Each of these materials would
have a specific set of physicochemical properties depending on their composition, size, shape,
and surface properties resulting in a unique physiochemical signature overall. The variety of NMs
that could theoretically be generated is vast. There are a number of considerations that must be
addressed when designing a NM platform for clinical translation- each potentially affected by
these physiochemical differences.
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Figure 4.1: Nanomaterials Can Be Made From a Wide Range of Components. Selected Examples
Include A) Dendrimers,8 B) Carbon Nanotubes,8 C) Polymer Micelles, D) Quantum Dots, E)
Gold Nanoparticles, and F) Lipid-Based Liposomes and Micelles.
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4.1.2. Preclinical Profiling of Nanomaterials
A full pre-clinical profile of a potential NM is necessary to understand the materials

biological interactions within the body, design the most appropriate material for the application,
and give the best possible awareness of potential toxicities. This begins with an understanding of
the pharmacokinetic profile, including circulation time, biodistribution, and clearance. Secondly,
it is important to study interactions of NMs with blood components, including the potentially
deadly effects they can have on red blood cells (RBCs) and platelets. Finally, interactions of NMs
with the immune system, including phagocytic uptake, complement activation, and antigenicity
will contribute in large part to material performance and toxicity. Knowledge of the systems
performance in each of these areas is advantageous to exclude potentially toxic materials from the
pipeline and build the most appropriate NM system for the application to give it the best chance
for clinical success (Figure 4.2).
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Figure 4.2: Pre-clinical Profiling of Nanomaterials Can Help Identify Appropriate Systems for the
Intended Application and Avoid Unnecessary Toxicities.
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When designing systems for a biomedical application, it must be understood that all of

the above factors will be variously affected by the physiochemical properties of the nano-scale
material under investigation. The size, shape, surface chemistry, charge, and degradability of the
NM will all play a role in how it circulates, deposits, clears, interacts with serum proteins, and
mediates toxic side effects. Because the large composition space available to NM designers, these
properties can vary greatly such that screening must be done in vitro and in vivo on a case-bycase basis. Ideally, NM systems could be rationally designed based on the known performance
trends of similar materials, however, this desire is not yet reality due to an absence of
understanding of NM structure-property relationships. The existing data is often fragmentary
because of the sporadic profiling of variable NM systems. Knowledge of overall trends
explaining how NP physical parameters affect the various aspects of in vivo performance is
therefore far from complete. What follows is a review of the known trends in how NP
physicochemical relationships affect pharmacokinetics, biodistribution, toxicity, and protein
adsorption.

4.2. Overview of Protein Adsorption

!
4.2.1. Introduction
It has recently been understood that protein coronas form around NMs immediately upon
exposure to serum and are relatively stable over time.9, 10 As materials circulate, quickly binding
proteins will be quickly replaced by those that bind more tightly. Surrounding this first layer of
strongly adsorbed proteins, called the “hard corona”, is a softer layer of proteins held in place by
hydrophobic or ionic interactions. This layer is variable and constantly in flux (Figure 4.3).
Different architectures have been shown to more effectively recruit surface proteins of specific
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identities, including serum albumins, immunoglobulins, and complement proteins, or to recruit
them in varying abundances.11-14 The relative quantities of adsorbed proteins do not often
correlate with abundances in plasma.12

Blood

Bare
Nanomaterial
Injection

Vascular Wall

Rapid Corona Formation

Replacement by Tightly Binding Hard Corona

Soft Corona Constantly in Flux

Time

Figure 4.3: Upon Injection, Nanomaterials Will Rapidly Accumulate a Serum Protein Corona.
The Identities of the Proteins in this Layer Will Principally Affect the In Vivo Performance of the
System.
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It is no longer sufficient to consider only the surface chemistries of a NM system when
drawing conclusions about in vivo system performance. Because interaction with the body
(including immune cells, serum proteins, epithelial barriers, cell membranes and organs) is
mediated not only by the NM surface, but also by the collection of adsorbed proteins, the true
functional unit of the system is the NM:Protein Corona complex. The composition of these
coronas has the potential to influence pharmacokinetics to either reduce or extend circulation
time, if NMs recruit opsonins or dysopsonins, respectively. Clearance will be affected if NMs
recruit proteins of the immune system. Toxicity can be brought about by recruitment of proteins
that would promote complement activation or hemolysis. Finally, biodistribution can be dictated
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by adsorption of lipoproteins, transferrin or other proteins with cell receptors.14 NM protein
corona is emerging as a major determinant of how nanomaterials behave in the body.15

4.2.2. Trends in Protein Abundance
Protein adsorption onto a NM surface has been shown to depend in large part on surface
charge and hydrophobicity.16, 17 A study comparing liposomes with neutral lipids found that those
materials with C16 chain lipids picked up more proteins those composed of their C14
counterparts.18 In addition, protein adsorption onto charged or hydrophobic NM surfaces is rapid,
while neutral or hydrophilic surfaces display slower opsonization.19 Comparison of poly (ethylene
glycol) (PEG)-poly (lactic-co-glycolic acid) (PLGA), PEG-poly (lactic acid) (PLA), and PEGpoly (caprolactone) (PCL) NPs (with similar PEG grafting densities) showed differences in the
relative amounts of protein adsorption with increasing core hydrophobicity,20 showing that even
effective PEG shielding cannot completely mitigate hydrophobic effects.
Strongly charged NMs, either positive or negative, will pick up proteins more strongly
than neutral particles of the same composition.1 One study found that positively charged particles
picked up a lower abundance of proteins than negatively charged particles.21 Another study from
the same group showed the opposite trend.16 Both studies used polystyrene particles, identical
incubation conditions, and detection by 2D gel electrophoresis. In this case, varying particle size
may be the explanation for differential adsorption with larger particles picking up a greater
quantity of adsorbed proteins regardless of charge.
A similar result was found when specifically comparing the surface adsorption of
particles of varying sizes. Smaller particles were found to adsorb a smaller quantity of serum
protein than were larger particles. In addition, a greater percentage of PEG coverage led to a
steady decrease in adsorption.22 This suggests that particles can be expected to pick up proteins in
proportion to their available surface area.
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4.2.3. Trends In Protein Identity
Beyond affecting the total amount of protein bound, particle size can also affect the

identities of the proteins binding in highest abundance. SiNPs of varying sizes (12 nm – 71 nm)
recruit vastly different abundances of similar proteins as shown by Tezner et al. The smallest
particles (12 nm) picked up apolipoprotein (Apo) C-III, ApoF, C4b, and Vitamin K-dependent
protein S as well as others in more than 5 fold greater quantities relative to 71 nm particles. In
contrast, 71 nm particles adsorbed prothrombin, Complement factor H-related protein 1, and
gelosin in an enhanced abundance.12 These proteins represent a variety of processes including
complement pathways, coagulation pathways, lipoprotein dysopsonins, and cellular components
that could lead to differing biological affects for the various particles.
Particle composition and architecture can also affect corona identities. Protein binding is
different for SWCNT and DWCNT as evidenced by their differential activation of immune
system complement pathways.23 Monopoli et al. found similar results when comparing 200 nm
particles composed of either Si or polystyrene (PS).14 Incubating each particle with 55% serum
revealed that the particles shared only 9 of their 15 most abundant proteins, with the differences
including each particle’s two most abundant proteins. SiNPs picked up ApoA-I and histidine-rich
glycoprotein in greatest abundance while PS NPs favored fibrinogen α- and β-chains.
PEG grafting density can also play a role in altering the adsorbed protein composition.
Walkey et al. used AuNPs with varying PEG grafting densities (from 0 to 1.12 PEG/nm2) to
confirm that, as expected, increasing PEG density would correspondingly decrease the total
protein adsorbed.24 Interestingly, they also found changes in the protein corona identity and
composition. This included a substantial decrease in complement C3 from 30% to 5% w/w of
total protein and an increase in kininogen from <2% to >13% when comparing naked AuNPs to
the most PEGylated AuNP.24 PEG grafting may preferentially shield certain proteins, possibly
dependent on binding efficiency to the NM core material.
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4.3. Nanomaterial Pharmacokinetics

!
4.3.1. Circulation Time
The circulation time of a NM refers to the time spent actually in contact with blood flow
within the body. This includes the time from injection until removal of the material from the
blood stream by phagocytic uptake, excretion from the body, or deposition in a particular organ.
This is important for therapeutic applications of NMs because it is a large contributing factor to
the bioavailability and toxicity of a therapeutic agent. One attractive aspect of the use of NPs over
traditional drug candidates is the ability to extend a drug’s circulation time by preventing rapid
removal from the blood by excretion or degradation. This keeps the drug in the body, increasing
its bioavailability and, therefore, the potential for the drug to end up at the target site of action.5
Conversely, an increased circulation time for a nanoparticulate formulation translates into a
corresponding increase in the blood contact time. This extends the interaction with blood
components, including blood cells and serum proteins, and increases the chances of triggering
blood-related toxicities. Blood circulation is a main indicator of just how much the performance
of an encapsulated drug is altered by NM encapsulation.
A material’s circulation time is governed by a number of factors. A primary mechanism
of NP removal from the blood are sieving of the material by excretory organs including the
spleen, liver, and kidney.25 Depending on the size, surface chemistry, and other physical
properties of the carrier, they may be removed from circulation through splenic, hepatic, or renal
pathways as blood flows through these organs. Second, systems can be cleared from circulation
by penetration into other organs of the body. This can include, but is not limited to, lymph nodes,
lungs, heart or brain tissue. Penetration into these organs will depend on what physiological
barriers the materials are able or unable to penetrate. Finally, foreign substances are actively
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pursued by phagocytic cells of the immune system and removed for degradation. Materials in
blood can interact with serum proteins called opsonins, including immunoglobulins and
complement proteins, which mark them for removal by professional phagocytes in the blood,
such as monocytes, or as they pass through tissue, such as Kupffer cells in the liver or dendritic
cells in the lymph nodes.5 A combination of these and other factors will dictate whole blood
circulation time of a given NP system.

4.3.2. Trends In Circulation Time
The first, and most extensively studied among these characteristics is the overall
hydrodynamic size of the system in question. NMs will be subject to size based sieving dictated
by the biological filtration capacity of a given organ. Very small particles will be quickly filtered
through the kidney in a manner similar to hydrophilic small molecules. Using quantum dots, Choi
et al. have shown that this cut-off is ~5.5 nm.26 NMs below this size will generally be lost through
the urine, while materials with a greater diameter will be retained. Additionally, NMs must be
small enough to avoid being filtered by the spleen and liver. Generally, the spleen contains
filamentous filtration with a spacing of roughly 300-500 nm and the liver contains fenestrae and
phagocyte-lined sieve plates with ~150-200 nm spacing.27, 28!In comparing liposomes of two
sizes, ~60 nm and ~220 nm, Moghimi, et al. found that the larger materials were cleared from
blood circulation more quickly.29 The difference can be seen in materials when simply changing
the chain lengths of surface grafted NM coatings. For instance, increasing the molecular weights
of PEG used to coat quantum dots from 750 Da to 5 kDa increases the circulation time from ~1
minute to hours.30
Additionally, particle shape and, in particular, aspect ratio (AR), has been shown to
influence circulation time. Filamentous, rigid-rod micelles circulate in blood for greatly extended
periods when compared to their spherical counterparts. Non-degradable versions of these
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filomicelles were shown to circulate up to one week after injection (Figure 4.4).31 This greatly
outlasted spherical micelles of the same composition, which persisted on the timescale of hours or
days. 31, 32 Increased evidence for this was recently shown by Shuckla et al. using Tobacco
Mosaic Virus (TMV) composed soft-matter rods with ARs varying from 3.5 to 16.5. In this study,
the particles with the lowest AR reached maximum tissue accumulation and left circulation three
times faster than the particles with the largest AR.33 It has been proposed that this is a result of
slowed uptake kinetics by macrophages due to high AR. Blood flow alignment and shortened
contact time also decrease the rate and efficiency of phagocytosis. Phagocytosis will be discussed
more extensively in Section 4.4.2.

A

B

Figure 4.4: Nanomaterial Shape Can Affect Circulation Time. A) Rod-Like Polymer Micelles
Circulate For a Greatly Extended Period When Compared to Spherical Stealth Vesicles. B)
Longer, Higher Aspect Ratio Micelles Circulate Longer Than Their Shorter Counterparts.31
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Particle surface charge and chemistry has also been shown to affect removal of NMs
from the blood, even when keeping the composition, flexibility and size of the systems as
constant as possible. Changing the surface charge on poly (amidoamine) (PAMAM) dendrimers
from cationic to anionic significantly increased the circulation time of the materials in rats. Only
2% of the cationic dendrimer injected dose was recovered from blood at 1 h, while 20-40% of the
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injected dose was recovered for the anionic counterpart.34 Additionally, the rate of blood
clearance of negatively charged liposomes was much quicker than PEGylated neutral
liposomes.35 This result is probably reflecting a combination of surface charge neutralization and
surface shielding mediated by PEG grafting.
PEGylation has become a common strategy for increasing the circulation time of a given
NM system. It is thought that this is brought about by slowing the adsorption rate of serum
proteins onto the NM surface through shielding effects. In an illustrative study by Panagi et al.,
naked PLGA NPs were rapidly sequestered by liver macrophages, with a blood T1/2 of less than a
minute, while their PEGylated counterparts exhibited half-lives on the order of 7 h.36 In
comparing liposomes, PEGylation was shown to increase the area under the curve (AUC) by sixfold relative to plain liposomes and 36-fold relative to free drug.37 PEG grafting has been so
widely employed on a large variety of NM platforms that it has become a standard “stealthing”
for extending circulation time.

4.3.3. Biodistribution and Clearance
Biodistribution is the family of organs into which a NM platform deposits after clearing
the blood. These are the areas of the body which will be most exposed to both the components of
the NM and the cargo it contains. Being aware of the distribution patterns for a particular material
is essential for screening the toxicological properties a system will display in a given application.
Ideally, a NM system will distribute preferentially into organs or areas of interest for a given
therapeutic application. An unfavorable biodistribution will result in large percentages of the
injected dose depositing in locations other than the desired active sites and, therefore, being less
efficacious.
Knowledge of the NM biodistribution allows for anticipation of potential organ-specific
toxicities, as the areas of the body with the highest concentration of deposited material are the
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most likely to experience toxic side effects. While NM systems are theoretically capable of taking
up residence in any number of organs with any pattern of distribution, there are organs more
commonly implicated in NM uptake because of their roles in blood filtering (e.g., the MPS).25
Finally, understanding the kinetics and routes NMs use while exiting the body allows for
determination of total residence time within the body (e.g., as hepatic clearance often takes much
longer than renal filtration), and will determine whether material retention is likely to cause toxic
side effects. Materials that bio-accumulate in the body are much more likely to do organ damage
than those that are lost through standard clearance pathways.

!

Figure 4.5: Upon Injection Into the Blood Stream, Nanomaterials are Transported Through the
Heart and Lungs Before Distribution Into the Other Organs.25

Upon venous injection into the blood stream, NMs will be carried with blood flow
through the heart before continuing out into the rest of the body.25 Accumulation in heart tissue is
usually highly undesirable as cardiac side effects can be quickly fatal. NMs are next carried
through the lungs as blood becomes oxygenated. Passage through the lung requires navigation of
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microcapillary beds that can be as narrow as 2 µm in diameter.38 From there, blood flow, and the
NM systems they carry, branches out in varying percentages to supply the other tissues of the
body (Figure 4.5). It is typically desirable for NMs to localize into specific target organs in order
to localize treatment of the disorder. 25 In this case, materials and physical properties for a system
must be selected to exploit a tissue’s innate physical properties such that a satisfactory
concentration of therapeutic can be achieved.
For conditions of the central nervous system (CNS), selective targeting will involve
systems that are capable of transcytosing the strict physical constraints of the blood-brain-barrier
(BBB) and the blood-cerebrospinal fluid (CSF)-barrier. These impediments are comprised of
selective tight junctions that stringently regulate the passage of solutes from whole blood into the
brain. Because these areas have evolved to only allow penetration of important and necessary
small molecules, NM systems often struggle to achieve appreciable brain and CNS
concentrations.39
Kidneys function by filtering unwanted components from the blood into the urine where
they can be excreted. Migration of NMs into the urine necessitates passage of a glycocalyx and a
collagen mesh before passage through a 5-6 nm glomerular filtration membrane.40 For NM
systems with physicochemical properties sufficient to allow glomerular passage, rapid renal
filtration can be expected. Often, attempts are made to prevent this filtration by raising NM
hydrodynamic diameters above this 5-6 nm size cutoff and prolong blood circulation.
While they may be the targets for a NM based therapy themselves, organs known to
either actively or passively scrub the blood of toxins and foreign material more often become
inadvertent hosts to increased dosages of NMs. The liver and spleen both function within the
MPS to actively remove pathogens and foreign materials from the blood. They are both home to
resident macrophages that actively seek opsonin-coated pathogens as the blood passes by these
scavenging cells.25 Splenic sieving is characterized by gaps that can be large, but typically do not
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exceed 500 nm.27 The organ is, therefore, set up to slow the passage of materials of large size and
high AR, making it effective at removing older more rigid RBCs and pathogens. The resident
macrophages of the liver, Kupffer cells, make up 80-90% of the total macrophage population.25
These cells remove foreign materials from whole blood as it enters the liver sinusoids and
attempts to degrade them before biliary excretion. Loss of NMs through this pathway occurs at a
much slower pace (5-10% of the injected dose over 8-48 h) than through renal filtration, often
giving rise to concerns for organ specific toxicities because of extended NM residence.25

4.3.4. Trends in Biodistribution
Similarly to how it affected circulation time, overall hydrodynamic size can also affect
biodistribution. Often, studies testing the structure property relationships of NM size are focused
on tumor uptake applications. In a study of variously sized liposomes containing
phosphatidylcholine, cholesterol, and ganglioside GM1, Liu and coworkers found that liposomes
in the 70-200 nm size regime circulated most extensively and deposited to a greater degree in
tumor tissue. Liposomes of ~400 nm in diameter were shifted toward filtering by, and deposition
in, the spleen (40-50% ID), while liposomes of less than <70 nm led to deposition of 70% ID in
the liver.41 In a study with PPG-PEG polymer based NMs, it was found that particles greater than
250 nm in diameter displayed biodistribution profiles that were characterized by splenic and
hepatic deposition. Interestingly, decreasing the NP size below 150 nm led to a greatly increased
deposition of the materials in the bone marrow.42
Decreasing NM diameters to much smaller size regimes (e.g., <20 nm), has been shown
to facilitate movement across biological barriers that are off limits to larger particles. This
includes enhanced extravasation through blood vessel walls, penetration across the BBB, and
movement through stomach epithelium.6 For instance, AuNPs in the range of 10-50 nm dispersed
into the majority of body tissues in mice at 24 hours. Increasing the NM size to 100-200 nm
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produced restricted deposition to the liver, lung, spleen, and kidneys.43, 44 These increasingly
small sizes can lead to deposition in less common organs and tissues, as well as more rapid
clearance through renal filtration.
The effects of surface charge and PEGylation are again evident when investigating
biodistribution. Upon injection into the blood stream, positively charged particles can induce
aggregation of negatively charged serum proteins. These NP:protein aggregates are increasingly
likely to deposit in lung microcapillaries and induce either transient or long term sequestration.45
Cationic PAMAM dendrimers have been found to accumulate preferentially in the kidney and
liver. Accumulation of these materials was also associated with organ-related toxicities.46, 47
Toxicities can be mitigated by neutralizing charge through PEGylation.48
The deposition of hydrophobic naked poly (cyanoacrylate) NPs occurred preferentially in
the liver and spleen. Upon PEGylation, the biodistribution of these materials was shown to shift
toward a splenic deposition.49 Changing the core unit of cationic dendrimers from PAMAM to
the more hydrophobic monomer polypropylene imine (PPI), led to an increased deposition in the
liver.50 Adding to this, hydrophobic pristine CNTs accumulate primarily in the liver.51 This may
be due to rapid recruitment of opsonins in serum onto exposed hydrophobic surfaces of the CNT
leading to increased MPS recognition. It has been shown that this type of interaction can promote
deposition in the liver.52
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4.3.5. Degradability and Clearance
While NMs with small hydrodynamic diameters are capable of being excreted through

the urine after renal filtration, larger materials must either be degraded by the body to suitable
sizes before renal filtration or excreted through bile and feces. Degradable materials are generally
preferred over non-degradable scaffolds because of the latter’s potential to bio-accumulate and
cause long-term toxicity. These materials are often sequestered by macrophages when they
cannot be metabolized for excretion. Non-degradable PAMAM dendrimers have been shown to
persist in the body with only 15% ID clearing after 48 hours.53 Treatment with pristine, nondegradable SWCNTs led to stable accumulation in the lung, liver, and spleen 90 days after
injection as shown by transmission electron microscopy (TEM) (Figure 4.6). Lack of clearance
coincided with an observable increase in blood lactate dehydrogenase and alanine transaminase—
parameter changes that are indicative of liver specific toxicity over time.54 While it is true that
degradable NMs are preferred, one must be aware of the possibility that these compounds can
yield intermediate degradation products with unexpected toxic side-effects themselves.55

Figure 4.6: Non-Degradable Nanomaterials Can Bioaccumulate for Greatly Extended Periods of
Time. Histopathological Analysis shows SWCNT Accumulation in the Organs of Mice After 90
Days. Arrows Indicate SWCNT Aggregation.54
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4.4. Immune System Interaction

!
4.4.1. Overview
The innate and adaptive arms of the immune system are biological defense pathways
responsible for protecting the body from foreign materials and pathogens (Figure 4.7). Broadly,
these systems function to either rapidly clear antigens (innate immunity) or to generate proteins or
cells that specifically recognize antigens over a much longer term (adaptive immunity),
respectively. Within both pathways, immune responses can be initiated and carried by either
cellular action or protein cascades. Often, these two components will work in tandem, linked and
dependent on one another.56
The innate immune system is the portion of the immune system responsible for the quick
and non-specific removal of pathogens. These systems are general, respond in similar manners to
every potential threat, and confer no specific long-term immunity towards repeat pathogens. Cells
of this immune pathway are largely professional phagocytes (e.g., macrophages, neutrophils and
dendritic cells) that engulf and digest foreign material. These cells exist in blood circulation but
also as organ resident macrophages, including Kupffer cells of the liver and B-cells of the spleen.
Protein-mediated innate immunity begins as relevant proteins, known collectively as opsonins
and including the general antibodies classes Immunoglobulins M and A (IgM and IgA), that
initiate first encounter with potential pathogens in circulation. These proteins will both signal
professional phagocytes that the pathogens they have marked need to be removed and activate
cascades that will lead to protein-mediated membrane rupture.56
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Figure 4.7: The Nonspecific Components of Innate Immunity Act Quickly to Neutralize
Pathogens by Removing Them From Circulation and Destroying Them. Adaptive Immunity
Involves the Generation of Antigen Specific Antibodies for Long Term Resistance.57

!
The adaptive immune system’s main role is to generate long-term immunity to repeat
challenges from recurring pathogens. The main cellular components are dendritic cells (DCs), TCells and B-cells whereas the main protein components are the antigen-specific antibodies,
known as the Immunoglobulin G (IgG) class.58 In the presence of foreign materials, DCs can
become activated to initiate a cascade that leads to the generation of antibodies tailored to singly
recognize particular antigens present on the foreign surface. IgG will be a long-term presence in
the body at low levels even after clearance of the pathogen. In this way, they are ready to quickly
recognize and remove subsequent challenges by target materials.
NMs, representing foreign intruders into the biological milieu, are prime candidates for
immune system recognition and interaction. This interaction can drastically alter a system’s PK,
toxicity, and potential for long term administration. Professional phagocytes will quickly clear a
NM that is readily recognized and marked by opsonins, thereby greatly diminishing the
circulation time for a given system. NMs that elicit activation of protein-mediated complement
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pathways can bring about severe hypersensitivity reactions.58 Toxic side effects such as these will
limit a NMs potential application. Finally, antigenic responses generated toward NM specific
antigens will cause increasingly rapid clearance with each systemic administration and greatly
limit the potential for repeated or long-term material administration.

4.4.2. Trends In Phagocytosis
Uptake by professional phagocytes is one of the better-studied aspects of NM in vivo
performance. Because of this, there are some general trends that can be used when designing
systems for specific purposes. Phagocytes are likely to take up hydrophobic particles more
rapidly than are their hydrophilic counterparts. This results in preferential deposition in the liver
of particles that are not coated with shielding layers.59-61 This is most often addressed by grafting
of hydrophilic neutral polymers onto NP surfaces, most commonly PEG.62 In fact, modification
with PEG-containing poloxamines reduced the phagocytic uptake of hydrophobic solid lipid
nanoparticles (SLNs) to 8-15% of their initial levels.63 A likely explanation is that hydrophobic
surfaces rapidly bind serum proteins that promote phagocytosis. PEGylation blocks this rapid
adsorption and prolongs serum contact before phagocyte recognition.
In addition to hydrophobic particles, macrophages are more likely to take up charged
NMs. In vitro macrophage experiments show that uptake of highly positively charged layer-bylayer poly-L-lysine, chitosan, heparin sulfate NPs was decreased by a factor of three upon PEG
grafting.64 By making a family of cholic acid-PEG micelle NPs ranging from -26.9 mV to
+37.0mV in surface charge, Xiao et al. showed that uptake of particles with surface charges of
+18.5 mV, +29.5 mV and +37.0 mV were 1.9x, 3.5x and 5.9x higher than a neutral control. This
suggests that the higher the positive surface charge, the more efficient the phagocytosis.
Interestingly, negatively charged NPs in this study were taken up by macrophages at levels that
were similar to the neutral control.65
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Finally, size and shape can affect removal of NMs from circulation by phagocytes. Zahr

et al. studied the in vitro macrophage uptake of PEG5k-cyanoacrylate-co-n-hexadecyl
cyanoacrylate of increasing size (80 nm, 171 nm, 243 nm). After incubations of one and two
hours, macrophage uptake increased with greater diameter.22 In addition, it has been argued that
particle shape is more important than size in affecting phagocytosis.66 Rod-like NMs with higher
ARs avoid macrophage uptake more effectively than their spherical counterparts. Discher et al.
showed that rod-like flexible filomicelles align with fluid flow and effectively avoid uptake by
immobilized macrophages (Figure 4.8D,F).31 In flow, they argue, the contact time between
macrophage and NM is shortened. Another study showed that shorter MWCNT were more
effectively taken up by macrophages than longer MWCNT.67 Additionally, time-lapse video
microscopy of the interactions between polystyrene particles of varying shapes and alveolar
macrophages showed less effective internalization for particles of higher AR (Figure 4.8A-C,E).66
The authors argue that phagocytosis is dependent upon local shape at the point of NP contact,
with contact along the broad side of a rod-like NM leading to inefficient actin remodeling and
failed phagocytosis. These experiments were done, however, in the absence of fluid flow. In any
case, a combination of the above factors, decreased contact time with flow alignment, and
inefficient local remodeling, means that high AR particles are likely to evade phagocytic uptake
longer than their more symmetrical counterparts.
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Figure 4.8: Nanomaterial Shape Plays a Role in Phagocytosis. A-C) Stills From Time-Lapse
Images of Phagocytes Engulfing Variously Shaped NMs.66 B) Uptake is Frustrated By Contact
Along the Long Axis.66 D) Immobilized Macrophages are Less Able to Take Up NMs in Flow
Conditions Due to Decreased Contact Time.31 E) Point of Phagocyte Contact Dictates Speed of
NM Uptake Based on Time-Lapse Imaging Analysis.66 F) Uptake of Rod-Like Filomicelles is
Decreased as Rod Lengths Increase.31

4.4.3. Overview of the Complement System
The complement system is a protein mediated immune pathway that functions alongside
cell-based systems (Figure 4.9). Complement activation can proceed through three different
pathways, known as the classical, lectin, and alternative pathways. Activation of classical and
lectin cascades is initiated by antibody binding, IgG/IgM or IgA to the NM surface, while the
alternative pathway is initiated by spontaneous binding of complement component C3b to foreign
surfaces. Both paths lead to either pathogen recognition by professional phagocytes or a
corresponding protein cascade that culminates in a membrane attack complex that attempts to
lyse foreign cells.56 Extensive activation of any complement pathway can lead to hypersensitivity
reactions to a given NM and, in general, should be avoided to limit side effects.58
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Figure 4.9: The Complement System is a Protein-Mediated Immune Response That is Divided
Into Three Distinct Pathways.68

!
4.4.4. Trends in Complement Activation
Size and shape have not yet been shown to be determining factors in NM-mediated
complement activation beyond the fact that NM size and shape affect protein adsorption. Systems
that tend toward increased interaction with serum proteins are, therefore, more likely to interact
with complement proteins and trigger the corresponding pathways.
It has been shown that charge and hydrophobicity can mediate complement activation can
determine which pathways are selectively activated. Polycationic cyclodextrin NPs,69 poly-lysine
polymers, and cationic liposomes all activate complement.70 In a study comparing variously
charged liposomes, Chonn et al. discovered that positively charged liposomes selectively
activated the alternative pathway, while negatively charged particles activated the classical
pathway. Neutral liposomes did not appreciably activate complement.71 This difference must be
explained by selective interaction with specific pathway initiating proteins based on charge. In
contrast, positively charged, negatively charged, and neutral PEG-PLGA particles all activate the
alternative pathway equally. It is clear that more than just surface charge can affect activation,

!

!

109

including surface topology and accessibility.72 In an analogous finding, SWCNT and DWCNT
were both found to activate complement by classical pathways. Only DWCNTs, however, were
found to activate the alternative pathway.23
In changing the surface chemistry of polypropylene sulfide (PPS) NPs, Reddy et al.
found evidence of how differing surface chemistry can change complement activation. PPS NPs
coated with either hydroxyl- or methoxy- terminated Pluronic copolymers both activated the
alternative complement pathway. The particles with hydroxyl- surface chemistry, however,
activated the pathway four times as effectively (Figure 4.10B). The authors propose that free
alcohols are better able to act as nucleophiles to effectively bind C3b, the first protein in the
alternative cascade.73 Likewise, modification of naked CNTs with either ε-caprolactam or Lalanine reduced activation of the classical pathway by 90% and 75%, respectively, potentially due
to lack of available nucleophiles on the surface.74
PEGylation, again, is a well-studied strategy capable of reducing complement activation,
likely due to decreased protein deposition overall.75, 76 Increasing the density of PEG grafting to
modulate conformational changes from the “mushroom” to the “brush” regime reduces
complement activation further (Figure 4.10A).77 Multiple studies have also shown that using
higher molecular weight PEG as a corona, usually 20 kDa, more effectively prevents complement
activation.78, 79 Bertholon et al. have also shown that polysaccharide coatings can have similar
effects in reducing complement activation. Grafting of both dextran and chitosan onto poly
(isobutylcyanoacrylate) NPs reduced complement activation when saccharide coatings were in
the “brush” regime.80 Of interest is the fact that chitosan coatings were more effective than those
comprised of dextran. It is argued that high grafting density left the polysaccharide alcohols
poorly accessible to proteins in solution and prevented activation.
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Figure 4.10: Surface Chemistry Affects Nanomaterial Complement Activation. A) Increased
PEGylation Decreases Activation of Every Complement Pathway.77 B) Methoxy-Coated NMs
Activate the Alternative Pathway to a Lesser Degree than do Polyhydroxylated NMs.73

!
4.4.5. Nanomaterial Immunogenicity
NM antigenicity can be a main factor in determining a system’s ability to be used
extensively in the body for therapeutic applications in treatment of chronic conditions.56 An IgG
response to a NM surface will translate into more rapid clearance and altered biodistribution with
repeat administration, thus limiting the number of times the NM can be applied. Some surfaces
are more likely than others to elicit memory immune responses; the goal of the therapeutic
application should be taken into consideration. Vaccine technology, for instance, could exploit
such surfaces for more powerful immune response. In some cases, NMs can function as adjuvants
and help initiate immune response and reinforce lasting immunities.58 Beyond this, most NM
systems would do well to avoid IgG generation. This section will cover immune recognition and
antibody generation as it factors into a NM’s PK, BD, and wider potential applications. In this
area, there have not been extensive and rational screens to determine broad trends in anti-NM
generation. More work needs to be done, but current information is summarized below.
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4.4.6. Trends in Immunogenicity
Increased hydrophobicity or charge does not seem to increase generation of NM specific

antibodies, despite increasing interaction with serum proteins. Upon administration of dendrimers
with cores of differing hydrophobicities, neither PAMAM- or PPI- based systems elicited specific
antibody production.46, 81 In addition, in looking at accelerated blood clearance (ABC) as an
indication of antibody recognition, Wang et al. saw no difference in the clearance rates of
subsequent liposome doses after pretreatment with positive, negative, or neutral liposomes.82
While one study detected antibody production upon challenge with hydrophobic fullerenes,83
other studies have failed to generate the same response.84 Finally, no antibody response was
found upon treatment of AuNPs.85
Although a common strategy for extending NM circulation times, PEGylation can illicit
IgG responses. It has been shown that anti-PEG IgG and IgM can be generated after
immunization of mice with varying lengths of methoxy-PEG.86 PEGylation contributes to the
ABC of PEGylated PLA NPs87, liposomes88, and micelles89. In a comparison of PEG with other
hydrophilic masking polymers, Ishihara et al. found that PEGylation led to ABC of micelles,
while polyvinylpyrrolidone grafting did not.90 Kaminskas et al. studied whether size of the
PEGylated particle would affect ABC of subsequent NM doses. They found that pre-treatment of
mice with PEGylated liposomes led to ABC of subsequent injections of either PEG-liposomes or
PEG-micelles (Figure 4.11). The inverse was not true. Pre-treatment with PEG-micelle did not
accelerate the clearance of a subsequent challenge of either liposomes or micelles.89 This suggests
that the PEG-micelle’s smaller size was less effective in generating an antibody response.
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Figure 4.11: Size May Effect Nanomaterial Immunogenicity. A) Pretreatment of Rats with
PEGylated Liposomes (Filled Circles) Leads to Accelerated Blood Clearance of a Second Dose
of Liposome (Open Circles). B) Pretreatment of Rats with PEGylated Micelles (Filled Triangles)
Does Not Affect the Circulation Time of a Subsequent Micelle Dose (Open Triangles).89

4.5. Blood Compatibility
A final set of information is generally necessary for an initial preclinical understanding of
a NPs course. These aspects relate to toxicities affecting blood cells. Blood is the biological fluid
responsible for carrying nutrients and oxygen throughout the body and transporting waste
products for removal. It is also home to a vast number of soluble proteins and components of the
immune system.25 Whole blood is ~45% cells by volume. This includes red blood cells, white
blood cells, platelets and cells of the immune system. The remaining ~55% is a combination of
dissolved electrolytes and soluble proteins known as plasma.25 Evidence of NP interaction with
blood components, including red blood cells (RBCs) and platelets, can be early indications of
toxic side effects that would prohibit clinical administration. Negative indications in either of
these explorations would be cause to re-evaluate the physiochemical properties of a NM system.

4.5.1. Red Blood Cells and Hemolysis Overview
RBCs are a main component of whole blood and are responsible for the distribution of
oxygen (O2) to, and the removal of carbon dioxide (CO2) from, tissues. Upon traveling to the
lungs, RBCs pick up O2 as it diffuses through their cell membranes. The O2 is stored in the iron
metalloprotein hemoglobin (Hgb) that RBCs contain in high concentrations. The cells then travel
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through the body and oxygenating tissues before transporting CO2 waste back to the lungs. RBCs
are large when compared to serum proteins, 6-8 µm in diameter, and make up the majority of
whole blood’s cellular fraction.91 This means that NM systems injected into the blood stream are
all but certain to come into contact with RBCs in circulation. As the circulation time of a NM is
extended, this potential for RBC interaction is likewise increased.
A main concern in the interaction of NMs with RBCs is the potential for membrane lysis,
known as hemolysis. Because RBCs distribute oxygen from the lungs to the tissues of the body,
hemolysis can result in starving the body of the oxygen it needs. Additionally, the release of
hemoglobin into free circulation in the blood stream can lead to oxidative damage of the walls of
blood vessels. Hgb can also damage the kidneys as it is filtered from circulation and contribute to
renal failure over time.91 On top of the potential toxicities, hemolysis can lead to NM systems
becoming decorated with Hgb and cellular fragments, rendering them more likely to be
recognized by phagocytes and contributing to their removal from the body.

4.5.2. Trends In Hemolysis
Particle size and geometry appear to play a role in NM blood compatibility. Yu et al.
studied the effects of geometry on the hemolytic activity of silica nanoparticles (SiNPs) of
different shapes and porosities.92 They tested a range of materials, including non-porous and
mesoporous spherical particles and mesoporous nanorods of ARs 2, 4, and 8. The naked SiNPs all
had negative surface charges. The non-porous spherical and shorter rod-like particles were less
hemolytic than their longer counterparts at higher concentrations. The authors attributed this to
increased surface charge and decreased exposed surface area. In addition, it was found that NPs
exhibited AR dependent hemolysis with spherical particles lysing the greatest percentage RBCs
(nearly 100% at 250 µg/mL) and the highest AR being the least lytic (20-25% lysis for AR=8)
(Figure 4.12A).92 Spherical SiNPs of small sizes (~100 nm) have been shown to be less toxic than
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larger counterparts of ~600 nm.93 The larger particles induced changes in RBC membranes and
triggered hemolysis. It has been suggested that high surface curvature, like that found in smaller
NPs and high AR nanorods, changes hemolysis by affecting binding energies and the ability of
RBC membranes to wrap around NPs.93

A

B

Figure 4.12: Shape and Charge Effect RBC Hemolysis. A) Bare, Negatively Charged, SiO2
Particles Exhibit Decreased Hemolysis as With Increased Aspect Ratios. Black = Non-Porous
Spherical Particles. Red = Porous and Spherical. Orange, Green, Blue = Increasing Aspect Ratios.
B) Conversion of Bare Particles to Cationic Particles Erases the Hemolytic Dependence on
Aspect Ratio.92

Interestingly, in the Si nanorod study above, when SiNP surface charges were inverted by
amine modification, all NPs were equally hemolytic (Figure 4.12B).92 This suggests a strong
connection between hemolysis and charge. In agreement with these studies, cationic amineterminated PAMAM dendrimers show hemolysis even after a one-hour incubation with RBCs at
concentrations as low as 10 µg/mL. Their carboxylic acid-terminated anionic counterparts were
not hemolytic until concentrations above 1 mg/mL. Similar results have been reported for
negatively charged and PEGylated chitosan/polyglutamic acid (CPGA) NPs of varying sizes from
100 nm to 1000 nm. In all cases, CPGA all showed less than 1% hemolysis.94 In general, cationic
macromolecules of many types have been found to effectively lyse cell membranes, a trend that
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holds for human RBCs.95 In these instances, charge neutralization by amine capping or
PEGylation reduces RBC hemolysis.96 This is also true for polymer NPs that must be stabilized
by hydrophobic surfactants. By replacing lauric acid stabilization with PEG modification, NP
mediated hemolysis was reduced by ~60%.97 The mechanism by which PEG dampens both
charge and hydrophobic surfactant induced hemolysis can be explained by corona shielding
effects that prevent or slow down NM/RBC interactions.

4.5.3. Platelets and Thrombogenesis Overview
Platelets are bone marrow derived cells whose main function is to repair breaks in
vascular lining. These cells are 2-3 µm in diameter and do not contain a nucleus. When breaks in
blood vessel walls occur, platelets are activated by the exposed extracellular matrix.98 This leads
to shape change through actin reorganization, release of soluble factors intended to recruit nearby
platelets, and adherence and aggregation in the exposed area. In this way, platelet activation and
aggregation serves to paper over breaks in vascular lining, thereby preventing blood loss and
maintaining homeostasis (Figure 4.13). Unfortunately, unnecessary activation of platelets can
lead to occlusion of blood vessels through the formation of non-essential blood clots. This
formation of intra-vessel plaques can lead to life threatening myocardial infarction or ischemic
stroke.98
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Figure 4.13: The Self-Reinforcing Process of Platelet Activation Works to Repair Breaks In
Vascular Lining.99

Interaction of NMs with platelets has the potential to disrupt the normal function of the
clotting system. This could come about either by initiating or preventing platelet activation.
Activation of platelets by NM systems would increase the potential for formation of intravascular
blood clots, while interference with normal coagulation cascades would increase the patient’s
chances of hemophilic complications5. Indications that either of these side effects are possible
would be cause to re-evaluate the physiochemical properties of a NM system such that they will
no longer interfere with the body’s natural thrombogenic mechanisms.

4.5.4. Trends in Platelet Activation and Thrombogenesis
Radomski et al. investigated the effects of geometry and architecture on platelet
aggregation and rat vascular thrombosis by comparing spherical C60 fullerenes (C60CS),
SWCNT, multi-walled carbon nanotubes (MWCNT), and a mixed population of industrial carbon
nanoparticles (MCN) at equivalent concentrations.100 They found that MCN incubation induced
aggregation most effectively and initiated rapid clot formation. SWCNTs were less effective than
MCN, but more effective than MWCNTs. Upon incubation, C60CS particles did not induce any
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platelet aggregation even at increasing concentrations. Specific conclusions about differences
between the materials could not be drawn because of the differential surface chemistries and size
distributions of the materials. CNT aggregates may simply be more effective at mediating cellcell contacts and interactions than C60CS.101 Similar results were found by Bihari et al. for
SWCNTs in an in vivo mouse thrombogenesis model.102 Additionally, both MWCNTs and
spherical SiNPs were found to sensitize platelets toward further agonism. The materials activate
platelets through similar pathways, showing that materials with differing sizes, shapes, and
surface characteristics can act similarly.103
In a study of the effects of surface charge and size on the platelet activation of hollow
spherical CPGA NPs, Dash et al. synthesized negative, neutral, and PEGylated NPs of 100 nm,
300 nm, 500 nm, and 1000 nm diameters. The authors found that particles of 500 nm and 1000
nm showed negligible platelet activation, regardless of surface chemistry. Reducing NP size to
100 nm and 300 nm significantly increased platelet activation mediated by negatively charged
particles, but a similar effect was not seen in the neutral and PEGylated groups (Figure 4.14).94
Thus, size may play an important role in mediating platelet activation.
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Figure 4.14: Size and Surface Charge Affect Platelet Activation Based On the Time to Clot
Formation. A) Smaller Particles are More Thrombogenic Than Larger Particles When Negatively
Charged. B) Negatively and Neutrally Charged Particles Can Be More Thrombogenic Than
PEGylated Particles of the Same Size.94

In a further study of the effect of surface charge, Bihari et al. tested the thrombogenic
potential of amine- and carboxyl-modified polystyrene particles (SPs). They found that positive
SPs increased the rate of vessel occlusion after thrombus induction, while negative (SPs) induced
a rate decrease. This is in agreement with studies showing that polycationic polymers aggregate
platelets more effectively than natural agonist adenosine diphosphate.104 However, another model
system in the same paper showed no effect on clot formation for either particle. Because differing
induction methods were used to trigger thrombosis in different ways, the authors suggest that NPs
have the ability to modulate certain pathways over others.102 In contrast to the previous results,
work showing that carboxyl-QDs activate coagulation cascades more effectively than amine-QDs
in in vitro studies suggests different trends at different size regimes.105
As shown above for hollow CPGA NPs, charge neutralization by PEGylation can reduce
platelet activation in some cases. In contrast, for surfactant coated PLGA NPs, PEGylation did
little to reduce the affects the NMs had on blood coagulation times and blood clot strengths when
dosed above 1% w/v.97 Coating polyvinyl chloride resin particles in a PEG corona, however,
completely mitigated the thrombogenic potential of the hydrophobic naked particles.106
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Differences in the effects of charge, hydrophobicity, and PEGylation points to a need for
increased systematic scanning of physiochemical properties and a likely dependence on multiple
coalescing properties.

4.6. Polyrotaxanes For In Vivo Applications
Polyrotaxanes (PRs) are nanomaterials comprised of macrocyclic hosts non-covalently
threaded onto polymer cores. Once threaded, the polymer termini are modified with bulky
blocking groups to prevent macrocycle dethreading.107 The guests can slide laterally along the
polymers or rotate around it, but they are locked onto their cores until cleavage of PR endcaps
allows for macrocycle loss from the polymer termini. As discussed in chapter 1, PRs are of
interest because they can be made from a wide range of polymers and macrocycles, including
those that are biocompatible, biodegradable or generally recognized as safe (GRAS) by the
FDA.108-110 In general, PRs have potential applications in drug delivery, gene delivery, diagnostic
imaging, vaccine development and many others. The Thompson Lab has recently reported PR
materials synthesized from GRAS Pluronic co-polymers and β-cyclodextrin or hydroxypropyl-βcyclodextrin (HP-β-CD) with applications in gene delivery and as therapeutic candidates for a
rare disease Niemann-Pick Disease Type C (NPC).110-113
Little is known, however, about the performance of PRs in vivo. Kumeno et al. has shown
that PRs composed of HP-α-CD threaded onto PEG with L-phenylalanine capping agents
inhibited the increase of intracellular calcium in platelets. This means that PRs of this
composition and structural properties may, while not inducing platelet aggregation, interfere with
normal clotting of blood.114 Secondly, a recent paper by Tamura and Yui showed that PRs
composed of HP-β-CD and Pluronic P123 did not cause any appreciable hemolysis in rat
erythrocytes.115 Finally, a number of studies have used PR-drug conjugates to attempt to slow
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tumor growth.116, 117 Kang et al. showed that PR-DOX-Micelles increased the maximum tolerated
dose of DOX by 2-fold.118
Given the limited sample size and restricted set of materials used, information needs to
be gathered about the PK, BD, and toxicity of PR materials before they can be useful scaffolds
for clinical translation. Additionally, because PRs can be synthesized with a variety of polymer
precursors and capping reagents, and threaded with a variety of macrocycles, there is the potential
for generation of families of PRs with varying average molecular weights, surface chemistries,
macrocycle copy numbers and threading efficiencies. These PRs would then have a range of
hydrophobicities, surface charges, rigidities, shapes, and surface areas. Even within a single PR
synthetic product, a distribution of materials will exist, given the inherent MW distribution of the
polymer precursors and the distribution in PR macrocycle copy number. This, in itself, will lead
to a range PR sizes and masses. Knowing if structure-property relationships exist in the in vivo
performances and toxicities of PR materials with differing physiochemical properties will aid in
tailoring PR architectures for the desired outcomes of the therapeutic target.
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CHAPTER FIVE: PRECLINICAL PROFILING AND TOXICITY STUDIES OF
2-HYDROXYLPROPYL-β-CYCLODEXTRIN POLYROTAXANES

5.1. Introduction

!
5.1.1. Nanoparticle Systems and Preclinical Profiling
Nanoparticles (NPs) continue to hold great potential to impact a wide range of
biomedical disciplines including drug delivery, diagnostic imaging and vaccines. Vastly different
resources and preparation techniques can be used to produce NPs containing varying materials,
including lipids,1 polymers,2 and metal NPs,3 with a variety of sizes, surface chemistries, and
shapes.4 As the field has developed, a large range of materials have been tested in vivo to draw
conclusions about what determines a NPs course through in the body. It has become evident that
changes in physical and chemical properties affect the residence times, toxicities, and fates of
nanomaterials upon in vivo injection.4-7 As such, it is beneficial to determine structure-property
relationships between or within classes of NPs to determine how changes in overall properties
will affect in vivo performance.
Clinical translation requires as much understanding as possible about the NP system’s
course and its effects on the body. Journey through the biological milieu means contact with a
vast number of bodily components all with the potential to determine NP circulation times and
drive NP-mediated side effects. Upon injection, NPs enter the blood stream, where they may
interact with serum proteins, blood cells, and the immune system.8, 9 There is potential for a wide
range of toxic effects including red blood cell lysis, thrombogenesis, or complement activation,
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all of which can increase the chances of anemia, renal failure, stroke, and inflammatory
responses.9-11 Ideally, NPs for drug delivery applications would be non-toxic to biological
components in whole blood circulation. For magnetic resonance imaging, NPs should be long
circulating, non-toxic, and avoid immune system activation.
Additionally, information about clearance and biodistribution can guide both the
targeting of specific organs for therapy or imaging and the monitoring of organ specific toxicity.
NPs with different physical characteristics are known to deposit and clear differently from the
body.12, 13 Once there, they have the potential to induce toxic effects if they are not cleared
effectively. Carbon nanotubes have been shown to deposit in the liver for extended periods,
increasing the potential for long term toxicity.14 Quantum dot challenges (e.g., Cds, CdSe) have
raised concerns about nephrotoxicity because of their heavy metal cores and renal filtration.15, 16
This is also a concern for Gd3+ carrying MRI materials where kidney deposition of Gd3+ can
cause renal failure, particularly in elderly patients or others at risk for nephrogenic systemic
fibrosis.17 Knowing the types of physical and chemical characteristics that lead to predictable
biodistribution patterns will inform the use and safety screening of NP vehicles under
consideration for drug delivery or imaging applications.
Finally, the NP corona is emerging as a major determinant of how nanomaterials behave
in the body.18 It has recently been understood that hard protein coronas form around nanoparticles
immediately upon exposure to serum and are relatively stable over time.19, 20 The composition of
these coronas has the potential to influence pharmacokinetics; if NPs recruit opsonins or
dysopsonins, clearance; if NPs recruit proteins of the immune system, and biodistribution; if NPs
recruit lipoproteins or other proteins with cell receptors.21 Different architectures have been
shown to differentially recruit surface proteins, including serum albumins, immunoglobulins, and
complement proteins, or to recruit them in different abundances.10, 21-23 Knowledge of a NPs hard
protein corona will go a long way toward explaining or predicting in vivo performance.
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5.1.2. Polyrotaxanes For In Vivo Use
Polyrotaxanes (PRs) are nanomaterials comprised of macrocyclic hosts non-covalently

threaded onto polymer cores. Once threaded, the polymer termini are modified with bulky
blocking groups to prevent macrocycle dethreading.24 The guests can slide laterally along the
polymers or rotate around it, but they are locked onto their cores until cleavage of the PR endcaps
from the polymer termini. PRs are of interest because they can be made from biocompatible,
biodegradable, or generally recognized as safe (GRAS) starting materials.25-27 The Thompson Lab
has recently reported PR materials synthesized from GRAS Pluronic co-polymers and βcyclodextrin or 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) and applied these materials to
problems in gene delivery and as therapeutic candidates for treatment of the rare disease,
Niemann-Pick Disease Type C (NPC).27-30
Little is known, however, about the performance of PRs in vivo. Information needs to be
gathered about the pharmacokinetics (PK), biodistribution (BD), and toxicity of PR materials
before they can be useful scaffolds for clinical translation. Additionally, because PRs can be
synthesized with a variety of polymer precursors, there is the potential for families of PRs with
varying average molecular weights, macrocycle copy numbers, and threading efficiencies.
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Figure 5.1: Pluronic Triblock Chemical Structure and Representative Images the Polymer Family
Utilized in this Study. Orange Represents PEG blocks and Black Represents PPG blocks.
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We sought to define structure-property relationships by synthesizing a family of
gadolinium (Gd3+) carrying PR materials from a set of poly(ethylene)glycol (PEG)poly(propylene)glycol (PPG)-PEG Pluronic co-polymers of varying molecular weights and
hydrophilic/lipophilic ratios (Figure 5.1). These materials have hydrophilic PEG flanks and
hydrophobic PPG cores.25 Based on the findings from these studies, conclusions can be drawn
about the effects of total molecular weight, threading efficiency, and polymer hydrophilicity on
PK, BD, toxicity, immune response, and protein hard corona composition. Development of
structure-property relationships related to the performances of PR materials will help with
tailoring PR architectures for the desired outcomes of a project.
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5.2. Polyrotaxane Family Pharmacokinetics

!
5.2.1. Polyrotaxane Family Characterization
To maximize the amount of potential property variation amongst the PR family to be
screened, five Pluronic co-polymer cores were chosen having largely disparate average molecular
weights (12.5 kDa – 1.9 kDa) and varying hydrophilic-lipophilic balances (HLBs) as determined
by the relative PEG-PPG block lengths (HLB 2-29) (Table 5.1). After HP-β-CD threading and
Gd3+:DOTA grafting, NMR analysis was used to determine the average molecular weight and
threading efficiency of the PR family members. Threading efficiency is determined by
comparison to the theoretical number of HP-β-CDs that could fit onto the co-polymer’s PPG core
if it were fully threaded. Overall average molecular weights of the PR family members ranged
from 53 kDa to 19 kDa and HP-β-CD threading efficiency ranged from 67% to 20% coverage of
the PPG segment. PR characterization is summarized in Table 5.1.

Table 5.1: HP-β-CD Polyrotaxane Family Characteristics
Polyrotaxane Characteristics

Polymer Core Characteristics

Total MW # CDs % Threading Gd Wt %

MW

PEG PPG

F127

44 kDa

14

44%

3.4

12.5 kDa

200

65

F68

26 kDa

3

20%

4.9

8.3 kDa

151

29

L35

19 kDa

4

50%

1.0

1.9 kDa

21

16

L64

29 kDa

6

40%

1.4

2.9 kDa

26

30

L81

53 kDa

14

67%

0.4

2.8 kDa

6

43

!

Representative PR structures are shown in Figure 5.2. The most highly threaded PR, L81,
is also the highest molecular weight, despite having a low molecular weight core. The central
triblock co-polymer carries 14 copies of HP-β-CD. Threading of this polymer may proceed to a
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greater extent because of high hydrophobicity brought on by short PEG flanks. The overall most
hydrophilic polymer, F68, yielded the lowest threading efficiency at 20%. The long PEG units of
F68 flanking a short PPG core may slow the threading rate relative to the other polymers of lower
HLB. The highest MW polymer core, F127, gave rise to the second highest molecular weight PR,
although with significantly less HP-β-CD threading efficiency than L81 at 44%. This may again
be due to the interference of lengthy PEG flanks. Finally, co-polymer L35 gave rise to the PR
that was the lowest in MW while also being the second most highly threaded. This set of
materials was then studied to gain insight into the roles of MW and threading efficiency on their
biological behavior.
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Figure 5.2: Gadolinium-Carrying HP-β-CD Polyrotaxane Representative Structures.
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5.2.2. Synthesis and Characterization of IR800CW-PR Family
In addition to Gd3+-carrying PRs, a near-infrared fluorescent (NIR) PR was synthesized

to study constructs with different surface chemistry in a parallel manner. The NHS-ester form of
the NIR dye IR800CW was conjugated to the PR scaffolds after amination using a carbonyl
diimidazole/2,2’-(ethylenedioxy)bis(ethylamine) sequence in DMSO. Each reaction was allowed
to run overnight. PR intermediates were purified by dialysis against water for two days with four
water changes, followed by lyophilization. IR800CW coupling was completed by dissolving the
amine-modified PRs in DMF before addition of 0.5 eq of IR800CW-NHS with stirring overnight.
Product purification by dialysis against water was performed before lyophilization. Every step
involving dye was carried out in the absence of light. The final products were deep blue fibrous
powders.
IR800CW was chosen for use in these experiments because of its exceptional extinction
coefficient for near IR absorption and efficient emission properties. These factors would allow for
sensitive imaging with diminished interference from autofluorescence. The dye was conjugated to
each PR base in good yield (Table 5.2). Targeting 0.5 equivalents of dye per PR was done in
order to prevent the stochastic addition of multiple fluorophores to the PR structure and potential
quenching of emission due to close spacing of IR800CW substituents. Fluorescence
measurements show that four members of the family carried between 0.83 and 1.21 copies of the
dye per mole of PR. L64 was an outlier carrying only 0.18 copies of the dye (Table 5.2).
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Table 5.2: NIR-Polyrotaxane Yields and IR800CW Coverage
IR800CW'PR) Percent)Yield) Mol)IR800CW/Mol)PR)
F127%

75.1%%

0.92%

F68%

93.6%%

1.03%

L35%

64.7%%

0.83%

L64%

77.1%%

0.18%

L81%

63.9%%

1.21%

5.2.3. Gadolinium-Carrying Polyrotaxane Pharmacokinetics and Biodistribution
Given the range of physical properties exhibited by these PR derivatives, the next aim
was to elucidate how differences in architectures may confer differences in the circulation time,
biodistribution, and clearance of the constructs. Pharmacokinetic profiles for the members of the
PR family are shown in Figure 5.3. All members of the family show a biphasic PK curve with
rapid accumulation and slower clearance phases. Circulation time appears to be most affected by
the PRs threading extent. L81, with the highest threading and the highest molecular weight, is the
longest circulating PR with an average of ~52% of the injected dose remaining in the blood at 30
minutes, ~21% remaining at 6 h and ~4.6% remaining at 24 h after injection. In this case, 2 of the
3 mice in the group had detectable Gd3+ in their blood at 24 h. The second longest circulating
construct is L35 with ~23% of the injected dose remaining at 30 min, ~9% at 6 h and ~1% at 24
h. Again, 2 mice in the group had detectable levels of Gd3+ in their blood on average at 24 h postinjection. This is an interesting and insightful case because L35 also exhibits the second highest
threading and, the lowest overall molecular weight, suggesting that the flexible rod-like
characteristics may be more important than PR molecular weight. The third longest circulating
PR is F127, with only ~4% of the injected dose remaining at 30 min and ~1% at 6 h. Only one of
the mice in this group had detectable gadolinium in the blood at 24 h. PRs F68 and L64, with
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threading efficiencies of 20% and 40%, were both cleared rapidly from blood circulation by 3 h
and 30 min, respectively.
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Figure 5.3: Blood Residence Times of HP-β-CD Polyrotaxane Family Members. n = 3.

It appears, then, that HP-β-CD coverage ratio is more important than overall molecular weight (or
polymer molecular weight) in determining circulation time. In fact, the second longest circulating
construct is the least massive overall. This may be because an increased HP-β-CD coverage of the
co-polymer cores imparts an increased rigidity to the constructs. Similar results have been
reported for flexible-rod micelles that have been shown to reside in the blood stream for extended
periods by aligning with blood-flow and avoiding macrophage uptake.5 The increased blood
residence is likely not coming from PEG shielding effects since the longest circulating agent,
L81, has the shortest PEG flanks (average of 3 units on each side), while the PRs with the longest
PEG flanks, F127 and F68, are more rapidly cleared.
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As observed in the pharmacokinetics experiments, we show that biodistribution at 24 h is

again affected by PR threading efficiency. There is little to no detectable residence of any PR in
the brain or heart (Figure 5.4). Each PR takes up residence to some extent in both the kidney and
the spleen, but without any clearly discernable structure-property trends. PRs of lesser threading
are shown to take up residence in the lung preferentially to other organs, including the liver. F68
and L64 showed lung deposition of ~36% ID/organ and ~46% ID/organ, respectively, while the
more highly threaded PRs, L81 and L35, deposited only ~10% ID/organ and ~0.5% ID/organ in
the lung, respectively. Conversely, the more highly threaded PRs showed deposition in the liver
preferentially to all other organs. PRs L81 and L35 showed liver deposition of ~67% ID/organ
and ~57% ID/organ, respectively, while F68 and L64 showed deposition of 23% ID/organ and
19% ID/organ.
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Figure 5.4: Biodistribution of HP-β-CD Polyrotaxane Family Members. n = 3.
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Strong lung deposition of less efficiently threaded PRs may be due to PR aggregation in

via their exposed PPG blocks. These aggregates, driven by the amount of available hydrophobic
core, could then be too large to effectively pass through microcapillaries of the lungs. This may
also explain the rapid loss of F68 and L64 from the bloodstream, as the lungs would quickly sieve
the dose after injection and passage through the heart. More highly threaded PRs, then, are able to
effectively shield their hydrophobic central blocks and pass through the lungs for final deposition
into the liver for hepatobiliary excretion. This differential deposition may be useful in designing
PR systems to specifically target lung or liver tissue.

5.2.4. Biodistribution and Residence Time of Near-Infrared Labeled Polyrotaxanes
Images taken 30 minutes after injection of the NIR-PRs reveal intense fluorescence
emission from the murine bladder, indicating rapid clearance through the urine (Figure 5.5). This
may be from the renal filtration of either low molecular weight PR species (i.e., members of the
PR population having a low degree of HP-β-CD threading), contaminating or dethreaded HP-βCD-IR800CW, or very rigid PRs that are able to move through the glomerulus along their
longitudinal dimension. Subsequent images reveal buildup of the remaining PR species largely in
the liver and kidneys. The liver is likely the predominant site of accumulation that is most visible
in the time-course images because it scavenges the PR extensively and is superficial to the skin.
For all PRs, the fluorescence persists in the mice until 120 h, suggesting that the PRs achieve
significant tissue residence times after administration (Figure 5.6).
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Figure 5.5: Live Animal Images 30 minutes (L64-F127) and 1 h (L35) after NIR-Polyrotaxane
Administration Via Tail Vein Injection
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Figure 5.6: Tissue Residence of NIR-Polyrotaxanes 24 h-120 h After Administration.

Differences existed in the rate at which PR family members left the tissues. To determine
these rates, radiant efficiency (RE) of the mouse was tracked over time as a fraction of maximum
RE at 30 min (Figure 5.7). PRs F68 and L35 cleared the body similarly, with 10% RE remaining
at 24 h. Both L81 and F127 were excreted slightly more slowly, with ~25% of the original RE
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remaining at 24 h. In contrast to these, L64 was found to clear very slowly. A full 80% of the
maximum RE was retained 24 h after injection. The cause of this retention is unknown and
further study would be necessary to elucidate causal links.
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Figure 5.7: Rate of NIR-Polyrotaxane Whole Body Fluorescence Loss. n = 3.
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Ex vivo fluorescence analysis shows PR accumulation in liver, kidney, spleen, lungs, and
intestines (Figure 5.8). Individual mice were sacrificed sequentially, giving single mouse
timepoints for each PR at 24 h, 48 h, and 120 h. The majority of the dose in each case was
deposited into the liver, with lower fluorescence found in all other organs except for F68 that
displayed higher kidney fluorescence than the liver at 48 h. The set of organs taking up
IR800CW-PR is consistent with the findings from the Gd3+:DOTA-PR study, however, the strong
lung deposition of PRs L64 and F68 is not seen in this study. This is likely due to of differing
surface chemistries brought on by PR modifications.
While both sets of post-modifications would be negatively charged, a main difference is
the fact that IR800CW-PRs were designed to carry only a single modification where as the
Gd3+:DOTA-PR family was designed to carry as many as possible. This would leave Gd3+:DOTA-
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PR with both a larger overall size and a higher overall charge, both of which could lead to
increase protein deposition. This may lead to increased transient deposition of large PR:protein
aggregates in the lung. Additionally, this high charge may lead to a more rapid HP-B-CD
dethreading, exposing more PR hydrophobic core and driving aggregation faster than in the
IR800CW-PR family. Further investigation will be necessary to define the exact mechanisms by
which this difference is being mediated.
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Figure 5.8: Ex Vivo Biodistribution of NIR-Polyrotaxanes at 48 h.
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5.2.5. Metabolism and Clearance of Gadolinium-Carrying Polyrotaxanes
Excretion of the PR systems through the feces was studied by ICPMS digestion and
analysis of mouse feces at discrete intervals after PR injection (Figure 5.9). At 0-1 h and 1-6 h,
the feces from 3 mice in each of the PR groups was collected from the cages, pooled, and
homogenized. In all cases except for L64, the amount of Gd3+ excreted increased from 0-1 h to 1-
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6 h, due to the time required for liver uptake and processing of the PRs prior to excretion. By 24
h, the more highly threaded PRs were excreted in greater amounts than those with lower degrees
of threading. This is consistent with the findings that the more highly threaded PRs avoid lung
deposition and renal filtration, thus providing greater opportunity for liver clearance after 24 h.
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Figure 5.9: Clearance of HP-β-CD Polyrotaxane Family Members in the Feces as Measured by
ICPMS. n = 3 for 24 h.
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NIR evidence of early PR clearance from the body led to questions about what form of
PR was able to rapidly clear the body. Intact PR scaffolds should be large enough in
hydrodynamic size to avoid glomerular filtration. The possibility existed that the PRs were being
metabolized, degraded, or otherwise dethreading in circulation to release free CD monomers
capable of being filtered through the kidneys. In contrast, it is conceivable that PRs with either
very low threading or very high threading efficiencies are eliminated via the urine either by not
achieving sufficient size, or by traversing the glomerular membrane along their longitudinal axis,
respectively.
To study this, urine samples were collected from mice 1 h after tail vein injection of
Gd3+:DOTA-PR and dialyzed against 3.5 kDa membranes. In theory, after dialysis against PBS,
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dethreaded modified Gd3+:DOTA-β-CDs released from metabolized PRs would be able to
permeate the membrane while intact Gd3+:DOTA-PRs would not. The study compared PR F127
and ProHance, which would be expected to bypass the dialysis membrane easily. At 1 h, >97% of
the Gd3+ in the ProHance sample was dialyzable (Figure 5.10), whereas only ~27% of the Gd3+ in
the PR sample was dialyzable under the same conditions. Therefore, the majority of the PR dose
leaving the body within the first hour of circulation consists of unmetabolized Gd3+:DOTA-PR
material.
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5.3. Gd3+:DOTA Polyrotaxane Toxicity and Blood Compatibility

!
5.3.1. General Toxicity and Serum Chemistry
Nanoparticles for biomedical applications should be designed to minimize side effects
upon parenteral administration. A study seeking to assess the systemic toxicological profile of the
PR family members was undertaken by measuring the body weights of PR treated groups over a
3-week treatment course (Figure 5.11). All groups of 9-week old mice received an initial PR
injection at Day 0. Additionally, groups treated with L35, L64, and L81 were challenged a second
time with an injection at Day 14. With termination of the experiment at Day 21, it was observed
that all groups were steadily gaining weight at rates that were similar to 15% DMSO:PBS-treated
controls. All groups were in within the weight limits for 12-week-old mice provided by Harlan
Laboratories. Therefore, PR treatment did not exhibit acutely toxic effects on mouse
development.
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Figure 5.11: Mouse Body Weight Growth of PR Treatment Groups. n = 3.
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Given the biodistribution of PR materials, blood chemistry tests were undertaken as an

indicator of liver, kidney, and lung function. Equal volumes of mouse serum collected at 21 d
after PR injection were pooled for each group to obtain mean values (Figure 5.12). Blood
creatinine and blood urea nitrogen (BUN) were taken as markers of kidney function and were
within normal limits for Balb/C mice, showing no evident kidney toxicity. This is an important
consideration given the potential use of Gd3+:DOTA-PRs as MRI contrast agents, since renal
damage is a main concern for currently approved Gd3+ contrast agents.17
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Figure 5.12: Kidney and Liver Function Tests

Additionally, alkaline phosphatase (ALKP) and alanine transaminase (ALT) were studied
as markers of liver damage (Figure 5.12). ALT was within normal limits indicating no evident
liver damage. ALKP was low or slightly below normal limits in most cases, including the PBS
control. While the reason for the low ALKP values is unknown, the presence of low ALKP values
in the control, and the fact that liver damage would be expected to elevate ALKP values, suggests
that the potential liver toxicity of the PR agents is low. Blood carbon dioxide (ECO2) was used as
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a marker of potential lung toxicity caused by PR deposition. In all cases, PR treated groups had
ECO2 values similar to PBS control, indicating no acute lung toxicity (Figure 5.13).
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Figure 5.13: Serum Carbon Dioxide Levels

5.3.2. Polyrotaxane Mediated Red Blood Cell Hemolysis
One of the most important aspects of blood compatibility is the effect of an injected NP
on circulating RBCs. NP-mediated RBC lysis can lead to a decrease in the levels of circulating
hemoglobin and, therefore, a lack of oxygen delivered to the tissues Oxidative damage to the
walls of blood vessels and the kidneys can also contributing to renal failure over time.31 To test
for possible PR mediated hemolysis, increasing concentrations of each PR were incubated with
human red blood cells and compared to a positive control of 1% Triton X-100. No evidence of
hemolysis greater than control was seen at any concentration for any PR (Figure 5.14).
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Figure 5.14: HP-β-CD Polyrotaxane Mediated Red Blood Cell Hemolysis.

5.3.3. Polyrotaxane Immunogenicity
Interaction of PR constructs with components of the immune system will have a major
impact on their ability to circulate extensively in the body, ultimately influencing their clearance,
metabolism, and distribution.32 Of particular importance for applications requiring repeated
injections or long-term administration-- including drug delivery applications, use as imaging
agents, or in the treatment of Niemann Pick Type C-- is the production of memory
immunoglobulin G (IgG) antibodies to particular antigens present on the PR surface. Eliciting an
IgG response would limit the capability of PRs to be administered long term, as they would be
cleared more rapidly upon re-injection.33 Because it has been previously shown that NPs featuring
PEGylated surfaces can induce the production of anti-PEG IgG,33 we sought to determine
whether the PEG flanks of the Pluronic-based PR polymer cores would similarly elicit an immune
response.
Anti-PEG IgG production was tested 14 d and 21 d after injection of the PR materials at 0
d. (Figure 5.15). At 14 d, groups of mice that were administered PRs L35, L64 and L81 at Day 0
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were re-challenged with a second injection before termination of the experiment at 21 d. All PRs
elicited some minimal amount of IgG production at 14 d beyond control, except for the longest
circulating PR L81. This may be because of the short (~3 units) PEG flanks that L81 features, as
6-7 repeating PEG units are believed to be necessary for IgG recognition.34 There is little
difference between the PRs that elicit immune responses in this experiment, suggesting that there
is no structure-property effect with regard to anti-PEG antibody production. At 21 d, PRs L35 and
L64 show little evidence of anti-PEG IgG production beyond PBS control, even with a second PR
administration. PRs F127 and F68 showed an enhanced IgG production at 21 d. PR F68, in fact,
showed a greatly enhanced IgG presence in blood from an average of 104 u/mL at 14 d to an
average of 269 u/mL at 21 d. This may be due to the fact that these PRs contain much longer PEG
flanks, 100 units for F127 and 75 units for F68. Furthermore, the low degree of HP-β-CD
threading onto F68 may lead to greater PEG recognition by the immune system because the
laterally and rotationally mobile CDs are capable of exposing more of the Pluronic core. In other
words, the larger number of HP-β-CDs carried by F127 relative to F68, (14 vs. 3 HP-β-CDs
respectively) may be serving to slow PR recognition by the immune system through PEG block
shielding. PR induced anti-PEG production is, therefore, influenced by the lengths of the PEG
blocks exhibited by the core co-polymer as well as either PR threading efficiency or HP-β-CD
copy number. An in vivo PR application necessitating repeated or long term administration would
be best served by employing highly threaded PRs composed of co-polymers with short PEG
segments.
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Figure 5.15: Anti-PEG IgG Generation in HP-β-CD Polyrotaxane Treated Mice. n = 3.

5.4. Polyrotaxane Hard Corona Proteomics
It has been shown that nanoparticles recruit protein coronas immediately upon injection
into blood and that the makeup of the coating may affect in vivo performance.21 Because of this
newfound understanding about the deterministic effects of protein recruitment, we sought to
determine whether differences in protein architecture would lead to differential recruitment of PR
surface proteins.
Total protein was found to vary across PR architectures as evidenced by total iBAQ
counts (Figure 5.16). F127 and F68 absorb equivalent quantities of protein despite their varying
CD copy numbers and threading efficiencies. L35 and L81, on average, have the lowest levels of
total protein. It is unknown how this protection is mediated, although the high threading
efficiency exhibited by these PRs may protect the constructs through lateral and rotational
shielding. A decreased propensity to interact with serum proteins, by whatever mechanism, could
partially explain the extended circulation time of these two highly threaded constructs. In
contrast, L64 contains the highest average protein abundances although the standard error in this
value is large. This error arises from variations in the amount of the amyloidogenic protein
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transthyretin (TTR) deposited on the PR surface. Two of the three biological replicates of the L64
samples accumulated large amounts of TTR, while a third only showed modest levels. In any
case, a strong accumulation of serum proteins onto L64 may explain the preference of this PR for
lung deposition. TTR is known to drive aggregation of TTR and other serum proteins when
partially denatured35. If this denaturation and aggregation were being preferentially driven by
contact with L64, the corresponding increase in PR size could lead to permanent or transient
deposition in lung microcapillaries.
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Figure 5.16: Total Protein Deposition onto Gd3+:DOTA-PRs.
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To elucidate differences in the total corona composition amongst the PR family members,
the proteins showing adherence to the PR surface were divided into their respective classes.
These groups included complement proteins, serum albumin, coagulation proteins,
immunoglobulins, lipoproteins, and other. When expressed as a percent of the total corona, it can
be seen whether PR family members are preferentially acting within certain pathways of interest.
A large percentage of complement proteins or immunoglobulins, for instance, would indicate a
possibility of hypersensitive reactions or accelerated blood clearance. In contrast, high
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percentages of dysopsonins would be positive indications for increased circulation time and
bioavailability.
PR L81 bound the greatest amount of serum albumin, accounting for 17.1% of total
protein corona composition on average (Figure 5.17). The serum albumin levels were similar for
F127 and L35 as well, which may help to explain the longer circulation of these species over F68
and L64. F127, F68 and L35 also picked up the largest percentage of immunoglobulins and
complement proteins. In these cases, the sugar residues of these more highly threaded PRs may
facilitate antibody recognition. Exposure of nucleophilic alcohols, such as those present on CD,
has been shown to promote activation of the alternative complement pathway.36 Finally, L35 and
L64 adsorbed significantly more proteins in the coagulation pathway than did F127, F68, or L81.
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Figure 5.17: Average Percent of Total Gd3+:DOTA-PR Corona
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Overall, the PR library members adsorbed lipoproteins in the largest amounts (Figure
5.17). This protein class represents the most significant portion of the corona (39-70%) in all
cases except for L64 (26%). Lipoproteins made up 56.4% and 70.1% of the coronas of F127 and
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F68 respectively. Since lipoproteins typically carry esterified and unesterified cholesterol through
the blood stream as a lipid-protein complex, their association with the cholesterol endcaps of the
PRs may mediate this large deposition of a low abundance family of serum proteins. If this is
true, these proteins may help promote cell uptake through receptor-mediated endocytosis upon
binding to the relevant surface receptor. Why the large deposition of lipoproteins onto F127 and
F68 does not lead to an extended circulation time is unknown.
The largest single protein class on the surface of L64 is the group of “other” proteins
(Figure 5.17). This group includes proteases, inhibitors, ion and hormone carriers, and many other
proteins. Significantly, this group also included TTR. TTR made up such a large portion of this
adsorbed protein corona on L64 such that it alone is responsible for ~36.9% of the total protein
corona content. TTR is an amyloidogenic protein when it partially denatures and can drive the
aggregation of further TTR and other serum components. If some characteristic of L64 is
recruiting and denaturing TTR, it would explain the high levels of TTR and the increased
amounts of total protein. Further, this aggregation may play a role in the lung sequestration of
L64, as large particles may have issues navigating lung microcapillaries.
The top twenty proteins on the surface of each PR are listed in Tables 5.2-5.6. The PRs
share a significant number of proteins. Ten proteins are common amongst each family member’s
most abundant. Despite their differences in physiochemical properties, the common components
of the PRs appear to be driving recruitment of common proteins. L64 had the most unique
proteins with three. L35 and L64 share the most proteins between those that are not present on
other PRs. This may be because of the similarity of their polymer cores. The most abundant
proteins for F127, F68, L35, L64 and L81 are apolipoprotein A-I, apolipoprotein A-I, vitronectin,
TTR, and serum albumin respectively.
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Table 5.3: Twenty Most Abundant Proteins in the F127 PR Corona

!
Protein ID
Average % Corona
Apolipoprotein A-I
23.68948669
Complement C3
8.263679457
Serum albumin
8.220708843
Apolipoprotein A-II
7.051049504
Apolipoprotein C-III
5.251471188
Apolipoprotein C-I
5.213928823
Apolipoprotein C-II
4.642077285
Ig kappa chain C region
4.499298055
Apolipoprotein E
4.059720575
Ig gamma-1 chain C region
2.983669078
Apolipoprotein A-IV
2.4906027
Alpha-2-HS-glycoprotein
1.849838394
Complement component C9
1.76530601
Clusterin
1.343077522
Transthyretin
1.188196742
Complement component C8 gamma chain
1.177818036
Ig lambda-1 chain C regions
1.129279556
Ig gamma-2 chain C region
0.842647227
Apolipoprotein D
0.812863719
Alpha-1-antitrypsin
0.77790649

!

!

!
Table 5.4: Twenty Most Abundant Proteins in the F68 PR Corona

!
Protein ID
Average % Corona
Apolipoprotein A-I
31.99542965
Apolipoprotein A-II
9.218839973
Apolipoprotein C-III
6.672272054
Apolipoprotein C-II
6.659471591
Apolipoprotein C-I
6.290285153
Complement C3
6.13462544
Alpha-2-HS-glycoprotein
4.46555885
Serum albumin
3.993341851
Apolipoprotein E
2.655028306
Apolipoprotein A-IV
2.448874185
Ig kappa chain C region
2.033188027
Complement component C9
1.538969444
Clusterin
1.485710311
Ig gamma-1 chain C region
1.202353223
Complement component C8 gamma chain
1.134662774
Apolipoprotein D
1.127944085
Prothrombin
0.813765188
Serum amyloid A-4 protein
0.797553547
Transthyretin
0.788184866
Ig lambda-1 chain C regions
0.644944697
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Table 5.5. Twenty Most Abundant Proteins in the L35 PR Corona

!

!
!

Protein ID
Average % Corona
Vitronectin
12.83014065
Apolipoprotein C-III
7.994388561
Serum albumin
6.900445584
Apolipoprotein C-II
6.722644919
Apolipoprotein A-II
6.460543675
Ig kappa chain C region
5.106817942
Hyaluronan-binding protein 2
4.756287373
Complement C3
4.653739172
Apolipoprotein A-I
4.456003931
Clusterin
3.557088095
Ig gamma-1 chain C region
3.123661581
Apolipoprotein E
2.78340154
Apolipoprotein C-I
2.694849924
Ig lambda-1 chain C regions
1.925077969
Prothrombin
1.913831307
Ig mu chain C region
1.371190996
Inter-alpha-trypsin inhibitor heavy chain H2
1.220287554
Platelet factor 4
1.155834789
Apolipoprotein D
1.14725169
Transthyretin
1.040334076 !

Table 5.6: Twenty Most Abundant Proteins in the L64 PR Corona

!

!

!

Protein ID
Average % Corona
Transthyretin
36.92882834
Apolipoprotein C-III
5.640337171
Apolipoprotein A-I
5.343226422
Prothrombin
4.491836376
Serum albumin
4.453993079
Apolipoprotein C-II
3.932134511
Apolipoprotein A-IV
3.646873692
Hyaluronan-binding protein 2
3.404816171
Vitronectin
3.20820959
Inter-alpha-trypsin inhibitor heavy chain H2
2.468669522
Clusterin
2.390341589
Apolipoprotein A-II
2.116701292
Ig kappa chain C region
2.007984058
Complement C3
1.904499153
Inter-alpha-trypsin inhibitor heavy chain H1
1.447922545
Alpha-2-HS-glycoprotein
1.424555287
Alpha-1-microglobulin
1.42007729
Inter-alpha-trypsin inhibitor heavy chain H3
1.206435029
Ig gamma-1 chain C region
1.005444601
Apolipoprotein E
1.004896536 !
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Table 5.7: Twenty Most Abundant Proteins in the L81 PR Corona

!
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Protein ID
Average % Corona
Serum albumin
17.11418567
Apolipoprotein C-III
10.94908584
Apolipoprotein A-I
7.466318677
Ig kappa chain C region
7.203133214
Apolipoprotein C-I
7.167013517
Complement C3
6.622339883
Apolipoprotein C-II
6.557470377
Ig gamma-1 chain C region
4.653725509
Clusterin
4.096785956
Apolipoprotein E
2.366180581
Apolipoprotein A-II
2.053647321
Ig lambda-1 chain C regions
1.777470732
Transthyretin
1.66188389
Complement C4-B
1.646949368
Alpha-1-antitrypsin
1.440540318
Ig gamma-2 chain C region
1.208887267
Complement component C9
1.084131271
Apolipoprotein A-IV
0.985567942
Ig mu chain C region
0.851889708
Alpha-2-HS-glycoprotein
0.820199699 !

Finally, a number of individual proteins abundances were changing in statistically
significant (p < 0.05) manners between the PR scaffolds. A principle component analysis of the
data revealed good separation between the groups at this significance level, thus enabling
meaningful comparisons (Figure 5.18). Proteins that generally make up high-density lipoprotein
(HDL) are overrepresented on PR F127 and F68 (Figure 5.19). The other PRs pick up less
abundant lipoproteins, including ApoF and ApoJ, which can make up low-density lipoprotein
(LDL), but also have other functions. Additionally, the coronas of F127 and F68 contain
significantly higher amounts of complement components that contribute to the terminal
membrane attack complex (MAC) formation, including complement C5, C6, C7 and C8. The
other members all overexpress classical pathway component C4. As discussed above, L64 shows
vastly enhanced levels of TTR.

!

!

159

Figure 5.18: Principle Component Analysis Plot Comparing Polyrotaxane Protein Coronas. Good
Separation Exists Between Biological Replicates at p = 0.05. Black = L64, Pink = L35, Red =
L81 Teal = F68, Blue = F127.
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Figure 5.19: Protein Heat Map. Enriched Proteins Are Shown in Red. Under-Represented
Proteins Are Shown In Green. p = 0.05.
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5.5. Conclusions
This chapter detailed the preclinical profiling of a family of Gd3+:DOTA-modified!and

near IR IR800CW-labeled HP-β–CD PRs. The analyses PR biodistribution, circulation time,
metabolism, excretion, hemolytic potential, immunogenicity, serum chemistry testing, and hard
protein corona composition were performed as a function of Pluronic polymer core type. It has
been shown that PRs of greater threading efficiency circulate for an enhanced period of time and
deposit preferentially in the liver. In contrast, PRs with lower degrees of threading leave
circulation quickly and deposit to a greater extent in the lungs. In all cases, subsets of PRs are
able to quickly leave circulation by renal filtration by a mechanism that is unclear at this time. In
the case of F127, the majority of this cleared PR content appears to be unmetabolized. PRs do not
exhibit any hemolytic potential, do not affect the growth rate of mice after administration, and do
not affect the natural serum chemistry in ways that would be indicative of organ damage. AntiPEG IgG generation was found to be dependent on the length of the flanking PEG blocks.
Finally, PRs constructed from differing polymer cores do exhibit differential recruitment of
serum proteins. PR L64 exhibits an increased deposition of serum proteins, while PRs L81 and
L35 show reduced deposition. In all cases, it was observed that PRs recruit significant amounts of
lipoproteins. The polymer core, and less so the CD copy number or threading efficiency, appear
to influence the variable recruitment of specific proteins from serum amongst the family
members. Additional work must be done before a comprehensive preclinical profile would be
complete and specific conclusions could be drawn about the physiochemical origins of specific
biological outcomes.
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5.6. Materials and Methods

!
5.6.1. Materials
HP-β-CD and Pluronic co-polymers were purchased from Sigma-Aldrich. Polymer
average molecular weights and hydrophilic-lipophilic balances were determined by the
manufacturer. Claritas PPT grade gadolinium standard was purchased from Fischer Scientific.
TraceMetal Grade nitric acid was purchased from Thermo Fischer Scientific. All dilutions were
made with either 18MΩ water or 2% HNO2 in 18MΩ water.

5.6.2. Polyrotaxane Characterization
For analysis of the amount of gadolinium in the materials, ~1 mg samples of each PR
were dissolved in 70% HNO3 at a concentration of 2 mg/mL. Samples were allowed to digest
overnight. Each PR solution was then diluted to a concentration of 10 ppb Gd3+ based on the
theoretical amount expected based on NMR integration of the DOTA peaks. A final nitric acid
concentration of all samples was 2%. The Pluronic methyl peak was integrated to the average of
protons for the given polymer with all additional peaks relative to this standard. Estimation of the
average number of HP-β-CDs resident on a given PR was done by comparing the integrals of the
HP-β-CD H-1 peak and the Pluronic core methyl group.

5.6.3. In vivo Studies of Pharmacokinetics and Biodistribution
Male Balb/c mice were purchased from Harlan Laboratories (Indianapolis, IN) and
allowed to acclimate for 2 weeks before PR administration. Injection was done at 9 weeks of age
with mice weighing 22-24 g. Anesthesia was done using isofluroane gas. All experiments were
done with approval from the Purdue Animal Care and Use Committee (Protocol # 1112000342).
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PRs were solubilized in sterile DMSO and sonicated for 10 min before dilution to 15%

DMSO with sterile PBS to give a final PR concentration of 2 mg/mL for Gd3+ materials and 4
mg/mL for IR800CW materials. Each PR was administered via tail vein in a 100 µL injection to a
group of 3 mice. Blood draws of ~50 µL were taken at 0 h, 0.5 h, 1 h, 2 h, and 6 h after
administration for analysis of PR pharmacokinetics. At 24 hours, mice were sacrificed by cervical
dislocation and cardiac blood draw. Liver, spleen, kidney, lungs, heart, and brain tissue were
dissected for ex vivo analysis of biodistribution. Organs were weighed and snap frozen in liquid
nitrogen. Blood, serum, and organs were all stored at -80°C until digestion and analysis were
performed.
Live animal NIR imaging was done using an IVIS Lumina II at 0, 0.25, 0.5, 1, 2, 6, 24,
48 and 120 h after PR administration. Dissection of one mouse in each group at 24, 48 and 120 hr
was done to remove the liver, spleen, kidneys, heart, lungs, and intestines for ex vivo
fluorescence analysis immediately after dissection.

5.6.4. PR Metabolism and Excretion
During the performance of the pharmacokinetics experiments, feces and urine were
collected to follow the excretion of PR materials as they cleared from the body. Cages were lined
with filter paper after injection. At selected intervals, feces were collected from the cage floor and
the filter paper was collected and stored for urine extraction. Pooled urine and feces produced by
3 mice in each group were collected at 0-1 h 1-2 h and 2-6 h time periods. At 24 h, each of the 3
mice were placed on individual petri dishes; the spontaneously produced urine and feces were
collected from each individual for analysis.
For pooled feces, samples were homogenized mechanically before digestion. Pooled
urine was extracted from filter paper by soaking in 40 mL of PBS for 48 h on a rocker plate with
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periodic vortexing. Filter paper fibers were separated by vacuum filtration and the filtered extract
lyophilized. The resulting powders were dissolved in 1 mL water and 10-20 µL of this solution
was added to 100 µL HNO3 for digestion. All unused samples were stored at -80°C.
To study PR metabolism, urine samples were dialyzed against 3.5 kDa MWCO
membranes such that intact PRs would be retained and degraded PRs would be dialyzed away.
Either individual or pooled urine (10-20 µL) was added to 10-100 µL Slide-A-Lyzer MINI
dialysis cups (Thermo Scientific). Dialysis cups were presoaked in H2O for 30 m before urine
addition and dialysis against 350 mL of PBS buffer for 24 h with 1 buffer change. The remaining
solution was then collected, digested, and analyzed by ICPMS. Gadolinium values collected in
these experiments were compared to bulk urine Gd3+ values for each time point to calculate
percent loss.

5.6.5. Digestion and Inductively Coupled Mass Spectrometry (ICPMS) Analysis
Blood, serum, and urine samples (5-20 µL) were typically digested by addition of 100 µL
of 70% nitric acid (HNO3). HNO3 mixtures were incubated at 80°C for 16 h to give pale yellow
solutions before dilution to 5-8 mL such that the final nitric acid content was 2%. Organs were
thawed, sectioned, weighed and homogenized before digestion with 100-200 µL HNO3 at 80 °C
for 16 h – 48 h. Livers, brains and kidneys required longer digestion times than did lungs,
spleens, and hearts. After digestion, hearts and brains were diluted to 5 mL volumes. Spleens,
kidneys and lungs were diluted to 5 mL volumes and then further by 1:10. Livers were diluted to
10 mL volumes and further by another 1:15. All final solutions were filtered through 0.2 µm
PTFE syringe filters (Macherey-Nagel, Bethlehem, PA). Final nitric acid concentration of all
samples was 2%. ICPMS analysis for
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Gd content was done using an ELEMENT-2

Mass Spectrometer (ThermoFinnigan, Bremen, Germany) in the medium resolution mode. The
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samples were introduced into the plasma using an Aridus desolvating system with a T1H
nebulizer (Cetac Technologies, Omaha NE).

5.6.6. Anti-PEG IgG Antibody Production and Body Weight Analysis
A second set of mice was used to probe for the production of anti-PEG antibodies after
challenge with the PR constructs. All groups contained three mice and were challenged once with
100 µL 2 mg/mL PR injections at Day 0. Blood (~50 µL) was collected at Day 14 and screened
for anti-PEG IgG antibodies. On Day 14, groups treated with L35, L64 and L81 were rechallenged with an additional 100 µL PR injection. At Day 21, mice were sacrificed, blood was
collected by cardiac blood draw and blood was allowed to clot and separated by centrifugation
before serum analysis by ELISA. For body weight analysis, all animals were weighed before
injection, and then at Days 1, 5, 9, 14 and 21. Values are presented as average body weight ± 1
SEM.

5.6.7. ELISA Studies
ELISA studies for antibody production were done using a Mouse Anti-PEG IgG ELISA
kit purchased from Life Diagnostics, Inc (West Chester, PA) and were conducted according to the
manufacturers protocol. Briefly, serum was diluted 1:100 or 1:50 and added to a BSA-PEG
coated 96 well plate in duplicate. After incubation for 1 h, secondary anti-mouse IgG-HRP
conjugate was added before incubation for 45 min. Final TMB substrate incubation for 20 min
was followed by addition of stop solution and quantifying absorption of the plate at 450 nm with
correction at 570 nm.
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5.6.8. Serum Chemistry
Terminally drawn serum from the three animals in the antibody production study was

pooled (150 µL each mouse) for each PR group. Mean values for the groups were determined for
ALT, ALKP, creatinine, blood urea, electrolytes, and blood CO2. Analysis was performed by the
Purdue Veterinary Teaching Hospital Clinical Pathology Lab (West Lafayette, IN). Samples were
run on a Vitros 5,1 FS from Ortho Clinical Diagnostic (Rochester, NY) per the manufacturer’s
protocols. Normal blood chemistry levels for Balb/C mice were obtained from Charles River
research models (http://www.criver.com/files/pdfs/rms/balbc/rm_rm_r_balbc_mouse_clinical_pathology_data.aspx).

5.6.9. Hemolysis Assay
Human red blood cells (RBCs) were purchased from Zen-Bio, Inc (Research Triangle
Park, NC) and stored at 4°C until use. RBC were washed 4 times with 150 mM NaCl and
subsequently diluted 1:50 before testing. Each PR was dissolved in DMSO and sonicated for 15
min before dilution with PBS and sonication for an additional 15 min. Final DMSO
concentrations were 1%. PRs were then serially diluted in 1% DMSO to give solutions of 800
µg/mL, 100 µg/mL, and 20 µg/mL. Aliquots of washed RBCs (190 µL) were then incubated with
10 µL PR for 1 h at 37°C. Final PR concentrations were 20 µg/mL, 5 µg/mL, and 1 µg/mL, with
final DMSO concentrations of 0.05%. 1% Triton X-100 was used as a positive control. After
incubation, cells were pelleted by centrifugation for 5 m at 600 x g and 100 µL of supernatant
was collected. All experiments were done in triplicate. Hemolysis was analyzed using a Nanodrop
ND-1000 (Thermo Scientific, Wilmington DE) by probing released hemoglobin absorption at 415
nm. Results were normalized to the Triton X-100 positive control.
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5.6.10. Protein Corona Analysis
Normal human serum was purchased from Complement Technology, Inc (Tyler, TX) and

thawed immediately before use. PRs (100 µg) were taken up in PBS and sonicated for 10 min
before incubation with undiluted human serum (1:1 v/v) for 1 h at 37°C. After incubation,
samples were centrifuged for 10 min at 4000 x g and PR pellets were washed four times with 150
µL cold PBS. Three separate incubations were done for each PR family member.
Tryptic peptides were separated on a nanoLC system (1100 Series LC , Agilent
Technologies, Santa Clara, CA). The peptides were loaded on the Agilent 300SB-C18 enrichment
column (5 x 0.3 mm, 5 µm) for concentration and the enrichment column was switched into the
nano-flow path after 5 min. Peptides were separated with the C18 reversed phase ZORBAX
300SB-C18 analytical column (0.75 µm × 150 mm, 3.5um) from Agilent. Column was connected
to the emission tip from New Objective and coupled to the nano-electrospray ionization (ESI)
source of the high-resolution hybrid ion trap mass spectrometer LTQ-Orbitrap XL. (Thermo
Scientific). The peptides were eluted from the column using acetonitrile /0.1% formic acid
(mobile phase B) linear gradient. For the first 5 min, the column was equilibrated with 95% H2O
/0.1% formic acid (mobile phase A) followed by the linear gradient of 5% B to 40% B in 65 min.
at 0.3ul/min, then from 40% B to 100% B in additional 10 minutes. Column was washed with
100% of ACN/0.1%FA and equilibrated with 95% of H2O/0.1%FA before next sample was
injected (total method time = 95 min.). A blank injection was run between samples to avoid
carryover.
The LTQ-Orbitrap mass spectrometer was operated in the data-dependent positive
acquisition mode in which each full MS scan (30,000 resolving power) was followed by eight
MS/MS scans where the eight most abundant molecular ions were selected and fragmented by
collision induced dissociation (CID) using a normalized collision energy of 35%.
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Database searching was conducted using MaxQuant for LFQ (Label Free Quantitation –

LFQ). The Human (SwissProt) annotated database was used for the search. Initial Spectral
Counting was performed using the Mascot Database search results. Statistical Analysis (Multi
regression Analysis) was performed using Qlucore software package.

5.6.11. Statistics
Biodistribution significance was assessed by two-way ANOVA

5.6.12. Calculations
Percent injected dose calculations are based on the experimentally determined Gd3+ load
of each PR, a concentration of 2 mg/mL PR, an injection volume of 100 µL, and an average total
blood volume of 78 mL/kg.37 All values are presented as mean ± SEM.
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CHAPTER SIX: PRECLINICAL CHARACTERIZATION OF POLYROTAXANES
CARRYING VARYING β-CYCLODEXTRIN MACROCYCLES

!
6.1. Introduction
The studies described in Chapter Five focused on a systematic investigation of the effects
of the polymer core on PR pharmacokinetic profile, biodistribution and toxicity. By varying
polymer lengths and hydrophilic/lipophilic ratios while maintaining a constant β-cyclodextrin (βCD) type gave information on the overall contribution of molecular weight, threading efficiency,
and polymer character. Further PR complexity can be introduced through the utilization of
alternative β-CD derivatives. This chapter will discuss this area of PR design space by focusing
on charge and surface chemistry through incorporation of β-CD derivatives as mixtures of species
on a Pluronic L81 core.

6.1.1. Common β-CD Derivatives
Native β-CD consists of a ring of glucose molecules with unmodified primary and
secondary alcohol rims (Figure 6.1).1 In the body, this would exhibit a rigid, β-1,4 glucosyl
structure that would be available for potential recognition by the immune system. Additionally,
free alcohols of carbohydrate origin with the complement system.2 Finally, unperturbed
placement of the primary and secondary alcohols along the β-CD periphery allows for effective
hydrogen bonding between β-CD units along the PR axis such that it could confer a greater
rigidity and decreased solubility to the final constructs. Chemical modification of these sites
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interrupts the intermolecular hydrogen bonding, thereby altering PR solubility, surface chemistry,
and, overall structure.
2-Hydroxypropyl-β-Cyclodextrin is one of the most commonly available modified β-CD
derivatives (HP-β-CD).3 HP-β-CD features non-specific modifications of both the primary and
secondary rim alcohols with hydroxypropyl- (HP) substituents (Figure 6.1). Little control can be
obtained over the number or location of the HP modifications. This means that any number of the
hydroxymethyl groups, secondary rim alcohols, or the secondary alcohols of the newly added HP
groups may be sites of HP modification. Because of this, HP-β-CD is a heterogeneous mixture of
as many as 60+ modified CDs, having a range of overall diameters and molecular weights.
Incorporation of HP-β-CD onto a PR scaffold, as was done in Chapter 5, would break up, and
potentially completely disrupt, PR backbone hydrogen bonding while retaining the reactive
alcohol functionalities on the CD substituents.
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Figure 6.1: β-CD Derivatives Used in Mixed Rotaxanation Reactions

In addition to HP-β-CD, methyl-β-cyclodextrin (Me-β-CD) and 4-sulfobutylether-βcyclodextrin (SBE-β-CD) are also widely available (Figure 6.1).4! Me-β-CD features
permethylated CD surface alcohols. Their utilization would completely block CD hydrogen
bonding along the PR axis, as well as block any potential reactivity of surface alcohols with
serum components. The incorporation of Me-β-CD would also make PR scaffolds more
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hydrophobic overall. In contrast, SBE-β-CD features a high negative charge because of the
sulfonate groups presented at the distal end of the butyl ether rim modifications of the β-CD
monomers carry. Incorporation of SBE-β-CD onto a PR scaffold would not only greatly weaken
inter-CD hydrogen bonding due to reduced number of hydroxyl groups, and may also introduce
some amount of CD-CD electrostatic repulsion. These sulfonate groups have the potential to
enhance PR solubility and drastically change the way PRs behave and interact with blood
components. Incorporation of any of these derivatives, β-CD, HP-β-CD, Me-β-CD, or SBE-βCD, exclusively or in mixtures will yield families of PRs with widely disparate surface
chemistries and physiochemical characteristics relative to the Gd3+:DOTA HP-β-CD PRs.

6.1.2. Performance Effects of Varying CD Incorporation
For the purpose of scanning these parameters, Pluronic L81 was chosen as the scaffold
and remained constant as the CD derivative content and their mixtures were scanned. Utilizing
this core allows for comparison with the best performing material from the studies in Chapter 5,
i.e., the Gd3+:DOTA carrying HP-β-CD-L81 PR that was found to exhibit the longest circulation
time of the materials studied. It is also non-immunogenic and showed a favorable protein corona
deposition that included serum albumin and lipoproteins. Seeing how these aspects of Gd3+-HPL81 performance change due to loss of Gd3+ chelator modification and incorporation of different
CD derivatives will provide insight into the overall physiochemical aspects that most influence
their biological performance.
Various aspects of the preclinical profile and in vitro performance were studied as the CD
composition was varied. Hemolysis assays were used to assess the hemolytic potential of various
PR structures. A more select group was used to study the effects on protein recruitment to the
hard corona from human serum.
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6.2. Results and Discussion

!
Table 6.1: Properties of Mixed β-CD PRs

!
PR

CD Feed Ratio

Total CD

SBE-β-CD

Other CD

MW

β-CD

100:0

18

0

18

26 kDa

HP-β-CD

100:0

11

0

11

22 kDa

Me-β-CD

100:0

8

0

8

16 kDa

SBE-β-CD

100:0

34

34

0

73 kDa

β-CD/SBE-β-CD

50:50

21

8

13

37 kDa

HP-β-CD/SBE-β-CD

50:50

19

10

9

38 kDa

Me-β-CD/SBE-β-CD

50:50

19

6

13

40 kDa

HP-β-CD/SBE-β-CD

70:30

27

8

19

58 kDa

HP-β-CD/SBE-β-CD

40:60

33

19

14

27 kDa
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6.2.1. Mixed Polyrotaxane Mediated Red Blood Cell Hemolysis
As discussed previously, NP mediated RBC lysis is important because it can lead to a

decrease in circulating hemoglobin, a lack of oxygen delivered to the tissues, oxidative damage to
blood vessels and kidneys, and contribute to renal failure over time.5 To study the effects of
varying CD chemistry on RBC interaction, an expanded family of β-CD PRs was utilized. This
collection included PRs carrying exclusively β-CD, HP-β-CD, Me-β-CD, and SBE-β-CD. In
addition, PRs were tested carrying a 50:50 feed mixture of SBE-β-CD and either β-CD, HP-βCD, or Me-β-CD. Increasing concentrations of each PR were incubated with human red blood
cells and compared to a positive control of 1% Triton X-100. No evidence of hemolysis greater
than control was seen at any concentration for any PR (Figure 6.2).
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Figure 6.2: Hemolytic Potential of Mixed Threading Rotaxanes

6.2.2. Polyrotaxane Hard Corona Analysis
Similarly to the way the PR core affected protein deposition onto the nanomaterial’s
surface, there are also differences in protein amounts and identities when changing the CD
derivative composition. Overall, total protein levels were greatly reduced relative to the
Gd3+:DOTA PRs in Chapter 5, indicating some involvement of the Gd3+:DOTA modifications in
recruitment. In addition, total amounts of adsorbed protein vary greatly across the CDs studied
(Figure 6.3). Unmodified β-CD amassed the largest quantity of surface proteins, possibly because
of the rigidity of the hydrogen bonded backbone and the availability of reactive surface alcohols
on the CD rim. HP-β-CD PRs had the second highest protein adsorption, potentially for similar
reasons. Decrease in HP-β-CD relative to unmodified β-CD PR may be mediated by a brush-like
shielding originating from the HP modifications. Me-β-CD and mixed threading PRs picked up
roughly the same amount of protein despite very different surface chemistries. Decreased
adsorption in Me-β-CD may originate from the capping of surface alcohols. Because of the
reduction relative to β-CD PRs and HP-β-CD, it appears that incorporation of charged CDs also
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reduces adsorption by some mechanism. Further careful study is necessary to definitively
pinpoint the mechanisms behind these differences.
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Figure 6.3: Total Protein Adsorption onto PRs of Varying CD Derivatives

When comparing protein groups, CD variation again led to changes in preferential

protein family deposition (Figure 6.4). Similar to the Gd3+:DOTA HP-β-CD PR family, PRs
carrying unmodified β-CD, Me-β-CD, HP-β-CD, and the SBE-β-CD mixture had high levels of
adsorbed lipoproteins. Levels of these proteins were similar to Gd3+:DOTA L81 PRs. The corona
featuring the lowest percentage of lipoprotein content was unmodified β-CD PR with this family
accounting for ~30% of the total corona. Incorporation of unmodfied CD appears to drive the
recruitment of other protein families, reducing the percentage occupied by lipoprotein
dysopsonins. In addition, because this PRs family and Gd3+:DOTA modified PRs adsorb similar
percentages of lipoproteins, it appears that association with these proteins is modified by the PRs
and not by the DOTA modificaitons.
Notably, β-CD PR and HP-β-CD PR achieve significantly greater immunoglobulin
deposition than their counterparts. This may be due to recognition of the 1,4-glucose architectures
or the repulsion of immunoglobulins by the Me-β-CD and charged PRs. Unmodified β-CD and
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HP-β-CD PR represent the largest fractions of serum album of the group while mixed SBE-β-CDcarrying scaffolds exhibit the lowest albumin recruitment. The charge on these PRs may be
preventing albumin-mediated recognition of the cholesterol PR endcaps. HP-β-CD PRs also
featured significantly diminished levels of complement adsorption despite available alcohols on
the CD surface. Conversely, Me-β-CD PRs were amongst the highest complement protein
recruiters despite the reduction of alcohol surface chemistry. All four scaffolds exhibit
significantly diminished deposition of coagulation pathway proteins.
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Figure 6.4: Average Percent of PR Protein Corona

The most abundant protein in the corona of unmodified β-CD and HP-β-CD PRs is serum

albumin. In both cases, the second most abundant protein is immunoglobulin kappa, reflecting the
high percentage of their coronas represented by albumins and immuglobulins. Both architectures
feature large numbers of lipoproteins in their top 20 proteins. Additionally, both PR coronas
feature serotransferrin, increasing the potential for blood-brain barrier (BBB) penetration.
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Me-β-CD and mixed SBE-β-CD PR share their top three most abundant proteins. These

proteins are complement C3, apolipoprotein E, and serum albumin, respectively. Complement C3
is the most abundant protein despite the reduction of reactive surface alcohols, which have been
shown to drive covalent attachment of complement C3b to nanomaterial surfaces.2 The high
percentage of apolipoprotein E on Me-β-CD the mixed threading PR, 16.9% and 12.2%
respectively, increases the chances for these architectures to cross the BBB. The similarities of
the proteins and corona percentages for these two PR, shows that they have similar biointeractions despite the differences in surface chemistry.
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Table 6.2: Twenty Most Abundant Proteins in the L81 β-CD PR Corona

!
Protein ID
Average % Corona
Serum albumin
16.53602536
Ig kappa chain C region
15.00432799
Complement C3
11.74536491
Ig gamma-1 chain C region
7.757086463
Apolipoprotein E
5.161341666
Apolipoprotein A-II
4.808387011
Apolipoprotein D
4.074641027
Apolipoprotein A-I
3.408645335
Ig lambda-1 chain C regions
3.358983503
Apolipoprotein B-100
2.938530875
Complement component C9
2.077125525
Ig gamma-2 chain C region
1.801673851
Transthyretin
1.609643609
Alpha-1-antitrypsin
1.401363144
Apolipoprotein C-I
1.370046556
Clusterin
1.286344099
Ig lambda-2 chain C regions
1.184513069
Haptoglobin
1.173103474
Serotransferrin
1.119652755
Complement C4-B
1.090155363
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Table 6.3: Twenty Most Abundant Proteins in the L81 Me-β-CD PR Corona

!
Protein ID
Average % Corona
Complement C3
17.35131077
Apolipoprotein E
16.92263363
Serum albumin
10.91695191
Apolipoprotein B-100
6.069452089
Ig gamma-1 chain C region
5.337392476
Ig kappa chain C region
5.311549879
Apolipoprotein A-II
5.010290265
Apolipoprotein D
3.573277261
Complement component C9
3.421953775
Apolipoprotein A-I
2.773780863
Complement C4-B
2.147698529
Serum paraoxonase/arylesterase 1
1.574657144
Apolipoprotein C-II
1.53214378
Apolipoprotein C-III
1.49304561
Apolipoprotein C-I
1.304540524
Clusterin
1.093414729
Apolipoprotein(a)
1.058981593
Transthyretin
0.965211466
Serum amyloid A-4 protein
0.928412544
Ig lambda-1 chain C regions
0.864075528

!
!
!

Table 6.4: Twenty Most Abundant Proteins in the L81 HP-β-CD PR Corona
Protein ID
Average % Corona
Serum albumin
21.76828436
Ig kappa chain C region
19.04835025
Apolipoprotein A-II
10.81040494
Apolipoprotein A-I
7.919583224
Apolipoprotein E
7.066407588
Apolipoprotein C-II
4.992757233
Apolipoprotein C-III
3.944752799
Ig gamma-1 chain C region
3.311732771
Transthyretin
1.985551149
Complement C3
1.908027079
Alpha-1-antitrypsin
1.650830489
Serotransferrin
1.593952712
Haptoglobin
1.546604427
Ig alpha-1 chain C region
1.482215949
Clusterin
1.035208084
Ig lambda-1 chain C regions
0.931474445
Ig kappa chain V-III region
0.773907913
Apolipoprotein D
0.753715631
Ig gamma-2 chain C region
0.647140603
Ig lambda-2 chain C region
0.604695051

!
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Table 6.5: Twenty Most Abundant Proteins in the L81 50:50 HP-β-CD:SBE-β-CD PR Corona

!
Protein ID
Average % Corona
Complement C3
19.76495094
Apolipoprotein E
12.28036258
Serum albumin
9.427281564
Apolipoprotein A-II
6.865297508
Apolipoprotein C-II
6.692607783
Ig gamma-1 chain C region
5.92949059
Ig kappa chain C region
4.87297314
Apolipoprotein B-100
4.636129789
Complement component C9
3.846580792
Apolipoprotein D
3.114959404
Apolipoprotein A-I
2.537299079
Complement C4-B
2.083473432
Trypsin-3
2.050791718
Apolipoprotein C-III
1.876260875
StAR-related lipid transfer protein 13
1.437949237
Ig gamma-2 chain C region
1.169451568
Haptoglobin
0.937229713
Clusterin
0.91590978
Apolipoprotein(a)
0.856763959
Ig lambda-1 chain C regions
0.797377646

!
!
6.3. Conclusions

!

The expanse of the design space available in PR construction warrants systematic

investigation of the numerous available parameters. This study shows that utilizing guest β-CD
macrocycles of varying surface modifications does little to affect the hemolytic potential of PR
scaffolds at the tested concentrations. In contrast, these changes will significantly impact the size
and composition of surface bound protein hard coronas. These differences are more evident in the
total protein abundance and the relative amounts of various protein families. The actual identities
of the proteins in the corona, however, can be very similar. This indicates that the overall PR
structure may be similar enough in most cases to promote recruitment of similar proteins onto the
PR surface.
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6.4. Materials and Methods

!
!
6.4.1. Hemolysis Assay
Human red blood cells (RBCs) were purchased from Zen-Bio, Inc (Research Triangle
Park, NC) and stored at 4°C until use. RBC were washed 4 times with 150 mM NaCl and
subsequently diluted 1:50 before testing. Each PR was dissolved in DMSO and sonicated for 15
min before dilution with PBS and a further 15 min of sonication. The final DMSO concentration
was 1%. PRs were then serially diluted in 1% DMSO to give solutions of 800 µg/mL, 100
µg/mL, and 20 µg/mL. Aliquots of washed RBCs (190 µL) were then incubated with 10 µL PR
for 1 h at 37°C. Final PR concentrations were 20 µg/mL, 5 µg/mL, and 1 µg/mL. The final
DMSO concentration was 0.05%. Triton X-100 (1%) was used as a positive control. After
incubation, cells were pelleted by centrifugation for 5 m at 600 x g and 100 µL of supernatant
was collected. All experiments were done in triplicate. Hemolysis was analyzed using a Nanodrop
ND-1000 (Thermo Scientific, Wilmington DE) by probing the released hemoglobin absorption at
415 nm. Results were normalized to the Triton X-100 positive control.

6.4.2. Protein Hard Corona Proteomics
Normal human serum was purchased from Complement Technology, Inc (Tyler, TX) and
thawed immediately before use. PRs (100 µg) were taken up in PBS and sonicated for 10 min
before incubation with undiluted human serum (1:1 v/v) for 1 h at 37°C. After incubation,
samples were centrifuged for 10 min at 4000 x g and PR pellets were washed four times with 150
µL cold PBS. Three separate incubations were done for each PR family member.
Tryptic peptides were separated on a nanoLC system (1100 Series LC , Agilent
Technologies, Santa Clara, CA). The peptides were loaded on the Agilent 300SB-C18 enrichment
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column (5 x 0.3 mm, 5 µm) for concentration and the enrichment column was switched into the
nano-flow path after 5 min. Peptides were separated with the C18 reversed phase ZORBAX
300SB-C18 analytical column (0.75 µm × 150 mm, 3.5um) from Agilent. Column was connected
to the emission tip from New Objective and coupled to the nano-electrospray ionization (ESI)
source of the high-resolution hybrid ion trap mass spectrometer LTQ-Orbitrap XL. (Thermo
Scientific). The peptides were eluted from the column using acetonitrile /0.1% formic acid
(mobile phase B) linear gradient. For the first 5 min, the column was equilibrated with 95% H2O
/0.1% formic acid (mobile phase A) followed by the linear gradient of 5% B to 40% B in 65 min.
at 0.3ul/min, then from 40% B to 100% B in additional 10 minutes. Column was washed with
100% of ACN/0.1%FA and equilibrated with 95% of H2O/0.1%FA before next sample was
injected (total method time = 95 min.). A blank injection was run between samples to avoid
carryover.
The LTQ-Orbitrap mass spectrometer was operated in the data-dependent positive
acquisition mode in which each full MS scan (30,000 resolving power) was followed by eight
MS/MS scans where the eight most abundant molecular ions were selected and fragmented by
collision induced dissociation (CID) using a normalized collision energy of 35%.
Database searching was conducted using MaxQuant for LFQ (Label Free Quantitation –
LFQ). The Human (SwissProt) annotated database was used for the search. Initial Spectral
Counting was performed using the Mascot Database search results. Statistical Analysis (Multi
regression Analysis) was performed using Qlucore software package.
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CHAPTER SEVEN: FUTURE DIRECTIONS

!
7.1. Introduction

!

Given the attractive features of the polyrotaxane (PR) systems outlined in the chapters

above, there are a number of directions in which PR technology can expand and mature. There is
potential for PR utilization in a number of biomedical applications that could follow from this
work. More directly, there are a number of ways the physiochemical design space of PR scaffolds
can be mapped further. Studies could be conducted into how these parameters further affect a
variety of PR functions, properties, and characteristics beyond those already initiated above.
What follows is a concise discussion of potential experimental directions most directly following
this work.

7.2. Potential Lines of In Vivo Experimentation

!
7.2.1. Completion of a Preclinical Profile for Gadolinium-Carrying PRs

!

While a large portion of a preclinical profile has been completed for gadolinium (Gd3+)

carrying hydroxypropyl-β-cyclodextrin (HP-β-CD) polyrotaxanes (PRs) of varying Pluronic
cores, there remains work that could be done to fully flesh out the safety profile of these
materials. Firstly, it remains to be seen whether these scaffolds interfere in any way with the
body’s clotting mechanisms. As discussed in Chapter Four, initiation or prevention of blood
clotting would be indicative of potential adverse reactions upon administration. This could be
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studied using either a coagulometer to directly measure time to clot formation in comparison to
positive and negative controls, or by incubating PRs with platelets and subsequently studying
either calcium flux or the appearance of specific surface antigens that would give the necessary
indications of platelet activation relative to agonist controls.
Additionally, elucidating trends in how PR physiochemical properties affect the rate of
macrophage uptake could factor into the choice of PR for a given application. Incubation of PR
scaffolds with macrophages in an in vitro time course study would be helpful in this regard. The
ability to do this with immobilized macrophages may be particularly useful given the inferred
rod-like structure of PRs in solution.1

!

Finally, there exist many ways in which our understanding of PR toxicity could be

enhanced. Serum chemistry studies have been done after single or double injections of PR
scaffolds. This should be extended to a broader hematology profile that includes complete blood
count, hemoglobin levels, and many of the other blood toxicology screens that cannot be done on
serum. Additionally, studying glomerular filtration rate by tracking the levels of aspartate
aminotransferase and alanine aminotransferase in the blood and urine over time, as well as tissue
sectioning and histological analysis would give a better indication of kidney damage. This is
especially necessary in the case of Gd3+:DOTA PRs where gadolinium-mediated nephrotoxicity is
a possibility.2 Doing these studies over longer time periods with multiple PR administrations is an
important study that must be performed to evaluate the safety profile of these scaffolds upon
repeated administration

7.2.2. Preclinical Profiling for Alternative PR Architectures
Preclinical profiles could also be built for PRs hosting other CD derivatives or containing
alternative central polymers. Of particular interest, because of its ability to significantly increase
PR solubility, would be how SBE-β-CD incorporation affects the pharmacokinetics,
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biodistribution and safety parameters. This solubilizing effect has the caveat that increasing
charge is likely to significantly alter biodistribution, circulation time, macrophage uptake,
hemolysis, immunogenicity, and many other aspects of the PR fate in vivo. These considerations
would need to be fully studied before moving forward with PRs containing higher SBE-β-CD
content.
In addition, it will be wise to study PRs containing polymers that are not Pluronic based.
These cores are likely to be non-degradable and a more attractive core would be one that the body
could process into excretable blocks. For instance, PRs containing polyesters or polycarbonates
would be much more viable, from a therapeutic standpoint, than those used herein. Secondly,
there is reason to believe that the PR scaffold would benefit from the excision of poly (ethylene
glycol) (PEG) from the design to minimize the potential for anti-PEG antibody production,
particularly in applications where repeated dosing will be required. The fact that we see the most
favorable PR pharmacokinetic profile exhibited by the PRs with the shortest PEG blocks supports
this hypothesis. For example, PRs F68 and F127 both leave blood circulation quickly, with no
boost in circulation from the large PEG blocks they contain. Also, PRs with long PEG blocks
appear to be more immunogenic when compared to their counterparts. This would suggest a
decreased likelihood for these PRs to be administered over the long term without experiencing an
accelerated blood clearance.
Finally, there is opportunity to study the administration of more complex PR
formulations. Analysis of the PR protein corona indicates that these scaffolds have a propensity to
associate with serum lipoproteins (LPs). Incubation of PR systems with high-density lipoprotein
(HDL) or low-density lipoprotein (LDL) particles may drive this PR:LP association into a more
controllable form. Pre-forming the protein complex will likely affect the pharmacokinetics and
toxicity properties relative to freely administered PR that will associate with many different blood
protein partners based on stochastic interactions. In fact, this may allow for LDL receptor-
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mediated uptake into cells, an opportunity that would be highly attractive for treatment of
Niemann-Pick Type C Disease.

7.2.3. Therapeutic Efficacy of PR Scaffolds in Niemann-Pick Type C Disease

!

While PR systems have been shown to be efficacious in in vitro NPC disease models, the

in vivo efficacy has yet to be directly studied. Lead compounds from the preclinical profiles
discussed above will need to be screened in NPC model organisms, initially NPC mice and
followed by NPC cats. Efficacy will need to be assessed by measurement of total cholesterol in
the organs of the body. This is most likely to be accomplished by gas chromatographic analysis of
saponified organs and comparison to untreated control.3 An additional measure of interest will be
any increase in survival of Purkinje cells of the brain because of the neurodegeneration associated
with NPC. These will need to be visualized by immunohistochemical labeling of sectioned neural
tissues. Finally, if testing in the cat model, there would need to be a study of the amelioration or
enhancement of ototoxicity. β-CD derivatives have been shown to engender significant hearing
loss in these animals.4 If PRs can overcome or delay this toxicity it would be a significant and
important step beyond the capabilities of the small molecule HP-β-CD drug.

!

An additional area of study will be how these therapeutic effects change with routes of

administration. Currently, β-CD administration is done through injections into the cerebral-spinal
fluid surrounding the spinal cord. PR compounds could, ideally, be administered through a less
invasive and painful route. Intravenous and intraperitoneal administration would be likely be the
first routes tested in vivo, despite not being the least clinically invasive methods. The therapeutic
effects mediated by these routes of administration would then be comparative benchmarks for
more attractive routes of parenteral administration. Oral administration will need to be
systematically studied as this would be one of the last detrimental to a patients quality of life. It
may be necessary to attempt PR formulation with polymer coatings capable of surviving the
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acidity of the stomach and gastrointestinal tract.5 Finally, a similarly attractive option would be to
administer PRs subcutaneously (SC). Efficacy after SC injection would mean that there is
potential to formulate PRs into an injection pen or as an adhesive or microneedle patch that could
be administered at home. This is a significant amount of potential in this area given that PRs have
already been shown to promote transdermal migration.6 Finally, intranasal administration could
be studied as a means to achieve blood-brain-barrier (BBB) penetration
BBB penetration will need to become a focus of PR treatment studies in order to avoid
spinal injections. This could potentially be done in many ways. Surface modification of PRs with
materials which have a propensity to cross the BBB or which have BBB specific receptors is one
potential route toward enhanced uptake. Decoration of PR scaffolds with transferrin or
Apolipoprotein E (ApoE), either covalently or through non-covalent (i.e. avidin-streptavidin)
interactions could facilitate transcytosis across the BBB.7 PRs could also be simply formulated
with ApoE through flow mixing or association with lipoprotein particles that contain large
amounts of the protein.8 Finally, there are polymeric materials, including polysorbate 80, that
engender enhanced BBB uptake through osmotic shrinkage mechanisms that and could be
included in the PR formulations.9

!
7.2.4. In Vivo Tissue Penetration and Cellular Association

!

Also of interest to NPC therapy is the extent to which PRs achieve tissue penetration

beyond simply macrophage uptake. This will give an idea of how widely PRs will be able to
affect therapeutic responses in the various cells of the body. This type of screening could be done
initially in two ways using fluorescently modified PRs. First, tissue digestion and flow cytometry
could be used to give a statistically significant look at the entire population of an organ’s cells.
Macrophages could be marked with antibodies for specific surface markers. F4/80 is a surface
protein that labels macrophages present in the liver, kidney, lung, spleen, and brain that could be
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utilized.10 After administration of labeled PRs, tissues would be harvest, digested, labeled, and
flow data would be acquired measuring the macrophage associated PR fluorescence against PR
fluorescence given by other cells. Secondly, PR penetration beyond exterior organ interfaces
could be studied by immunohistochemical examination of tissue sections. Images would allow for
visualization of whether PRs are deposited along external organ membranes, for instance in the
airways of the lungs, or perfused more deeply into the tissue. Evidence that PRs are associated
only with macrophages or are not penetrating tissue would need to be addressed by system design
changes.

!
7.3. Potential Lines of In Vitro Experimentation

!
!
7.3.1. Internalization Pathways

!

When studying the mechanisms by which PRs interact with the cell, it will be important

to understand how PR systems are internalized. These routes could easily be probed through the
use of fluorescently labeled PRs and small molecule inhibitors. Blocking endocytosis pathways
sequentially and tracking PR uptake by flow cytometry would give the necessary information.
Clathrin-independent and clathrin-dependent endocytosis can be inhibited by the small molecules
geninstein and chlorpromazine, respectively. In addition, rottlerin is a potent inhibitor of
macropinocytosis. Alternatively, siRNA gene silencing could be used to selectively inhibit
specific pathways. Establishing trends in internalization pathway for PRs of varying CDs and
polymer content would enable tailoring of PR scaffold to the necessary applications. Knowing if
PR uptake is by a receptor-mediated pathway could also inform design choices to reinforce or
diminish this effect.
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7.3.2. Kinetics and Mechanisms of PR Therapeutic Effects and Intracellular Dethreading
Along with studying the mechanisms by which PRs enter the cell, it would be useful to

know the timescale by which they enter the cell and the kinetics by which their therapeutic effects
occur. This information will be especially important for NPC applications. It would allow for
selection of materials that are rapidly internalized and degraded. Maximum therapeutic potential
could be achieved by selecting for materials that are able to trigger cholesterol efflux from sites of
sequestration most effectively.
Understanding the mechanisms by which PRs mediate their cholesterol mobilization will
require knowledge of how and when PR systems release their CD cargo. The current hypothesis
is that endcap cleavage is driven by endolysosomal esterases. This could be tested by the use of
esterase inhibitors or carbamatase siRNA knockdowns. The kinetics of this release could be
measured by cell lysis at specific time points followed by analysis of free CD content by HPLC.

7.4. Additional Applications and Therapeutic Models.

!
7.4.1. Magnetic Resonance Imaging

!

Magnetic Resonance Imaging (MRI) is an important means by which three-dimensional

structures or body organs and tissues can be investigated. It has applications in a wide range of
disease diagnostics.11 MRI images are often improved by the use of contrast agents, including
Gd3+. Unfortunately, these agents are often small molecule scaffolds that clear rapidly from the
body.11 Alternatively, macromolecular contrast agents that do not biodegrade may exhibit
extended residence time in the body and raise the potential for Gd3+ related nephrotoxicity.12-13
As discussed in Chapter 5, PR scaffolds can be modified with Gd3+ and, therefore, could serve as
effective MRI contrast agents. Long circulation achieved by PRs would allow for increased
contrast enhancement over time and breakdown of the PR scaffolds into biocompatible and
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excretable components that would avoid bioaccumulation and potential heavy metal mediated
toxicity. Design parameters would need to be scanned, as discussed above, to find long
Gd3+:DOTA PRs capable of long circulation and favorable metabolism to find the most effective
potential MRI scaffolds.

7.4.2. Tumor Penetration
As an extension of the use of PRs as MRI agents, these compounds could also be used as
tumor penetrating drug delivery or diagnostic systems. In particular, constructs from the
pharmacokinetic and MRI screening experiments described above could be used in
immunodeficient mouse tumor models to see if they provide sufficiently enhanced tumor uptake,
residence, and contrast. These studies would yield an efficient and biocompatible MRI contrast
agent for use in cancer diagnostics. Similar animal models could be used to test the effectiveness
of cancer treatment with PRs modified with small molecule drugs. Using synthetic schemes
similar to those we have previously used, PRs could be modified with anti-tumor therapeutics
(i.e. doxorubicin) and administered to tumor bearing mouse models. Growth rates of the tumor
mass and the average lifetimes of mice treatment and control groups would provide information
into the therapeutic effectiveness of the system. In this area, PRs have to potential to become
generalizable drug delivery scaffolds.

7.4.3. Alzheimer’s Disease

!

Using PR constructs to treat NPC is desirable because therapeutic activity comes from

the β-CD derivatives they inherently carry as part of their scaffold. This means there is no need
for post-modification with drugs and the actual therapeutic represents a large percentage of the
mass of the administered dose. This same potential exists in Alzheimer Disease (AD) where β-
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CD derivatives have recently been shown to be therapeutically useful in diminishing amyloid-β
plaques and slowing neurodegeneration.14 Pursuing this line of experimentation would allow the
re-purposing of existing materials for another life-threatening neurological disorder.
In this same literature, data exists showing effective use of gene delivery to prevent
memory loss in rats and non-human primates.15 Therapeutic delivery of brain-derived
neurotrophic factor (BDNF) was done with a lentiviral vector that acted without affecting plaque
deposition. Many of the PR constructs listed above have the potential to be modified with cations
and used to deliver genes, including BDNF. This would deploy a dual therapy upon dethreading,
i.e. plaque dissolution and BDNF remediation. In fact, the Thompson Lab has published multiple
papers on the use of PRs as gene delivery vectors.16, 17 There exists in AD therapy an opportunity
to bring to bear single or multifunctional therapeutic options using the scaffolds presented and
discussed in this thesis.
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Figure A.1: 1H NMR spectra of (1) β-CD, (2) F68-TREN, (3) β-CD:F68 PR
β-CD:F68 PR 1H NMR: (400Mhz, DMSO-d6, 22°C) δ 8.9-8.89(br. s., 8H, TNB), 5.74-5.63 (m,
196H, O2H, O3H of CD), 4.83-4.77 (s, 98H, H1 of CD), 4.46-4.39 (t, 98H, O6H of CD), 3.65-3.55
(m, 196H, H3, H6, H5, H4 of CD), 3.51-3.44 (m, 132H, PPO and PPG-CH2-), 1.05-0.98 (d, 87H,
PPG-CH3)
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Figure A.2: 1H NMR spectra of (1) β-CD, (2) L64-TREN, (3) β-CD:L64 PR
β-CD:L64 PR 1H NMR: (400Mhz, DMSO-d6, 22°C) δ 8.891-8.814 (s., 8H, TNB), 5.76-5.6 (m,
168H, O2H, O3H of CD), 4.84-4.76 (s, 84H, H1 of CD), 4.52-4.38 (t, 84H, O6H of CD), 3.67-3.59
(m, 336H, H3, H6, H5, H4 of CD), 3.51-3.43 (m, 194H, PPO and PPG-CH2-), 1.05-0.95 (d, 90H,
PPG-CH3)
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Figure A.3: 1H NMR spectra of (1) β-CD, (2) L35-TREN , (3) β-CD:L35 PR
β-CD:L35 PR NMR: (400Mhz, DMSO-d6, 22°C) δ 8.93-8.91(s., 8H, TNB), 5.75-5.65 (m, 98H,
O2H, O3H of CD), 4.84-4.78 (s, 49H, H1 of CD), 4.45 (t, 49H, O6H of CD), 3.67-3.59 (m, 532H,
H3, H6, H5, H4 of CD), 3.51-3.48 (m, 995H, PPO and PPG-CH2-), 1.06-0.98 (d, 48H, PPG-CH3)
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Figure A.4: NOESY Spectra of β-CD:F127
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Figure A.5: NOESY Spectra of β-CD:F68 PR.
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Figure A.6: NOESY Spectra of β-CD:L64 PR.
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Figure A.7: NOESY Spectra of β-CD:L35 PR.
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Figure A.8: β-CD:F127 PR GPC Traces.
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Figure A.9: β-CD:F68 PR GPC Traces.
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Figure A.10: β-CD:L64 PR GPC Traces.
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Figure A.11: β-CD:L35 PR GPC Traces.
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Figure A.12: β-CD:F68 PR AUC Trace.
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Figure A.13: β-CD:L64 PR AUC Trace.

!
Figure A.14: β-CD:L35 PR AUC Trace.
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Figure A.15: AFM Images of (A) β-CD:F68 PR at 10-5 mg/mL, (B) β-CD:L64 PR at 10-5
mg/mL, and (C) β-CD:L35 PR at 10-9 mg/mL. Scale bar represents 500 nm.
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Figure A.16: β-CD:F127 PR MALDI Mass Spectrometry.
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Figure A.17: β-CD:F68 PR MALDI Mass Spectrometry.
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!
Figure A.18: β-CD:L64 PR MALDI Mass Spectrometry.

!
Figure A.19: β-CD:L35 PR MALDI Mass Spectrometry.
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Figure A.20: HILIC Free β-Cyclodextrin Standard Curve
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Figure A.21: RPLC Free β-Cyclodextrin Standard Curve
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Figure A.22: 1H NMR of Unthreaded F68-TNB
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Figure A.23: UV Spectra of F68-TNB After Incubation With 5 mM Glutathione in PBS at pH 7.
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Figure A.24: UV Spectra of F68-TNB After Incubation With 5 mM Glutathione in PBS at pH
5.5.
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Figure A.25: H NMR of Short PEG – TNB.
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Figure A.26: NMR Spectra of Short PEG-TNB After 48 h Incubation withC Glutathione at 37°C.
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Figure A.27: 1H NMR spectra for A) PR Incubated with DMSO/Minimum Essential Media, B)
PR Incubated with DMSO/PBS Buffer and C) Control PR Sample.
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Figure A.28: Self-Diffusion Coefficients Vs. Molecular Weight for β-CD:L35 PR, β-CD:L64 PR,
and β-CD:F68 PR. Dashed Line is a Least Squared Fit to the Data.
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Figure A.29: Spectra and Self-Diffusion Coefficients for β-CD:L35 PR.
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Figure A.30: Spectra and Self-Diffusion Coefficients for β-CD:L64 PR.
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Figure A.31: Spectra and Self-Diffusion Coefficients for β-CD:F68 PR.
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Figure A.32: Filipin Staining Experiments Showing Cholesterol Efflux From npc2-/- Fibroblasts.
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Appendix B
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Figure B.1: IR800CW PR Standard Curve.
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Figure B.2: Representative Pre-injection NIR Image.
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Figure B.3: IR800CW F68 PR Timecourse.
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Figure B.4: IR800CW L64 PR Timecourse.
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Figure B.5: IR800CW L81 PR Timecourse.
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Figure B.6: IR800CW PR 24 h Organ Distribution.
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Figure B.7: IR800CW PR 120 h Organ Distribution.
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Figure B.8: IR800CW PR Organ Distribution Radiant Efficiency.
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Figure B.9: Gd :HP PR Organ/Body Weight Ratios 21 Days After Administration.
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Figure B.10: Gd3+:HP PR Serum Electrolytes 21 Days After Administration.
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Figure B.11: Additional Serum Chemistry 21 Days after Gd3+:HP PR Administration.
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Figure B.12: Further Serum Chemistry 21 Days after Gd3+:HP PR Administration.
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Figure B.13: Gd3+:HP PR Mediated Human Red Blood Cell Hemolysis.

Table B.1: Full Protein Corona For Gd3+:HP-β-CD F127 PR
Protein ID
Apolipoprotein A-I
Complement C3
Serum albumin
Apolipoprotein A-II
Apolipoprotein C-III
Apolipoprotein C-I
Apolipoprotein C-II
Ig kappa chain C region
Apolipoprotein E
Ig gamma-1 chain C region
Apolipoprotein A-IV
Alpha-2-HS-glycoprotein
Complement component C9
Clusterin
Transthyretin
Complement component C8 gamma chain
Ig lambda-1 chain C regions
Ig gamma-2 chain C region

!

Gd3+:HP L81 PR

Percent PR Corona
23.68948669
8.263679457
8.220708843
7.051049504
5.251471188
5.213928823
4.642077285
4.499298055
4.059720575
2.983669078
2.4906027
1.849838394
1.76530601
1.343077522
1.188196742
1.177818036
1.129279556
0.842647227

!
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Apolipoprotein D
Alpha-1-antitrypsin
Complement C5
Complement component C6
Platelet factor 4
Serum amyloid A-4 protein
Ig mu chain C region
Ig lambda-2 chain C regions
Apolipoprotein C-IV
Vitronectin
Serotransferrin
Kininogen-1
Complement component C8 alpha chain
Alpha-1-acid glycoprotein 1
Ig alpha-1 chain C region
Complement component C7
Complement C4-B
Properdin
Apolipoprotein B-100
Serum amyloid A-1 protein
Prothrombin
Ig kappa chain V-III region
Haptoglobin
Ig heavy chain V-III region
Complement component C8 beta chain
Alpha-2-macroglobulin
Ig kappa chain V-I region
Ig kappa chain V-IV region
Antithrombin-III
Coagulation factor X
Serum amyloid P-component
Apolipoprotein M
Secreted phosphoprotein 24
Serum paraoxonase/arylesterase 1
Vitamin K-dependent protein C
Inter-alpha-trypsin inhibitor heavy chain H2
Histidine-rich glycoprotein
Hemopexin
Ig kappa chain V-I region
Hemoglobin subunit beta
Plasma protease C1 inhibitor
Inter-alpha-trypsin inhibitor heavy chain H4
Ig gamma-4 chain C region
Integrin alpha-M
Alpha-1-microglobulin
Alpha-S1-casein
Hemoglobin subunit alpha
Alpha-1-acid glycoprotein 2
Ig kappa chain V-II region

!

0.812863719
0.77790649
0.727512772
0.682837914
0.579958284
0.568312149
0.537593438
0.52351147
0.509073811
0.443029334
0.411663216
0.408572675
0.394673404
0.388432005
0.360224829
0.350408181
0.348490537
0.34043785
0.315072774
0.306051745
0.281454303
0.275511648
0.262253153
0.259189982
0.258203987
0.213920632
0.211241187
0.183280206
0.158366291
0.152111554
0.107284277
0.103351409
0.097129455
0.093964233
0.086723995
0.083963117
0.077874255
0.065339865
0.064885988
0.064873797
0.061897832
0.056681786
0.055677006
0.054038598
0.051589591
0.049818026
0.048519382
0.048075723
0.046492326

!
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Ceruloplasmin
Complement factor B
Alpha-1-antichymotrypsin
Complement factor H
Apolipoprotein(a)
Haptoglobin-related protein
Hemoglobin subunit alpha
C4b-binding protein alpha chain
Fibronectin
Phospholipid transfer protein
Virion-packaging protein
Coagulation factor IX
Alpha-1B-glycoprotein
Vitamin D-binding protein
Lipopolysaccharide-binding protein
Myosin light chain 4
Coagulation factor VII
Ig gamma-3 chain C region
Dystrophin
Apolipoprotein F
Inter-alpha-trypsin inhibitor heavy chain H1
Apolipoprotein L1
Gelsolin
Protein S100-A7
Heparin cofactor 2
Ig lambda chain V-III region LOI
Ig mu heavy chain disease protein
Coagulation factor V
Bovine serum albumin precursor
Vitamin K-dependent protein S
Complement factor H-related protein 1
Retinol-binding protein 4
Glyceraldehyde-3-phosphate dehydrogenase
Alpha-2-antiplasmin
Zinc-alpha-2-glycoprotein
Complement C4-A
Plasminogen
Angiotensinogen
Vitamin K-dependent protein Z
Melanoma-associated antigen B3
Ig alpha-2 chain C region
Beta-2-glycoprotein 1
Alstrom syndrome protein 1
Junction plakoglobin
Thyroid receptor-interacting protein 11
Fibrinogen alpha chain
Filaggrin-2
Inter-alpha-trypsin inhibitor heavy chain H3
Hyaluronan-binding protein 2

!

0.04622634
0.045937114
0.043530752
0.043322168
0.04317659
0.040441025
0.037714761
0.033862303
0.033549542
0.032842187
0.032486179
0.03179155
0.030934665
0.028933039
0.028903828
0.027195711
0.025920957
0.024733054
0.024004662
0.023305555
0.022148596
0.021885655
0.019207083
0.018603779
0.017337087
0.016265495
0.01389369
0.013161321
0.012433301
0.012332399
0.012249404
0.01212186
0.010818937
0.010512345
0.010305449
0.008968295
0.008951262
0.008415168
0.007606276
0.007489954
0.007414991
0.006513962
0.004523926
0.003855662
0.003446788
0.002542826
0.002270906
0.001997603
0.00129618

!
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BPI fold-containing family B member 1

!

Table B.2: Full Protein Corona For Gd3+:HP-β-CD F68 PR

Protein ID
Apolipoprotein A-I
Apolipoprotein A-II
Apolipoprotein C-III
Apolipoprotein C-II
Apolipoprotein C-I
Complement C3
Alpha-2-HS-glycoprotein
Serum albumin
Apolipoprotein E
Apolipoprotein A-IV
Ig kappa chain C region
Complement component C9
Clusterin
Ig gamma-1 chain C region
Complement component C8 gamma chain
Apolipoprotein D
Prothrombin
Serum amyloid A-4 protein
Transthyretin
Ig lambda-1 chain C regions
Complement component C6
Complement C5
Vitronectin
Alpha-1-antitrypsin
Ig gamma-2 chain C region
Complement component C8 alpha chain
Ig mu chain C region
Coagulation factor X
Complement component C7
Vitamin K-dependent protein C
Apolipoprotein C-IV
Properdin
Apolipoprotein B-100
Ig lambda-2 chain C regions
Complement component C8 beta chain
Serum amyloid A-1 protein
Complement C4-B
Ig alpha-1 chain C region
Ig kappa chain V-III region

!

0.000421925

Percent PR Corona
31.99542965
9.218839973
6.672272054
6.659471591
6.290285153
6.13462544
4.46555885
3.993341851
2.655028306
2.448874185
2.033188027
1.538969444
1.485710311
1.202353223
1.134662774
1.127944085
0.813765188
0.797553547
0.788184866
0.644944697
0.584552077
0.511521581
0.424684704
0.371398632
0.365379064
0.351054313
0.336750745
0.328234473
0.305902386
0.270904472
0.265705108
0.258461451
0.211974335
0.191403458
0.183038036
0.161193182
0.151806751
0.138911016
0.13552322

!
Haptoglobin
Ig heavy chain V-III region
Serotransferrin
Secreted phosphoprotein 24
Kininogen-1;Kininogen-1 heavy chain
Ig kappa chain V-I region
Alpha-1-acid glycoprotein 1
Platelet factor 4
Ig kappa chain V-IV region
Antithrombin-III
Alpha-2-macroglobulin
Coagulation factor VII
Coagulation factor IX
Integrin alpha-M
Serum paraoxonase/arylesterase 1
Apolipoprotein M
Myosin light chain 4
Inter-alpha-trypsin inhibitor heavy chain H2
Apolipoprotein(a)
Vitamin K-dependent protein S
Complement factor B
Vitamin K-dependent protein Z
Ig kappa chain V-I region CAR
Virion-packaging protein
C4b-binding protein alpha chain
Hemoglobin subunit beta
Lipopolysaccharide-binding protein
Hemopexin
Ig gamma-4 chain C region
Zinc finger FYVE domain-containing protein 1
Serum amyloid P-component
Histidine-rich glycoprotein
Plasma protease C1 inhibitor
Inter-alpha-trypsin inhibitor heavy chain H4
Alpha-1-microglobulin
Apolipoprotein F
Fibronectin
Complement factor H
Haptoglobin-related protein
Apolipoprotein L1
Hemoglobin subunit alpha
Vitamin D-binding protein
Alpha-1-acid glycoprotein 2
Ceruloplasmin
Zinc-alpha-2-glycoprotein
Complement factor H-related protein 1
Gelsolin
Alpha-1B-glycoprotein
Alpha-1-antichymotrypsin

!
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0.134637583
0.132940282
0.131142529
0.116843661
0.114281305
0.108644652
0.106762106
0.087991827
0.087919773
0.081305193
0.079591525
0.067886684
0.058775535
0.055784832
0.053473618
0.050678852
0.049670782
0.042035827
0.041214205
0.037175123
0.034587627
0.033661102
0.033567277
0.029101171
0.028870479
0.0283774
0.025215943
0.025212402
0.025077765
0.02419474
0.023928273
0.023246885
0.022726697
0.020428572
0.020253214
0.019206169
0.018752376
0.017938007
0.017677155
0.01756036
0.017467754
0.017167583
0.014494482
0.014024362
0.01331371
0.012633155
0.011985716
0.011441113
0.010788476

!
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Phospholipid transfer protein
Melanoma-associated antigen B3
Ig lambda chain V-III region
Dystrophin
Glyceraldehyde-3-phosphate dehydrogenase
Heparin cofactor 2
Coagulation factor V
Inter-alpha-trypsin inhibitor heavy chain H1
Thyroid receptor-interacting protein 11
Ig alpha-2 chain C region
Ig mu heavy chain disease protein
Plasminogen
Complement C4-A
Beta-2-glycoprotein 1
Fibrinogen alpha chain
Retinol-binding protein 4
Junction plakoglobin
Alpha-2-antiplasmin
Angiotensinogen
Serum albumin precursor
Inter-alpha-trypsin inhibitor heavy chain H3
Filaggrin-2
Coagulation factor V precursor

0.010301834
0.009708493
0.008128606
0.006729086
0.006254356
0.006079758
0.005818274
0.005259805
0.005250333
0.004713103
0.004651338
0.004113757
0.003394206
0.003332363
0.003322615
0.003282424
0.00198218
0.001665667
0.00158319
0.001457638
0.000896388
0.000809962
0.000206553

Table B.3: Full Protein Corona For Gd3+:HP-β-CD L35 PR

!
Protein ID
Vitronectin
Apolipoprotein C-III
Serum albumin
Apolipoprotein C-II
Apolipoprotein A-II
Ig kappa chain C region
Hyaluronan-binding protein 2
Complement C3
Apolipoprotein A-I
Clusterin
Ig gamma-1 chain C region
Apolipoprotein E
Apolipoprotein C-I
Ig lambda-1 chain C regions
Prothrombin
Ig mu chain C region
Inter-alpha-trypsin inhibitor heavy chain H2
Platelet factor 4

!

Percent PR Corona
12.83014065
7.994388561
6.900445584
6.722644919
6.460543675
5.106817942
4.756287373
4.653739172
4.456003931
3.557088095
3.123661581
2.78340154
2.694849924
1.925077969
1.913831307
1.371190996
1.220287554
1.155834789

!
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Apolipoprotein D
Transthyretin
Complement C4-B
Apolipoprotein A-IV
Alpha-2-HS-glycoprotein
Ig lambda-2 chain C regions
Alpha-2-antiplasmin
Alpha-1-antitrypsin
Ig gamma-2 chain C region
Complement component C9
Ig heavy chain V-III region BRO
Serum paraoxonase/arylesterase 1
Inter-alpha-trypsin inhibitor heavy chain H1
Apolipoprotein B-100
Apolipoprotein M
Ig alpha-1 chain C region
Serum amyloid A-4 protein
Apolipoprotein C-IV
Antithrombin-III
Phospholipid transfer protein
Serum amyloid A-1 protein
Apolipoprotein F
Vitamin K-dependent protein C
Alpha-1-microglobulin
Haptoglobin
Coagulation factor X
Serotransferrin
Ig kappa chain V-III region
Ig kappa chain V-IV region
Alpha-1-acid glycoprotein 1
Galectin-3-binding protein
Coagulation factor IX
Secreted phosphoprotein 24
Ig kappa chain V-I region WAT
ATM interactor
Inter-alpha-trypsin inhibitor heavy chain H3
Vitamin K-dependent protein Z
Complement component C8 gamma chain
Haptoglobin-related protein
Serum albumin precursor
Complement C5
Alpha-2-macroglobulin
Complement component C6
Kininogen-1
Inter-alpha-trypsin inhibitor heavy chain
Apolipoprotein(a)
Plasma protease C1 inhibitor
Ig kappa chain V-I region
Complement component C8 alpha chain

!

1.14725169
1.040334076
1.0396153
0.984705935
0.837271274
0.763197687
0.761857589
0.74847711
0.71790249
0.684143621
0.57254594
0.543715789
0.510336179
0.471271247
0.469243498
0.460902948
0.450129272
0.384815461
0.378568664
0.362558495
0.362468608
0.356046797
0.342648542
0.33603681
0.312616949
0.310989243
0.278797984
0.275119207
0.271003853
0.255279118
0.242933872
0.214829598
0.202161722
0.196739734
0.196053693
0.193857071
0.181873137
0.162488848
0.159558871
0.152009542
0.135913718
0.118851938
0.116367636
0.115004353
0.082429201
0.081398177
0.080776568
0.075748873
0.061999252

!
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Complement factor H
Properdin
Melanoma-associated antigen B3
Complement component C7
Hemopexin
Alpha-1-acid glycoprotein 2
Complement component C8 beta chain
C4b-binding protein alpha chain
Trypsin-3
Apolipoprotein L1
Alpha-1-antichymotrypsin
Fibronectin
Ig mu heavy chain disease protein
Histidine-rich glycoprotein
Coagulation factor VII
Lipopolysaccharide-binding protein
Ig gamma-4 chain C region
Ig gamma-3 chain C region
Ceruloplasmin
Zinc finger FYVE domain-containing protein 1
Alpha-1B-glycoprotein
Serum amyloid P-component
Complement factor H-related protein 3
Angiotensinogen
Virion-packaging protein
Complement factor B
Gelsolin
Vitamin K-dependent protein S
Ig lambda chain V-III region
Complement C4-A
Vitamin D-binding protein
Heparin cofactor 2
Hemoglobin subunit alpha
Ig lambda-3 chain C regions
Hemoglobin subunit alpha
Plasminogen
Hemoglobin subunit beta
Lumican
Ig alpha-2 chain C region
Zinc-alpha-2-glycoprotein
Retinol-binding protein 4
Beta-2-glycoprotein 1
Junction plakoglobin
Coagulation factor V
Dystrophin
Glyceraldehyde-3-phosphate dehydrogenase
Thyroid receptor-interacting protein 11
BPI fold-containing family B member 1
Complement factor H-related protein 1

!

0.059623033
0.057301549
0.057204784
0.051996426
0.051530336
0.044049449
0.041599954
0.039647186
0.039063791
0.038808678
0.035346266
0.034286961
0.033488025
0.03332859
0.029976776
0.028507289
0.028422687
0.027383973
0.027217812
0.026894805
0.026457563
0.025255192
0.024630404
0.022646486
0.022320933
0.020601153
0.019936472
0.019160592
0.017913911
0.017281794
0.016991855
0.014825762
0.012862119
0.011874866
0.0116793
0.010348966
0.010266856
0.008654928
0.00833412
0.007584108
0.007340766
0.007284382
0.006746253
0.006657744
0.006337971
0.00481623
0.004010944
0.003884575
0.003142598

!
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Protein Z-dependent protease inhibitor
Alstrom syndrome protein 1
Filaggrin-2
Fibrinogen alpha chain
Coagulation factor V precursor

0.002767364
0.002165109
0.001187266
0.00110959
0.000160718

Table B.4: Full Protein Corona For Gd3+:HP-β-CD L64 PR
Protein ID
Transthyretin
Apolipoprotein C-III
Apolipoprotein A-I
Prothrombin
Serum albumin
Apolipoprotein C-II
Apolipoprotein A-IV
Hyaluronan-binding protein 2
Vitronectin
Inter-alpha-trypsin inhibitor heavy chain H2
Clusterin
Apolipoprotein A-II
Ig kappa chain C region
Complement C3
Inter-alpha-trypsin inhibitor heavy chain H1
Alpha-2-HS-glycoprotein
Alpha-1-microglobulin
Inter-alpha-trypsin inhibitor heavy chain H3
Ig gamma-1 chain C region
Apolipoprotein E
Complement C4-B
Apolipoprotein C-I
Retinol-binding protein 4
Alpha-1-antitrypsin
Ig lambda-1 chain C regions
Antithrombin-III
Kininogen-1
Platelet factor 4
Plasma protease C1 inhibitor
Complement component C9
Apolipoprotein D
Serum amyloid A-1 protein
Serum amyloid P-component
Lumican
Alpha-1-antichymotrypsin

!

Percent PR Corona
36.92882834
5.640337171
5.343226422
4.491836376
4.453993079
3.932134511
3.646873692
3.404816171
3.20820959
2.468669522
2.390341589
2.116701292
2.007984058
1.904499153
1.447922545
1.424555287
1.42007729
1.206435029
1.005444601
1.004896536
0.926836926
0.909890523
0.804254485
0.767491151
0.606262844
0.538761909
0.477711863
0.473345395
0.469965752
0.403608715
0.351008701
0.272371526
0.240046094
0.22256942
0.20068889

!
Ig gamma-2 chain C region
Apolipoprotein F
Ceruloplasmin
Ig lambda-2 chain C regions
Ig alpha-1 chain C region
Integrin alpha-M
Apolipoprotein C-IV
Vitamin K-dependent protein C
Alpha-2-antiplasmin
Coagulation factor X
Alpha-1-acid glycoprotein 1
Haptoglobin
Serum paraoxonase/arylesterase 1
Ig kappa chain V-III region
Coagulation factor IX
ATM interactor
Serotransferrin
Heparin cofactor 2
Apolipoprotein B-100
Complement component C8 gamma chain
Ig kappa chain V-IV region Len
Ig mu chain C region
Apolipoprotein M
Complement C1s subcomponent
Vitamin K-dependent protein S
Serum amyloid A-4 protein
Complement C5
Alpha-2-macroglobulin
Coagulation factor V
Secreted phosphoprotein 24
Vitamin K-dependent protein Z
Inter-alpha-trypsin inhibitor heavy chain
Complement component C6
Fibronectin
Properdin
Ig heavy chain V-III region
Alpha-1-acid glycoprotein 2
Complement C4-A
Complement component C8 beta chain
Complement component C8 alpha chain
Alpha-1B-glycoprotein
Hemopexin
Virion-packaging protein
Angiotensinogen
Zinc finger FYVE domain-containing protein 1
Coagulation factor VII
Ig lambda chain V-III region LOI
Lipopolysaccharide-binding protein
Protein Z-dependent protease inhibitor

!
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0.192116812
0.143355345
0.137814099
0.135135608
0.134466404
0.129901011
0.11797449
0.111432101
0.109772303
0.108681552
0.089894765
0.085065625
0.080363152
0.074537397
0.073994393
0.071650532
0.06452884
0.062297109
0.059946943
0.059632176
0.054765379
0.049350375
0.04492418
0.038062794
0.03651887
0.035002193
0.033944174
0.033293991
0.032879545
0.028040823
0.025804357
0.025693961
0.025578459
0.024755654
0.022761783
0.018972975
0.018430936
0.017760539
0.017112765
0.015196272
0.013571499
0.01255781
0.012410339
0.011667359
0.011378758
0.010987358
0.01007801
0.009771991
0.009585967

!
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Histidine-rich glycoprotein
C4b-binding protein alpha chain
Carboxypeptidase N subunit 2
Ig gamma-4 chain C region
Haptoglobin-related protein
Complement component C7
Apolipoprotein(a)
Gelsolin
Complement factor B
Hemoglobin subunit beta
Vitamin D-binding protein
Apolipoprotein L1
Peptidase inhibitor 16
Biotinidase
Galectin-3-binding protein
Zinc-alpha-2-glycoprotein
Fibulin-1
Complement factor H
Insulin-like growth factor-binding protein complex acid labile subunit
Ig gamma-3 chain C region
Ig alpha-2 chain C region
Melanoma-associated antigen B3
Phospholipid transfer protein
Hemoglobin subunit alpha
Golgi-specific brefeldin A-resistance guanine nucleotide exchange
factor 1
Glyceraldehyde-3-phosphate dehydrogenase
Dystrophin
Bovine serum albumin precursor
Alstrom syndrome protein 1
Beta-2-glycoprotein 1
Thyroid receptor-interacting protein 11
Complement factor H-related protein 1
Coagulation factor V precursor

0.009491318
0.009006857
0.008879723
0.008588134
0.008343286
0.007963676
0.00794482
0.00728464
0.007281434
0.006780236
0.006760971
0.005780626
0.004961467
0.00489594
0.004892097
0.003960639
0.003926677
0.003322653
0.003030425
0.002981662
0.002334308
0.002300667
0.002270665
0.002193323
0.001694413
0.001387415
0.001274781
0.001250752
0.001086554
0.000922916
0.000645284
0.000311923
0.0002335

Table B.5: Full Protein Corona For Gd3+:HP-β-CD L81 PR
Protein ID
Serum albumin
Apolipoprotein C-III
Apolipoprotein A-I
Ig kappa chain C region
Apolipoprotein C-I
Complement C3
Apolipoprotein C-II

!

Percent PR Corona
17.11418567
10.94908584
7.466318677
7.203133214
7.167013517
6.622339883
6.557470377

!
Ig gamma-1 chain C region
Clusterin
Apolipoprotein E
Apolipoprotein A-II
Ig lambda-1 chain C regions
Transthyretin
Complement C4-B
Alpha-1-antitrypsin
Ig gamma-2 chain C region
Complement component C9
Apolipoprotein A-IV
Ig mu chain C region
Alpha-2-HS-glycoprotein
Serotransferrin
Ig lambda-2 chain C regions
Vitronectin
Apolipoprotein B-100
Ig alpha-1 chain C region
Haptoglobin
Apolipoprotein C-IV
Apolipoprotein D
Ig heavy chain V-III region
Ig kappa chain V-III region
Alpha-1-acid glycoprotein 1
Alpha-2-macroglobulin
Ig kappa chain V-IV region
Phospholipid transfer protein
Prothrombin
Antithrombin-III
Kininogen-1
Complement component C8 gamma chain
Complement factor H
Complement C5
Integrin alpha-M
ATM interactor
Secreted phosphoprotein 24
Ig kappa chain V-I region
Serum amyloid A-4 protein
Apolipoprotein M
Serum paraoxonase/arylesterase 1
Complement component C6
Inter-alpha-trypsin inhibitor heavy chain H2
C4b-binding protein alpha chain
Lipopolysaccharide-binding protein
Haptoglobin-related protein
Plasma protease C1 inhibitor
Inter-alpha-trypsin inhibitor heavy chain H4
Complement component C8 alpha chain
Properdin

!
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4.653725509
4.096785956
2.366180581
2.053647321
1.777470732
1.66188389
1.646949368
1.440540318
1.208887267
1.084131271
0.985567942
0.851889708
0.820199699
0.763060085
0.709683265
0.691084103
0.605295156
0.54865245
0.513437652
0.49431673
0.491007078
0.474002846
0.412235808
0.325917387
0.270595297
0.26032636
0.256456115
0.241541169
0.239160589
0.228064236
0.208190854
0.208154523
0.207399227
0.19222514
0.189552396
0.18123971
0.169103338
0.165667627
0.160574074
0.149060121
0.132584484
0.12542807
0.116129399
0.098632283
0.097369727
0.09432651
0.094258288
0.09387331
0.084740856

!
Ig gamma-4 chain C region
Ceruloplasmin
Hemopexin
Serum amyloid A-1 protein
Apolipoprotein(a)
Complement component C7
Apolipoprotein F
Coagulation factor IX
Zinc finger FYVE domain-containing protein 1
Alpha-1-antichymotrypsin
Alpha-1B-glycoprotein
Vitamin K-dependent protein C
Complement factor B
Serum amyloid P-component
Apolipoprotein L1
Fibronectin
Ig gamma-3 chain C region
Coagulation factor X
Trypsin-3
Heparin cofactor 2
Histidine-rich glycoprotein
Alpha-1-microglobulin
Gelsolin
Complement component C8 beta chain
Inter-alpha-trypsin inhibitor heavy chain H1
Hemoglobin subunit alpha
Coagulation factor VI
Vitamin D-binding protein
Alpha-2-antiplasmin
Platelet factor 4
Melanoma-associated antigen B3
Hemoglobin subunit beta
Plasminogen
Virion-packaging protein UL25
Protein S100-A7
Beta-2-glycoprotein 1
Vitamin K-dependent protein Z
Complement C4-A
Ig lambda chain V-III region LOI
Ig alpha-2 chain C region
Vitamin K-dependent protein S
Angiotensinogen
Complement factor H-related protein 1
Dystrophin
Sorting nexin-25
Glyceraldehyde-3-phosphate dehydrogenase
Ig mu heavy chain disease protein
Hemoglobin subunit alpha
Inter-alpha-trypsin inhibitor heavy chain H3

!
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0.08122044
0.080970148
0.078256929
0.069949226
0.068815812
0.065100318
0.063089415
0.059848337
0.059628285
0.058212412
0.056996919
0.055856779
0.05464146
0.053646413
0.053048689
0.052225051
0.051516351
0.048804145
0.048100147
0.047674481
0.046309415
0.04590583
0.043439513
0.041366985
0.041269102
0.038360329
0.038250484
0.036154865
0.030340658
0.028203418
0.02780215
0.027551364
0.026457209
0.026188993
0.025486454
0.022188076
0.019566054
0.017411295
0.016635952
0.014571562
0.012993529
0.012544486
0.012294497
0.011698827
0.011139946
0.009815528
0.009751499
0.009114132
0.007733188

!
Hyaluronan-binding protein 2
Zinc-alpha-2-glycoprotein
Myosin light chain 4
Complement C1s subcomponent
Thyroid receptor-interacting protein 11
BPI fold-containing family B member 1
Alstrom syndrome protein 1
Lumican
Junction plakoglobin
Coagulation factor V
Filaggrin-2
Bovine serum albumin precursor
Fibrinogen alpha chain

!
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0.007700139
0.005453507
0.005418754
0.005384176
0.005323248
0.004398327
0.004326538
0.004006985
0.003557358
0.003300065
0.003163411
0.002865957
0.001487573

!
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Appendix C

!
!

Me-β-CD PR Hemolysis

β-CD PR Hemolysis

50:50 SBE-β-CD:HP-β-CD PR Hemolysis

Figure C.1: Representative Human Red Blood Cell Hemolysis of Various Threaded PRs.
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Figure C.2: Venn Diagram of Protein Coronas for PRs Threaded with Various CDs
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Table C.1: Full Protein Corona For 100% Me-β-CD PR

!
Protein ID
Complement C3
Apolipoprotein E
Serum albumin
Apolipoprotein B-100
Ig gamma-1 chain C region
Ig kappa chain C region
Apolipoprotein A-II
Apolipoprotein D
Complement component C9
Apolipoprotein A-I
Complement C4-B
Serum paraoxonase/arylesterase 1
Apolipoprotein C-II
Apolipoprotein C-III
Apolipoprotein C-I
Clusterin
Apolipoprotein(a)
Transthyretin
Serum amyloid A-4 protein
Ig lambda-1 chain C regions
Ig gamma-2 chain C region
Complement component C8 gamma chain
Alpha-1-antitrypsin
Ig alpha-1 chain C region
Complement C5
Ig lambda-2 chain C regions
Apolipoprotein A-IV
Vitronectin
Haptoglobin
Complement component C6
StAR-related lipid transfer protein 13
Complement component C8 alpha chain
Apolipoprotein M
Ig mu chain C region
Trypsin-3
Complement C3 precursor
Serotransferrin
Ig kappa chain V-III region
Alpha-2-macroglobulin
Ig kappa chain V-II Region
Ig kappa chain V-IV region
Complement component C7
Complement component C8 beta chain
Alpha-2-HS-glycoprotein
Alpha-1-acid glycoprotein 1
Bovine serum albumin precursor

!

Percent PR Corona
17.35131077
16.92263363
10.91695191
6.069452089
5.337392476
5.311549879
5.010290265
3.573277261
3.421953775
2.773780863
2.147698529
1.574657144
1.53214378
1.49304561
1.304540524
1.093414729
1.058981593
0.965211466
0.928412544
0.864075528
0.723246176
0.67356527
0.599975658
0.575594754
0.533477927
0.530984734
0.471891492
0.441088529
0.426356289
0.425590389
0.384695112
0.360745597
0.359177197
0.355445431
0.316173635
0.314145462
0.291926866
0.219937471
0.180829896
0.159345924
0.151155363
0.138784673
0.125416043
0.122913118
0.116044253
0.11226316

!
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Virion-packaging protein
Ig heavy chain V-III region
Prothrombin
Complement factor B
Kininogen-1
Apolipoprotein C-IV
Complement factor H
C4b-binding protein alpha chain
Ig gamma-3 chain C region
Inter-alpha-trypsin inhibitor heavy chain H2
Antithrombin-III
Alpha-1-acid glycoprotein 2
Integrin alpha-M
Ig gamma-4 chain C region
Fibronectin
Properdin
Ig lambda-3 chain C regions
Kinesin-like protein KIF14
Plasminogen
Hemopexin
Vitamin D-binding protein
Complement C4-A
Thyroid receptor-interacting protein 11
Haptoglobin-related protein
Ceruloplasmin
Lipopolysaccharide-binding protein
Apolipoprotein L1
Inter-alpha-trypsin inhibitor heavy chain H4

0.104959681
0.091750199
0.091467918
0.088788385
0.084874068
0.066036277
0.064479154
0.059855223
0.053852204
0.052548384
0.051148376
0.04660158
0.044774863
0.040199133
0.039148087
0.034597398
0.031109361
0.027876126
0.026237346
0.022435728
0.022092966
0.019611471
0.01757897
0.015992161
0.014079815
0.010576861
0.008129117
0.007654362

Table C.2: Full Protein Corona For 100% β-CD PR
Protein ID
Serum albumin
Ig kappa chain C region
Complement C3
Ig gamma-1 chain C region
Apolipoprotein E
Apolipoprotein A-II
Apolipoprotein D
Apolipoprotein A-I
Ig lambda-1 chain C regions
Apolipoprotein B-100
Complement component C9
Ig gamma-2 chain C region
Transthyretin
Alpha-1-antitrypsin

!

Percent PR Corona
16.53602536
15.00432799
11.74536491
7.757086463
5.161341666
4.808387011
4.074641027
3.408645335
3.358983503
2.938530875
2.077125525
1.801673851
1.609643609
1.401363144

!
Apolipoprotein C-I
Clusterin
Ig lambda-2 chain C regions
Haptoglobin
Serotransferrin
Complement C4-B
Ig alpha-1 chain C region
Apolipoprotein C-III
Ig kappa chain V-III region
Apolipoprotein(a)
Alpha-2-HS-glycoprotein
Serum amyloid A-4 protein
Ig kappa chain V-IV region
Vitronectin
Apolipoprotein C-II
Alpha-1-acid glycoprotein 1
Complement component C8 gamma chain
Apolipoprotein A-IV
Prothrombin
Ig mu chain C region
Ig kappa chain V-II region
Complement C5
Alpha-2-macroglobulin
Complement component C6
Serum paraoxonase/arylesterase 1
Trypsin-3
Ig heavy chain V-III region
Ig lambda-3 chain C regions
Alpha-1B-glycoprotein
Apolipoprotein M
StAR-related lipid transfer protein 13
Kininogen-1
Complement factor H-related protein 3
Ig gamma-4 chain C region
Complement component C8 alpha chain
Complement factor H
Complement component C8 beta chain
Vitamin K-dependent protein S
Hemopexin
Ceruloplasmin
Serum amyloid P-component
Integrin alpha-M
Alpha-1-acid glycoprotein 2
Inter-alpha-trypsin inhibitor heavy chain H2
Complement component C7
Ig kappa chain V-I region
Antithrombin-III
Ig gamma-3 chain C region
C4b-binding protein alpha chain

!
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1.370046556
1.286344099
1.184513069
1.173103474
1.119652755
1.090155363
0.910046172
0.785609786
0.711515336
0.611002255
0.599766338
0.526835897
0.41330472
0.399344949
0.396346063
0.368698926
0.352681316
0.33923101
0.338574104
0.330838953
0.315459061
0.309866416
0.25471217
0.223347339
0.201263818
0.17630581
0.13827517
0.132262268
0.125124813
0.120461273
0.115661118
0.106938194
0.102301557
0.098285175
0.09588706
0.093727719
0.083179893
0.081113763
0.071740997
0.070374189
0.06797167
0.067079838
0.065530194
0.064962681
0.060031227
0.057912853
0.056426389
0.051334256
0.051141564
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Hemoglobin subunit alpha
Vitamin D-binding protein
Immunoglobulin J chain
Complement factor B
Plasma protease C1 inhibitor
Fibronectin
Haptoglobin-related protein
Virion-packaging protein UL25
Plasminogen
Ig alpha-2 chain C region
Alpha-1-microglobulin
Inter-alpha-trypsin inhibitor heavy chain H1
Properdin
Beta-2-glycoprotein 1
Kinesin-like protein KIF14
Inter-alpha-trypsin inhibitor heavy chain H4
Thyroid receptor-interacting protein 11
Hemoglobin subunit alpha
Histidine-rich glycoprotein
Retinol-binding protein 4
Complement C4-A
Ig lambda chain V-III region LOI
Inter-alpha-trypsin inhibitor heavy chain H3
Heparin cofactor 2

0.05083386
0.0465446
0.046265831
0.044157128
0.043953647
0.039297599
0.032577358
0.027102111
0.026321724
0.023512734
0.019298157
0.017941292
0.017598707
0.016747021
0.014765174
0.013872733
0.012113308
0.011058311
0.009965854
0.008762275
0.00807529
0.007280351
0.006762819
0.004492358

!
!
!
!

Table C.3: Full Protein Corona For Mixed 50:50 HP-β-CD: SBE-β-CD PR

Protein ID
Complement C3
Apolipoprotein E
Serum albumin
Apolipoprotein A-II
Apolipoprotein C-II
Ig gamma-1 chain C region
Ig kappa chain C region
Apolipoprotein B-100
Complement component C9
Apolipoprotein D
Apolipoprotein A-I
Complement C4-B
Trypsin-3
Apolipoprotein C-III
StAR-related lipid transfer protein 13
Ig gamma-2 chain C region
Haptoglobin
Clusterin

!

Percent PR Corona
19.76495094
12.28036258
9.427281564
6.865297508
6.692607783
5.92949059
4.87297314
4.636129789
3.846580792
3.114959404
2.537299079
2.083473432
2.050791718
1.876260875
1.437949237
1.169451568
0.937229713
0.91590978

!
Apolipoprotein(a)
Ig lambda-1 chain C regions
Transthyretin
Ig kappa chain V-III region
Complement C5
Ig lambda-2 chain C regions
Vitronectin
Virion-packaging protein UL25
Alpha-2-HS-glycoprotein
Ig alpha-1 chain C region
Complement component C6
Complement component C8 alpha chain
Serotransferrin
Prothrombin
Apolipoprotein A-IV
Apolipoprotein M
Ig kappa chain V-II region TEW
Complement component C8 gamma chain
Alpha-1-antitrypsin
Serum amyloid A-4 protein
Zinc finger FYVE domain-containing protein 1
Ig mu chain C region
Kinesin-like protein KIF14
Kininogen-1
Complement component C8 beta chain
Alpha-2-macroglobulin
Complement factor H
Alpha-1-acid glycoprotein 1
Complement component C7
Hemoglobin subunit alpha
Integrin alpha-M
C4b-binding protein alpha chain
Serum paraoxonase/arylesterase 1
Alpha-1B-glycoprotein
Inter-alpha-trypsin inhibitor heavy chain H2
Properdin
Ig gamma-3 chain C region
Ig gamma-4 chain C region
Fibronectin
Antithrombin-III
Complement C4-A
Plasminogen
Inter-alpha-trypsin inhibitor heavy chain H4

!
!
!
!

!
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0.856763959
0.797377646
0.508421658
0.472864812
0.409102322
0.408439993
0.386887198
0.373320683
0.370567282
0.351367489
0.35043853
0.338142243
0.322695802
0.312206117
0.288919612
0.282081709
0.277292021
0.251238506
0.236792051
0.168315796
0.163808249
0.163277059
0.159029894
0.155152083
0.136685208
0.125795225
0.124140998
0.112376881
0.086259676
0.074191017
0.065432259
0.06140164
0.04911196
0.047913856
0.047756275
0.041372879
0.040607109
0.039725469
0.039566759
0.023736557
0.015649696
0.013425822
0.011348498
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Table C.4: Full Protein Corona For 100% HP-β-CD PR

!
Protein ID
Serum albumin
Ig kappa chain C region
Apolipoprotein A-II
Apolipoprotein A-I
Apolipoprotein E
Apolipoprotein C-II
Apolipoprotein C-III
Ig gamma-1 chain C region
Transthyretin
Complement C3
Alpha-1-antitrypsin
Serotransferrin
Haptoglobin
Ig alpha-1 chain C region
Clusterin
Ig lambda-1 chain C regions
Ig kappa chain V-III region
Apolipoprotein D
Ig gamma-2 chain C region
Ig lambda-2 chain C region
Apolipoprotein C-I
Ig kappa chain V-IV region
Complement factor B
Complement component C9
Apolipoprotein A-IV
Serum amyloid A-4 protein
Alpha-1-acid glycoprotein 1
Ig kappa chain V-II region
Ig lambda-3 chain C regions
Hemopexin
Alpha-1-acid glycoprotein 2
Apolipoprotein B-100
Ig mu chain C region
Alpha-2-HS-glycoprotein
StAR-related lipid transfer protein 13
Prothrombin
Complement C4-B
Apolipoprotein M
Ig lambda chain V-IV region Hil
Ig heavy chain V-III region
Vitronectin
Vitamin D-binding protein
Ceruloplasmin
Alpha-2-macroglobulin
Alpha-1B-glycoprotein
Antithrombin-III

!

Percent PR Corona
21.76828436
19.04835025
10.81040494
7.919583224
7.066407588
4.992757233
3.944752799
3.311732771
1.985551149
1.908027079
1.650830489
1.593952712
1.546604427
1.482215949
1.035208084
0.931474445
0.773907913
0.753715631
0.647140603
0.604695051
0.577602372
0.566482484
0.491751743
0.44836062
0.432932847
0.295004027
0.274771898
0.24360112
0.238716143
0.212616684
0.193231301
0.189701937
0.184108676
0.183975192
0.151046784
0.144881134
0.121920477
0.120745176
0.111804397
0.109882251
0.09080639
0.090624704
0.087865351
0.079340777
0.071703656
0.057020177
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Apolipoprotein(a)
Complement component C8 gamma chain
Transmembrane protein 108
Trypsin-3
Virion-packaging protein UL25
Ig gamma-4 chain C region
Immunoglobulin J chain
Inter-alpha-trypsin inhibitor heavy chain H2
Properdin
Inter-alpha-trypsin inhibitor heavy chain H1
Plasma protease C1 inhibitor
Complement factor H
C4b-binding protein alpha chain
Complement component C6
Kinesin-like protein KIF14
Kininogen-1

0.056716458
0.056231927
0.050667755
0.050159271
0.037443861
0.034376382
0.027815042
0.023979446
0.019515406
0.018916383
0.017867315
0.014151158
0.014079214
0.013544596
0.010562691
0.007878089
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ABSTRACT: Several lines of evidence suggest that βcyclodextrin (β-CD) derivatives initiate the eﬄux of
accumulated, unesteriﬁed cholesterol from the late endosomal/lysosomal compartment in Niemann Pick C (NPC)
disease models. Unfortunately, repeated injections or continuous infusions of current β-CD therapies are required to
sustain suppression of symptoms and prolong life. In an eﬀort
to make CD treatment a more viable option by boosting
eﬃcacy and improving pharmacokinetics, a library of Pluronic
surfactant-based β-CD polyrotaxanes has been developed
using biocompatible poly(ethylene glycol) (PEG)−polypropylene glycol (PPG)−PEG triblock copolymers. These
compounds carry multiple copies of β-CD as shown by 1H NMR, 2D nuclear Overhouser eﬀect spectroscopy, gel permeation
chromatography/multiangle light scattering, analytical ultracentrifugation analysis, matrix assisted laser desorption/ionization
mass spectrometry, and diﬀusion-ordered spectroscopy. Analyses of free β-cyclodextrin contamination in the compounds were
made by reverse phase high pressure liquid chromatography and hydrophilic interaction liquid chromatography. Dethreading
kinetics were studied by reverse phase high pressure liquid chromatography, UV/vis, and 1H NMR analysis. Filipin staining
studies using npc2−/− ﬁbroblasts show signiﬁcant reversal of cholesterol accumulation after treatment with polyrotaxane
compounds. The rate and eﬃcacy of reversal is similar to that achieved by equivalent amounts of monomeric β-CD alone.

1. INTRODUCTION

NPC2 are responsible for the eﬄux of unesteriﬁed cholesterol
(UC) from the LE/LY compartment into the cytosol and are
generally thought to function in a common UC eﬄux pathway.6
The dysfunction of either NPC protein causes aberrant
sequestration of UC in the LE/LY compartment.5 The
accumulation of UC, in turn, causes lysosomal swelling,
upregulation of the genes controlling cholesterol synthesis
and LDL uptake, elevation in intrinsic total cholesterol
synthesis and lipoprotein uptake, and neurological eﬀects
including demyelination of brain cell axons and the death of
Purkinje cells.3,7,8 Additionally, the onset of macrophage
activity in aﬀected tissues results in the release of proinﬂammatory cytokines in most organs.7,9−11 The cumulative

Niemann-Pick Type C (NPC) disease is one of a large set of
lysosomal storage disorders that arise as a consequence of
abnormal function within the late endosome/lysosome (LE/
LY) compartment. In this rare disease, the accumulation of
cholesterol and other lipids within the LE/LY compartment
gives rise to various disease states in the patient.1−3 Often, the
defect manifests itself in the form of neurological, hepatic, and/
or pulmonary symptoms that increase in intensity over time.4
These can involve enlargement of organs, dysarthria, dysphagia,
ataxia, and other neurological symptoms including epilepsy and
dementia.2 NPC typically manifests in children and is ultimately
fatal, even with current treatment regimens.5
The underlying causes of NPC are genetic mutations that
disrupt the function or localization of either the NPC1 (95% of
cases) or NPC2 (5% of cases) proteins. These proteins are
ubiquitously expressed and are localized to the LE/LY
compartment.1,2 In a normally functioning cell, NPC1 and
© 2013 American Chemical Society
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Scheme 1. Synthesis of β-CD/Pluronic PRTxa

a

For Pluronic base F127, m = 100 and n = 32.

began reaccumulating cholesterol shortly after dosing was
terminated.8,9,11 β-CD derivatives, therefore, overcome cholesterol transport defects in NPC1 disease, but the alleviation is
temporary such that repeated or continuous infusions are
needed for prolonged eﬀects.7,9 Increasing the eﬃciency of βCD delivery, by improving the pharmacokinetics and
biodistribution of the dose, would make β-CD much more
viable as a possible NPC therapeutic. One potential method for
achieving these goals would be to deliver β-CD via a high
molecular weight, long circulating vehicle. A β-CD formulation
oﬀering improved circulation time and lower clearance rates
could potentially deliver a more eﬃcacious dose and be
beneﬁcial in NPC treatment.
Polyrotaxanes (PRTx) are supramolecular assemblies that
have been of considerable interest in biomaterials applications
such as drug and gene delivery and hydrogel formation.15−19
These complexes are typically prepared by threading macrocycles noncovalently onto a polymer core to produce a
pseudopolyrotaxane with subsequent addition of bulky endcaps onto the central polymer termini to yield a polyrotaxane.
The end-caps prevent macrocycle dethreading and can be
tuned to be bioresponsive toward changes in pH20 or toward
enzyme activity,21,22 allowing for control over when and how
the PRTx degrades to release its macrocyclic cargo. Cyclodextrin-based PRTx derivatives have been synthesized using

impact of these factors is cell death and presentation of the
NPC disease state.
Since its demonstration by Camargo et al., an increasing
body of evidence shows that derivatives of β-cyclodextrin (βCD), a macrocycle consisting of 7 glucose subunits, are able to
initiate the eﬄux of accumulated UC from the LE/LY
compartment of npc1 and npc2 deﬁcient cells.3,4,7−13 Dietschy
and co-workers have recently reported several studies that
demonstrate the ability of β-CD derivatives (e.g., HP-β-CD) to
mobilize UC in the murine model of NPC1 disease.3−5,8,9,14
Upon treatment with HP-β-CD, a normalization of intracellular
UC levels, suppression of intrinsic cholesterol synthesis,
activation of the target genes for the LXR nuclear receptors,
and suppression of target genes for SREBP were observed in
several organs. All of these factors contribute to rapid egress of
sequestered UC from sites of abnormal storage.8,10,11 When
injected directly into the CNS, similar eﬀects were seen in the
brains of npc1−/− mice,4,7 and continuous infusion with β-CD
derivatives was shown to prevent expected neurodegeneration.7
β-CD has also been shown to have similar positive eﬀects in
npc2−/− mice.13 At the cellular level, addition of β-CD to either
npc1−/− or npc2−/− patient ﬁbroblasts has been shown to rescue
the cholesterol accumulation phenotype of these cells.12,13
While reversal of UC storage in mice was seen after
administration of β-CD, evidence indicated that the animals
3243

dx.doi.org/10.1021/bi3010889 | Biochemistry 2013, 52, 3242−3253

243
Biochemistry

Article

many polymer cores including polyesters,23 polyamides,24
poly(ethylene glycol) (PEG), 25−27 polypropylene glycol
(PPG),28 and many di- and triblock copolymers.29
In this study, a library of PRTx derivatives has been
synthesized using Pluronic block copolymers and β-cyclodextrin as building blocks. Pluronic polymers have a PEG−
PPG−PEG triblock copolymer architecture that diﬀers in the
relative lengths of the PEG and PPG blocks. Molecular weights
of the Pluronics used in this study range from 1900 to 12 600
g·mol−1. These polymers were chosen because of their previous
uses in pharmaceutical applications and their known biocompatibility.30 Our aim was to increase the eﬃciency of β-CD
delivery into NPC cells using biocompatible Pluronic-derived
β-CD PRTx.
The PRTx library was subsequently characterized by
solubility tests, nuclear magnetic resonance (NMR), 2D nuclear
overhouser eﬀect spectroscopy (NOESY), gel permeation
chromatography (GPC), analytical ultracentrifugation (AUC),
atomic force microscopy (AFM), matrix assisted laser
desorption/ionization mass spectrometry (MALDI), and
diﬀusion-ordered spectroscopy (DOSY). Analyses of free βCD contamination levels in the compounds were made by
reverse phase high-pressure liquid chromatography (RPLC)
and hydrophilic interaction liquid chromatography (HILIC).
Dethreading kinetics were studied by RPLC, 1H NMR, and
UV/vis analysis. Finally, the capacity of these compounds to
mobilize UC in npc2−/− ﬁbroblasts was evaluated by ﬁlipin
staining, while PRTx localization to LE/LY compartments was
studied by ﬂuorescent PRTx colocalization with Lysotracker
Blue.

(3 × 350 mL), before collection by centrifugation and drying
overnight under a vacuum. The TREN derivatives of L35 and
L64 were isolated as viscous yellow liquids, whereas the F127
and F68 derivatives were isolated as white solids. TRENpolymers proved diﬃcult to purify completely and as such were
used without further puriﬁcation. Extensive washing and
dialysis of the ﬁnal PXR compounds would serve to remove
any impurity retained after the earlier steps.
2.3. Threading, End-Capping, and Puriﬁcation of
TREN-Terminated β-CD:Pluronic Polyrotaxanes. TRENF127 (2.5 g) was added to a saturated aqueous solution of βCD (5.9 mmol β-CD in 361 mL H2O). After dissolution of the
polymer, the solution was bath sonicated for 10 min at 65 °C to
ensure complete mixing. Finally, the solution was probe
sonicated using a 1/2 in. tipped transducer for 3 min, followed
by agitation on a rocker plate for 14 days to promote threading.
For the liquid polymers L35 and L64, a white precipitate
formed in the ﬂask almost immediately and increased over time.
The threading progressed much more slowly for the solid
polymers (F127 and F68), with precipitate appearing usually
after 24 h and increasing thereafter.
After completion of the threading reaction, TNBS (4 equiv,
1.5 mmol, 5.1 mL in a 10% solution) was added to the reaction
mixture and left on the rocker plate overnight to eﬀect the endcapping reaction.
The L35-, L64-, and F68-based PRTx were ﬁrst collected by
centrifugation from the reaction mixture for 3 min at 7000 rpm.
They were then diluted with 30 mL of H2O, vortexed, and
recentrifuged under identical conditions. Water washes were
continued in this manner until the washes ran nearly clear;
usually 3−5 repetitions. The F127-based PRTx was not
collected by centrifugation due to the formation of viscous
suspensions; therefore, this product was puriﬁed by extensive
dialysis as described below.
The products were again suspended in 30 mL of H2O and
dialyzed against H2O using dialysis tubing correlating to the
estimated MW of the ﬁnal product. L35- and L64-based PRTx
were dialyzed with MWCO 3500 and 6−8000 kDa tubing,
respectively. F68 and F127-based PRTx were dialyzed against
water in MWCO 12−15 kDa tubing. The products were
dialyzed for 3 days with an average of six water changes, or until
water remained clear for two consecutive water changes.
Upon completion of dialysis, the puriﬁed products were
frozen and lyophilized to yield yellow-orange powders. βCD:F127 PRTx was obtained in 32.9% yield (1.883 g). βCD:F68 PRTx, β-CD:L64 PRTx, and β-CD:L35 PRTx gave
13.29% (0.502 g), 29.1% (4.773 g), and 19.1% (1.12 g) of solid,
respectively. F127 1H NMR: (400 MHz, DMSO-d6, 22 °C) δ
8.94−8.76 (br s., 8H, TNB), 5.73−5.65 (m, 266H, O2H, O3H
of CD), 4.8 (s, 133H, H1 of CD), 4.45 (t, 133H, O6H of CD),
3.67−3.59 (m, 532H, H3, H6, H5, H4 of CD), 3.51−3.48 (m,
995H, PPO and PPG −CH2−), 1.04−1.01 (d, 195H, PPG
−CH3).
After the initial puriﬁcation processes, the PRTx were
analyzed by both RPLC and HILIC, with the two methods
consistently agreeing within 8%. Initial free CD measurements
for β-CD:F127 PRTx were 19.9% by HILIC and 26.9% by
RPLC. Samples containing >5% free β-CD by RPLC were
suspended in 15 mL of H2O, vortexed for 2 min, and gathered
by centrifugation as previously described. After three
repetitions, the samples were lyophilized and reanalyzed for
free β-CD content. This process was repeated until the HILIC

2. MATERIALS AND METHODS
2.1. Materials. (1,1)-Carbonyldiimidazole (CDI) and 2,4,6trinitrobenzenesulfonic acid (TNBS) were purchased from
Research Organics. Tris(2-aminoethyl)amine (TREN), βcyclodextrin, Pluronic polymers, and 2,2′-(ethylenedioxy)bis(ethylamine) were purchased from Sigma-Aldrich. The four
Pluronics used in this study were F127, F68, L64, and L35. All
solvents were dried and distilled from an appropriate desiccant
prior to use unless otherwise noted. Human ﬁbroblasts cells
from an apparently healthy donor (GM03652) and from an
NPC2 patient (GM18455) were from Coriell Institute of
Medical Research (Camden, NJ). Filipin and ﬂuorescein were
purchased from Sigma and Lysotracker Blue from Molecular
Probes.
2.2. Synthesis of TREN-Terminated Pluronics. The
synthesis of F127 Pluronic-based β-CD polyrotaxane will be
described in detail below. All other β-CD:Pluronic PRTx were
synthesized and puriﬁed in the same manner, except where
noted.
The Pluronic precursor was added to a dry round-bottom
ﬂask under a dry N2 atmosphere and then dissolved in benzene
before solvent evaporation. This azeotropic drying procedure
was repeated three times before ﬁnally drying the polymer
under a vacuum at 80 °C overnight.
Pluronic F127 (4.0 g) was dissolved in 20 mL of
dichloromethane (DCM) and added to CDI (9.5 mmol, 30
equiv, dissolved in 20 mL of DCM) by syringe over the course
of 6 h. The solution was stirred for 18 h at 20 °C before
concentration by evaporation and addition to TREN (6.4
mmol, 20 equiv, dissolved in 20 mL of DCM) over 3 h. After
being stirred at 20 °C for 24 h, the solution was concentrated
by rotary evaporation, and the residue was precipitated in ether
3244
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and/or RPLC analyses indicated that the free β-CD content
was ≤5% free β-CD.
The inability to wash and collect β-CD:F127 PRTx by
centrifugation made them more diﬃcult to purify of free and/or
entrained β-CD contamination. Samples containing >5% free βCD contamination after initial puriﬁcation were resuspended in
H2O, vortexed for 3 min, and again left to dialyze against water
in either MWCO 12−14 kDa dialysis tubing or a 20 kDa
dialysis cassette for 2 days, lyophilized, and retested. This
process was repeated until the HILIC and/or RPLC analyses
indicated that the free β-CD content was ≤5% free β-CD.
Fluorescein modiﬁed β-CD:F127 PRTx was synthesized by
dissolution of 400 mg β-CD:F127 PRTx in dry DMSO before
activation with CDI (6.1 mmol) and coupling to ethylene
diamine (7.4 mmol). A second activation with CDI (6.1
mmol), followed by ﬂuorescein coupling (6.1 mmol), and
precipitation twice in MeOH yielded the ﬂuorescent PRTx
derivative. Fluorescent PRTxs were used without further
puriﬁcation.
2.4. Determination of Threading Eﬃciency by 1H
NMR. 1H NMR spectra were acquired on a 400 MHz Bruker
ARX400 spectrometer, using the solvent peak as the reference
standard and the chemical shift given in parts per million.
NOESY spectra were taken on a 500 MHz Bruker DRX500
spectrometer with a 5 mm TBI probe. DMSO-d6 was used as
NMR solvent unless otherwise noted. Determinations of PRTx
threading eﬃciencies were initially performed by 1H NMR
spectral integration. The characteristic β-CD H1 proton at ∼4.8
ppm was directly compared to the PPG methyl protons of the
polymer at 1.0 ppm. The PPG resonance was normalized to the
average number of hydrogens expected for that speciﬁc
Pluronic’s methyl group. Given that each β-CD monomer has
seven acetal protons, the corresponding integration for the
number of β-CD H1 protons present in the sample was divided
by seven. This yielded an average number of β-CDs per PRTx.
This estimate of threading eﬃciency was then recalculated once
the amount of free, unthreaded β-CD in the sample was
determined by chromatographic analysis.
2.5. Determination of Free β-CD in β-CD/Pluronic
PRTx. Determinations of free β-CD in PRTx samples were
done in two ways. First, PRTx solutions of ∼1 mg/mL were
prepared in H2O for analysis on a custom-made HILIC silica
packed column with 700 nm nonporous silica nanoparticles
that were surface-modiﬁed with amide groups.31 Before
analysis, PRTx were subjected to two rounds of vortexing for
2 min and bath sonication at 50 °C for 10 min. The
temperature of the column oven was maintained at 25 °C. All
runs were performed under the gradient conditions of 90−70%
acetonitrile (ACN) with 0.1% formic acid. Determinations were
made on a Thermo Accela UPLC system (Thermo Fischer
Scientiﬁc, MA, USA) and LTQ Velos LC-MS. Mobile phases A
and B were ACN with 0.5% (v/v) formic acid and water with
0.5% (v/v) formic acid. Chromatographic separation started at
an initial mobile phase of 95% A, held for 1 min, then followed
by a linear gradient from 80 to 60% mobile phase A in 15 min.
The solvent composition then changed to 50% A over 0.1 min
and was maintained for 5 min before being re-equilibrated to
95% A. The ﬂow rate was 150 μL/min.
Mass spectrometric data were acquired in the positive ion
mode. The ESI conditions were as follows: ESI spray voltage, 4
kV; temperature setting, 300 °C; sheath gas ﬂow, 30 U
(arbitrary units); auxiliary gas ﬂow, 8 U.

Additionally, PRTx solutions in H2O (∼1 mg/mL) were
analyzed by RPLC using an H2O:ACN gradient elution as
described by Agueros, Campanero and Irache.32 Analyses were
performed using an Agilent Technologies 1200 Series HPLC
equipped with an ESA Corona Detector and an Agilent Zorbax
Eclipse XDB-Phenyl column (2.1 × 1250 mm, 5 μm particles).
Known concentrations of β-CD were used for both HILIC and
RPLC measurements to construct standard curves for ﬁtting
the PRTx sample data.
2.6. Gel Permeation Chromatography. Corroboration of
NMR molecular weight measurements and threading eﬃciencies were made by gel permeation chromatography (GPC)
analysis. PRTx samples (∼30 mg/mL in DMSO) were
prepared and analyzed as described by Beirne, Truchan, and
Rao.33 GPC measurements were made using an Agilent
Technologies GPC system equipped with an OHpak SB803HQ column (8 mm × 300 mm), Dawn Helios II multiangle
light scattering detector (Wyatt Technology Corporation), and
Optirex RI detector (Wyatt Technology Corporation) using
DMSO as the mobile phase. The detectors were normalized
using 25 kDa pullulan and calibrated using 11.6 kDa and 48.6
kDa dextran standards. The ﬂow rate was 0.16 mg/mL and a
100 μL injection volume was used.33
2.7. Analytical Ultracentrifugation. Analytical ultracentrifugation was done in the Purdue Bindley Bioscience
Center on a Beckman Coulter XLI (Beckman-Coulter, CA)
ultracentrifuge using absorbance optics at 346 and 422 nm and
interference optics at 675 nm. PRTx were characterized in PBS
buﬀer at pH 7.4 at concentrations of 0.1, 0.2, and 0.4 OD.
Sedimentation equilibrium (SE) experiments were done at
speeds of 25 000, 35 000 and 40 000 rpm for a total of 67.8 h
and analyzed by the species analysis model in SEDPHAT (v.
9.4).34 The system was standardized by running unmodiﬁed
F127 Pluronic (found to be 12 500 g/mol as expected).
Sedimentation velocity experiments were conducted at 50 000
rpm using a 2 channel charcoal centerpiece for 15 h and
analyzed using SEDFIT (v. 12.43). 35 All experiments were
carried out at 20 °C using an Anton 60 Ti rotor. Buﬀer density
and viscosity were calculated using SEDNTERP.36 The partial
speciﬁc volume of polyrotaxane without a PEG derivative was
calculated to be 0.62 mL/g.37 The partial speciﬁc volume of the
polyrotaxanes with PEG derivatives was 0.85 mL/g, which
agrees well with published values.38
2.8. Atomic Force Microscopy. AFM images were
acquired by depositing and drying 1 μL of probe sonicated
PRTx-DMSO solution onto a mica plate. All samples were ﬁxed
∼5 min after probe sonication. Images were obtained using a
Dimension 3100 AFM from Veeco Instruments (USA).
Tapping mode images were collected using an NSC15/AIBS
325 kHz cantilever with a 46 N/m force constant and an
amplitude set point of 1 V.
2.9. Mass Spectrometry Analysis. An ionic liquid matrix
(ILM) was made for analyzing the PRTx by MALDI. The ILM
was made as follows: 2′,4′,6′-trihydroxyacetophenone monohydrate (THAP) and 1,1,3,3-tetramethylguanidine (TMG)
were mixed at a molar ratio of 1:2 in methanol. The solution
was then sonicated for 15 min at 40 °C. After removal of
methanol by centrifugal evaporation in a SpeedVac for 3 h at 20
°C, ILMs were left under a vacuum overnight. Final solutions
were then prepared at a concentration of 90 mg/mL in DMF
for use as a matrix. The polyrotaxane samples were prepared at
3 mg/mL in DMF. The samples for MALDI-MS analysis were
prepared by mixing the PRTx sample and ILM in a 1:80 ratio.
3245
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Figure 1. 1H NMR spectra of free β-CD and PRTx-F127 product in DMSO-d6. Peak broadening shows inclusions of polymer inside β-CD core.

Then, 0.6 μL of the mixture was deposited on a mirror polished
stainless steel MALDI target and allowed to dry at 20 °C and
atmospheric pressure overnight. The spectra were acquired at a
laser power of 6500 using 600 laser shots in linear mode on an
AB4800 MALDI TOF/TOF analyzer.
ESI mass spectrometry of the TNB terminated 2,2′(ethylenedioxy)bis(ethylamine) was done on a Waters ZQ
electrospray mass spectrometer in negative ion mode.
2.10. Dethreading Analysis. Bulk dethreading experiments of β-CD:Pluronic PRTx were done by suspending each
PRTx in H2O, adjusted to pH 7.4 or 5.5, at concentrations of 1
mg/mL. Samples were placed in a constant temperature bath at
37 °C and sampled at 1, 2, 4, 8, 16, and 24 h. Aliquots were
analyzed by RPLC as described above to monitor the increase
in free β-CD in each sample. 1H NMR analysis of similarly
incubated PRTx was also conducted to reveal any changes in
TNB peaks characteristic of successful end-capping.
A short, unthreaded TNB end-capped PEG-bis-amine (MW
570.4 g/mol) was synthesized to better visualize any possible
changes in the encap 1H NMR spectrum in the presence of
glutathione (structure, synthesis, and NMR given in SI). This
compound was subjected to a D2O solution of 10 mM
glutathione at pH 7.4, incubated at 37 °C, and monitored at
intervals for 48 h. The PEG-TNB concentration was 1 mg/mL.
UV/vis analyses of TNB end-caps were made using an
Agilent HP 8453 UV/vis spectrophotometer (Agilent Technologies, Inc., Santa Clara, CA, USA). PBS solutions of an
unthreaded F68-TNB polymer were dissolved at 1 mg/mL with
10 mM glutathione at either pH 7.4 or 5.5. Emission spectra

were taken at 1, 2, 4, 8, 16, 24, and 48 h, with monitoring at 346
and 420 nm wavelengths.
2.11. Diﬀusion-Ordered Spectroscopy. Experiments
were performed on a Bruker AVIII300WB spectrometer using
a diﬀ50 diﬀusion probe with a maximum gradient strength of
30 T/m. The pulse sequence used was a stimulated echo
diﬀusion sequence (PGSTE)39 with an additional spoiler
gradient in the diﬀusion period. Signal attenuation was achieved
by varying the gradient strength while all the timings in the
pulse sequence were kept constant. The main experimental
parameters were as follows. The eﬀective gradient pulse
duration (δ) was 1 ms using a sinusoidal gradient shape, the
diﬀusion time (Δ) was 20 ms, and the repetition time 2 s. The
gradient amplitude was varied in 64 steps linearly between 9
and 572 G/cm (90−5720 mT/m). For each gradient step, 64
scans were performed. The samples were dissolved in DMSO at
1 mg/mL and the temperature was kept constant at 25 °C.
Data was processed using the Bruker Dynamics Center
program.
2.12. Cell Studies. Human ﬁbroblasts from npc2−/− or
unaﬀected patients were seeded on eight-well tissue culture
slides at a density of 6 × 103 cells, in Eagle’s minimum essential
medium with Earle’s salts and nonessential amino acids +15%
FBS at 37 °C with 5% CO2. Sterile β-CD:Pluronic PRTx
samples were solubilized in DMSO and diluted in culture media
to a concentration that would yield 25 μM β-CD. The ﬁnal
DMSO concentration in all preparations was ≤0.001% (v/v).
Treatments were administered to cells 36−48 h after plating.
Following varying incubation periods, as indicated, cells were
3246
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Figure 2. Partial 2D-NOESY spectra of PRTx-F27. The characteristic cross-peak between β-CD hydrogens H3/H5 and the PPG methyl group is
shown.

molecular weights, produce limited solubility of these
derivatives.19 Pluronic-based β-CD PRTx were expected to
have similar properties.
This characteristic was exploited to purify the PRTx from the
β-CD and Pluronic precursors that are both quite water-soluble.
Free Pluronic polymers, TREN-terminated Pluronic intermediates, and free β-CD were removed by repeated aqueous
washing of the relatively water-insoluble PRTx products.
Unsuccessfully and partially end-capped PRTx are also
expected to dethread upon repeated suspension in water
since there is nothing obstructing diﬀusion of β-CD oﬀ the end
of the unreacted polymer core, eventually rendering these
byproducts water-soluble and removable by the washing and
dialysis processes.
Multiple lines of 1H NMR evidence suggest that PRTx
formation was successful. End-cap peaks were observed
indicating successful reaction of TNBS with the terminal
amines of the TREN-pseudorotaxane intermediate. These
peaks were present in NMR spectra of each β-CD:Pluronic
PRTx species. There was also evidence of broadening in the βCD O2H, O3H, H1, and O6H protons as well as in the signal
corresponding to the Pluronic PPG methyl group. These
characteristic changes, previously reported for β-CD PRTx, are
a result of restricted β-CD mobility upon threading onto the
Pluronic core.40
2D NOESY NMR was also performed as an additional
conﬁrmation of PRTx formation. Signals corresponding to the
inward facing protons (H-3 and H-5) of the β-CD cavity
(Figure 2) and the proton resonances of the Pluronic PPG
methyl groups are found to be cross-correlated. The close
proximity of these substituents indicates that the cyclodextrin
molecules are threaded onto the Pluronic core.41
Initial characterization of the threading eﬃciency was done
using 1H NMR integration with subsequent correction for the
free β-CD contamination levels present in the sample as
determined by chromatographic analysis. Since β-CD has seven
identical H1 protons at the acetal position of each glucose

rinsed with PBS and ﬁxed in situ with 10% buﬀered formalin.
Cell density and viability, determined by trypan blue exclusion,
were determined using cells collected immediately prior to
ﬁxation. No changes in cell numbers or viability (>95%) were
found, indicating an absence of toxicity under the range of
conditions used in the present studies. Fixed cells were washed
with PBS and stained with 50 μg/mL ﬁlipin in PBS for 1 h.
Images were acquired using a DAPI ﬁlter set on a Nikon
Eclipse E800 epiﬂuorescence microscope (Nikon Inc.),
equipped with NIS-Elements BR 3.2 software (Nikon Inc.).
Antifade mounting agents and microscope light settings
ensured the absence of photobleaching. Filipin accumulation
in cells was determined using NIS-Elements selection tools and
calculated as a ratio of ﬁlipin area to cell area. The results in βCD:Pluronic PRTx and β-CD treated cells were normalized to
ﬁlipin accumulation in untreated npc2−/− ﬁbroblasts and are
expressed as mean ± SE.
Fluorescein labeled β-CD:F127 PRTx was prepared as
described above and administered to npc2−/− ﬁbroblasts
approximately 24 h after plating. Cells were rinsed with PBS
0.5 or 1 h after addition of the compound and incubated with
50 nM Lysotracker Blue (Life Technologies) in PBS for 10
min. Cells were rinsed again and ﬁxed in situ with buﬀered
formalin. Images were obtained using DAPI and B-2A ﬁlter sets
for the ﬂuorescent PRTx and Lysotracker, respectively.

3. RESULTS AND DISCUSSION
3.1. β-CD/Pluronic PRTx Characterization. Multiple
techniques were used to characterize the β-CD:Pluronic
PRTx products, including veriﬁcation of successful end-capping
reactions, characterization of β-CD threading eﬃciencies,
determination of PRTx product molecular weights, and analysis
of their purity with respect to free β-CD content.
The β-CD:Pluronic PRTx products were poorly soluble in all
solvents tested, except DMSO. Poor solubility is a well-known
property of PEG-based PRTx compounds.40 Poor solvent
access to the threaded polymer core, combined with their high
3247
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subunit that appear at ∼4.8 ppm, the intensity of this signal can
be directly related to the signal intensity of the Pluronic PPG
block methyl group. This method indicated that the PRTx
threading eﬃciencies typically ranged between 62 and 100%.
Initial attempts to produce highly threaded Pluronic PRTx
were less than satisfactory, with threading eﬃciencies often in
the range of 20−30%. We attributed these failed attempts to
aggregation of the Pluronic precursors. Since the critical
aggregation concentration for the Pluronic precursors used is
quite low (0.004−1 wt %), we attempted to disperse the
micelles into Pluronic unimers in the threading mixture.31
Decreasing the Pluronic feed concentration and addition of a
probe sonication step into the threading procedure increased
the threading eﬃciencies for each of the Pluronic PRTx cores
(Table 1). It is hypothesized that probe sonication of solutions

sedimentation equilibrium experiments (Figure 4). Taken
together, these data suggest that the average molecular weight

Table 1. Average Number of CDs per PRTx, Threading
Eﬃciencies, Yields, and Free CD Content
β-CD
PRTx

base MW
(Da)

PEG:PPG

#
CDs

%
threading

%
yield

% free
CD

F127
F68
L64
L35

12,500
8,350
2,900
1,900

200:65
151:29
26:30
22:16

15
14
12
5

71.4
100
92
63

32.9
13.3
29.1
19.1

4.4
3.6
2.4
1.2

Figure 4. Sedimentation equilibrium (SE) proﬁle of β-CD:F127
PRTx. The data were ﬁtted using SEDPHAT using a species analysis
model. The molecular weight obtained from the SE experiment agrees
well with the apparent molecular weights calculated from the
sedimentation velocity.

at the initiation of the threading reaction disrupts micelle
formation, thus allowing for the initial threading of β-CD
molecules onto the Pluronic unimer which, in turn, prevents
the immediate reformation of micelles and allows for further
threading (Figure 3).

of β-CD:F127 PRTx is ∼31 kDa. Molecular weights for each
member of the β-CD:Pluronic PRTx library corresponded well
with respect to GPC, AUC, and NMR analysis (Table 2).
Table 2. Molecular Weight Measurements by NMR, GPC,
and AUC

Figure 3. Hypothesized mechanism of increased β-CD threading upon
probe sonication.

Quantiﬁcation of the free β-CD content in a given PRTx
sample is an important parameter to measure so that the
performance of these compounds can be properly evaluated
during in vitro and in vivo testing of cholesterol mobilization in
NPC models. By having PRTx compounds essentially free of
unthreaded β-CD, it can be safely assumed that any observed
increases in cholesterol eﬄux or decreases in cholesterol
synthesis are a product of β-CD initially entering the cell as a
PRTx complex where it is then dethreaded into the active
monomeric form. A goal of ≤5% free CD was selected as an
acceptable target of purity. PRTx that did not meet this
criterion were further puriﬁed as described. One round of
further puriﬁcation was usually enough to bring the PRTx
samples below the 5% free β-CD threshold as determined by
RPLC and/or HILIC.
GPC analysis of PRTx compounds produced molecular
weight estimates that were in agreement with the masses
determined by NMR (after correction for free β-CD). The βCD:F127 PRTx molecular weight was 30 800 g/mol. GPC
analysis indicated a mass of 33 300 g/mol, with evidence of low
levels of free β-CD noted in all samples analyzed. A mass of 30
000 g/mol was determined by both sedimentation velocity and

CD:Pluronic PRTx

NMR (g/mol)

GPC (g/mol)

AUC (g/mol)

F127
F68
L35
L64

30,800
25,500
11,000
17,700

33,300
28,500
13,200
17,100

30,000
27,000
12,000
21,000

MALDI-MS analysis gave additional conﬁrmation of the βCD:F127 PRTx molecular weights as well as information about
the heterogeneity of the material. The spectrum contains a
mass peak at ∼30 kDa, representing a PRTx with a threading of
15 β-CDs as found by other measures. Other peaks in the
spectrum correspond to members of the β-CD:F127 PRTx
population with greater and lesser degrees of threading.
Speciﬁcally, additional m/z peaks corresponding to 18, 8, 7,
6, and 1 threaded CD also appear (Figure 5). As expected,
there is some heterogeneity in the amount of threading on any
given PRTx. Additionally, MALDI spectra of lower molecular
weight PRTx showed evidence of dimer formation. This ﬁts
well with the aggregation behavior noted in AFM analysis (see
below). Full MALDI spectra for each PRTx are available in
Supporting Information.
AFM analysis of the β-CD:F127 PRTx material produced
evidence of PRTx aggregation after DMSO evaporation. To try
and image nonaggregated particles, PRTx samples were probe
sonicated before ﬁxation onto mica plates. Sonication did not
prevent aggregation, but did decrease the diameter and height
3248
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Figure 5. MALDI-MS spectrum of β-CD:F127 PRTx at laser power 6,500. Peak assignments were made by addition of modiﬁed polymer MW and
1135n where n is the potential number of bound CDs. Lesser peaks ﬂanking assigned masses can be attributed to variations in MW inherent in the
base polymer.

Figure 6. AFM images of β-CD:F127 PRTx at 10−5 mg/mL (A), 10−7 mg/mL (B) and 10−9 mg/mL (C) with probe sonication. Scale bar represents
500 nm. Size distributions are shown below images.

of imaged particles. It is hypothesized that β-CD:Pluronic
PRTx are forming hollow micelles in solution as previously
reported in a related β-CD:Pluronic PRTx system.41 Consistent
with this expectation, we found that higher PRTx concentrations produced larger aggregates. Samples at a concentration
of 10−5 mg/mL produced an average diameter of 45 nm after
probe sonication. Samples at 10−7 mg/mL averaged 41 nm in
diameter, while concentrations of 10−9 mg/mL gave particles
with an average diameter of 32 nm (Figure 6A−C). Thus,
higher β-CD:F127 PRTx concentrations promote aggregation
and micellization into particles whose diameter depends on the
PRTx concentration in solution.
DOSY measurements were also able to conﬁrm rotaxanation
and provide further insight into how the β-CD:Pluronic PRTx
constructs behave in solution. The diﬀusion constants (D) for
β-CD:L35, β-CD:L64, and β-CD:F68 PRTx were 5.84 × 10−11
m2/s, 5.30 × 10−11 m2/s, and 3.38 × 10−11 m2/s, respectively.
These diﬀusion constants scale with molecular weight and are
in reasonably good agreement with the diﬀusion behavior of
similar systems.42,43 Additionally, the least-squares ﬁt of a
log(D) vs log(MW) plot gave a scaling constant of −0.63
(plots, spectra, and diﬀusion constants available in Supporting
Information S.10). Scaling constants < −0.6 are indicative of
semiﬂexible wormlike systems,44 showing that the PRTx system

has more rigidity in DMSO solution than would a well-solvated
unbranched random coil polymer.45
3.2. Dethreading Behavior. Experiments were performed
to characterize the dethreading behavior of the β-CD:Pluronic
PRTx under acidic and reducing conditions in an attempt to
mimic the LE/LY environment (Figure 7). Experiments in
which β-CD:Pluronic PRTx were suspended in solutions at
either pH 7.4 or 5.5 and then sampled at various time intervals
showed no increase in free β-CD levels by RPLC analysis up to
24 h after dissolution. This was in agreement with the design of
the PRTx, which were intended to be stable under acidic
conditions.
Additionally, 1H NMR and UV/vis studies were conducted
to monitor changes in end-cap status upon exposure to acidic
pH and 10 mM glutathione. 1H NMR analysis of a short bisamine PEG-NH-TNB (SI Section S.8) analogue showed no
changes in the characteristic TNB peaks even after 48 h
incubation with glutathione at 37 °C, indicating that the TNB
nitro groups had not been reduced. Similarly, the UV/vis
spectra of the F68-TNB end-caps remained unchanged even
after 48 h of incubation in glutathione at both acidic and neutral
pH. We infer from these ﬁndings that dethreading of βCD:Pluronic PRTx is not triggered by acid-mediated end-cap
cleavage or glutathione reduction of the TNB end-cap.
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Figure 7. Hypothesized and experimentally tested mechanisms for PRTx dethreading. (A) Glutathione incubation with PRTx at acidic and neutral
pH and (B) acid catalyzed dethreading at 37 °C showed no signs of dethreading. Hypothesized dethreading (C) by enzymatic cleavage of carbamate
linkages yields free β-CD in vitro.

It is worth noting that the levels of β-CD monomers used in
the present studies are within the range of eﬀective
concentrations shown by Peake and Vance to clear cholesterol
from murine npc1−/− neurons and glial cells,46 as well as by
Storch and co-workers, to clear cholesterol from human
npc2−/− ﬁbroblasts.12 Levels that were demonstrated to cause
neuronal cell toxicity, e.g., 10 mM, were not used in the present
studies.46 In addition, although the ﬁbroblasts were exposed to
potentially cytotoxic TNB upon end-cap release, no alterations
in cell density or viability were observed in any of the cell
samples (Figure 8C).
While each of the compounds induces rapid eﬄux of
cholesterol in a manner similar to monomeric β-CD,
diﬀerences in the eﬃcacy of the PRTx species are apparent.
For example, L35, carrying 5 β-CDs, stimulates the lowest
degree of cholesterol eﬄux from npc2−/− cells while L64, with
12 β-CD monomers, is the most eﬀective (p < 0.05). These
diﬀerences in relative cholesterol clearance by the PRTx species
suggest that end-cap cleavage and dethreading of CD is
occurring within the LE/LY, following bulk phase endocytosis
of the intact compounds (Figure 8B). Furthermore, if
dethreading were occurring in the media prior to cellular
uptake, approximately equal degrees of cholesterol clearance
would instead be expected for all the β-CD:Pluronic PRTx

Finally, the possibility that β-CD:Pluronic PRTx were
dethreaded upon solubilization in DMSO and addition to the
cell culture media was investigated. 1H NMR analysis of PRTx
samples showed that neither incubation with DMSO/MEM
nor DMSO/PBS buﬀer resulted in any changes in the threaded
extent of the samples when compared to PRTx controls
(Supporting Information, Figure S.9). β-CD:Pluronic PRTx
should, therefore, be stable in culture before cellular encounter
and internalization.
3.3. Cell Studies. Npc2−/− ﬁbroblasts were incubated with
each β-CD:Pluronic PRTx derivative, and reductions in cellular
cholesterol accumulation were monitored over time to evaluate
their impact on a cellular model of NPC disease. Initially, it was
hypothesized that this library of PRTx constructs, which was
not designed to be either acid sensitive or reductively labile,
would stimulate little or no reduction in npc2−/− cholesterol
accumulation. Figure 8A and B, however, shows that a single
dose of any β-CD:Pluronic PRTx species, yielding 25 μM βCD, results in a reduction of approximately 60−75% in
accumulated cholesterol levels by 6 h, relative to untreated
controls. Results were similar to monomeric β-CD, which
decreased cholesterol levels to ∼30% of the level of untreated
cells over the same time period.
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Figure 8. Filipin accumulation in NPC2-deﬁcient ﬁbroblasts treated with β-CD:Pluronic PRTx. Human NPC2 deﬁcient ﬁbroblasts were incubated
with 25 μM monomeric β-CD or PRTx yielding 25 μM β-CD and were ﬁxed and stained with 0.05 mg/mL ﬁlipin at varying time points. (A)
Representative images reveal stimulation of cholesterol eﬄux from npc2−/− ﬁbroblasts by β-CD and two PRTx compounds over time. (B) Filipin
accumulation was determined as the ratio of ﬁlipin stain area to total cell area. Results are expressed relative to control untreated cells, and are
represented as mean ± SE (n = 3). (C) Viability of npc2−/− ﬁbroblasts was determined by Trypan Blue staining 6 h after administration of each βCD:Pluronic PRTx. Results are expressed relative to control untreated cells.

compounds, since each treatment would yield 25 μM
monomeric β-CD.
In order to determine whether the β-CD:Pluronic PRTx
compounds were in fact entering the LE/LY compartment, a
ﬂuorescein labeled β-CD:F127 PRTx was synthesized. Thirty
minutes after addition of the compound to npc2−/− ﬁbroblasts,
ﬂuorescein was observed to overlap entirely with Lysotracker
Blue staining, indicating localization of the compound to the
LE/LY (Figure 9). Therefore, it is likely that the carbamate
linkages used to attach the PRTx end-caps are being cleaved by
enzymatic activation within the LE/LY. Hydrolysis of
carbamate linkages has been previously reported and, indeed,
has been used as a method for designing prodrugs.47−49 Thus,
carbamate cleavage would allow for dethreading of β-CD
monomers at high concentration within the LE/LY and
subsequent eﬄux of cholesterol from this compartment.

Figure 9. Fluorescein-labeled β-CD/F127 PRTx localizes to the LE/
LY in npc2−/− ﬁbroblasts. (A) Representative image of ﬂuorescein
localization in NPC2 deﬁcient ﬁbroblasts following a 1 h incubation
period with labeled β-CD:F127 PRTx. (B) Lysotracker Blue staining
identiﬁes LE/LY compartments. (C) Fluorescein ﬂuorescence overlays
with Lysotracker Blue, indicating presence of labeled β-CD:F127
PRTx in the LE/LY compartment. (D) Intensity plot for each stain
throughout an image section as indicated by the white arrow in panel
C. Overlap in the localization of peak intensities is shown.

4. CONCLUSIONS
We have synthesized a family of β-CD:Pluronic PRTx
compounds as potential therapeutics for treating NiemannPick Type C disease. The threading eﬃciency, molecular
weight, and free β-CD contamination in these analogues have
been characterized. Each of the compounds has shown the
capacity to trigger the eﬄux of cholesterol from npc2−/−
ﬁbroblasts in vitro via ﬁlipin staining studies. The rate and
eﬃcacy of β-CD:Pluronic PRTx mediated cholesterol removal
has been shown to be comparable to monomeric β-CD
treatment alone. On the basis of these ﬁndings, β-CD:Pluronic
polyrotaxanes warrant further investigation with regard to their
safety, pharmacokinetics, biodistribution, and durability of

response toward cholesterol eﬄux and/or synthesis suppression
in an in vivo model of Niemann-Pick C disease.
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Microﬂuidic assembly of cationic-β-cyclodextrin:
hyaluronic acid-adamantane host:guest pDNA
nanoparticles†
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Transfection complexes are typically formed by bulk mixing, producing particles with high polydispersity and limited control over
vector size. Herein, we demonstrate the use of a commercial
microreactor to assemble pDNA:cationic cyclodextrin:pendant
polymer nanoparticles using a layer-by-layer approach. Our
studies reveal that the particles formulated via microﬂuidic assembly have much smaller sizes, lower polydispersity, lower ζ-potentials, and comparable cell viability and transfection proﬁles in
HeLa cells than bulk mixed particles. The complexes also show a
ﬂow rate-dependent stability, with particles formed at slower
ﬂow rates giving rise to more stable complexes as determined by
heparin challenge experiments. Our ﬁndings suggest that microﬂuidic reactors oﬀer an attractive method for assembling reproducible, size-controlled complexes from multi-component transfection complex assemblies.

Gene therapy is a promising alternative to conventional
chemotherapy due to its high specificity and modest oﬀ-target
eﬀects.1 While various viral vectors exist for the delivery of
nucleic acids, they suﬀer from issues such as safety, scalability
and immunogenicity. Non-viral carriers that can condense the
nucleic acids into ≤200 nm positively charged nanocomplexes
are gaining prominence because of their modest immunogenicity and ease of production.2,3 Many diﬀerent carrier designs
based on cationic polypeptides,4 cationic lipids,5 polymers6–8
and cyclodextrin9 nanoparticles have been developed. While
most of these materials are able to eﬀectively condense and
deliver pDNA, they still exert relatively little control over the
vector assembly process and final dimensions. This introduces
large polydispersities and little control over initial physical
characteristics such as diameter or ζ-potential of the transfection
complexes.10 Vortex mixing and/or bulk mixing is the most
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common process used by researchers to assemble such nanoparticle complexes, but these complexation methods have high
inherent variability due to gradients in concentration and temperature that are formed during the mixing process. Such batchto-batch inconsistency can lead to poor reproducibility and false
negative results in biological experiments.11
Microfluidics-based techniques such as flash nanoprecipitation (FNP)12–14 and hydrodynamic flow focusing (HFF)15–17
have been demonstrated as robust techniques for the formulation of drug-loaded polymeric nanoparticles, but similar
control has yet to be shown for the formulation of nucleic acid
cargo. Microfluidic formulation of nucleic acid-loaded nanoparticles has been previously performed for the rapid generation of libraries of siRNA-containing lipid nanoparticles18
and pDNA-containing cyclodextrin-based supramolecular
nanoparticles.19 While these techniques are excellent tools for
high throughput screening of nucleic acid nanoparticles,
control over the physical properties of the nanoparticle complexes, in most cases, has not been demonstrated. Recently,
Cullis et al., have demonstrated the formulation of limit-sized
lipid nanoparticles and lipid-siRNA nanoparticles using rapid
microfluidic mixing of lipids dissolved in an ethanol
stream.20,21 The authors demonstrated that microfluidic
mixing was a powerful technique for formulation of both polar
and non-polar core structures. They also showed that they
could achieve particle sizes as small as 20–50 nm with encapsulated siRNA using this technique. Leong et al., have developed the technique of microfluidics-assisted confinement of
complexes in picoliter oil droplets. They demonstrated a
reduction of size, polydispersity index (PDI), ζ-potential and
cytotoxicity, as well as higher transfection eﬃciency than the
bulk mixed counterparts.22 The ability to tune the physical
characteristics based on flow rate alone, in a manner similar
to FNP or HFF, has still not been demonstrated. Herein, we
demonstrate the flow rate-dependent control over particle
characteristics such as diameter, PDI, ζ-potential, and decomplexation rate. To control these properties, we formulated the
transfection complexes in a commercially available glass
Chemtrix microreactor (Fig. 1). Our results suggest that the
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Fig. 1 Conceptual diagram of HA-Ad:CD-PEI:pDNA transfection complex
preparation by microﬂuidic assembly. CD-PEI (far left) is ﬁrst mixed with pDNA
(mid-left); intermediate polyplexes (center) are mixed with HA-Ad (mid-right),
resulting in the ﬁnal nanoparticles (far right) of controlled diameter, composition, and low polydispersity.

microreactor provides improved control over the physical
characteristics of the nanoparticles generated under a wide
range of feed conditions and flow rates. We also show that the
flow mixing technique is a reproducible, operator-independent, and potentially scalable technique that can improve the
uniformity and performance of nucleic acid nanoparticle complexes for transfection.
As an extension of our previously reported poly(vinyl
alcohol)-based pendant polymer designs,23,24 we developed a
new hyaluronic acid (HA)-based pendant polymer system
capable of forming complexes with cationic cyclodextrins and
pDNA. HA (350 kDa) was chosen for its high water solubility,
CD44-targeting capabilities, and biocompatibility.25,26 Adamantane-conjugated HA (HA-Ad) was synthesized via EDC
mediated coupling between HA and adamantane methylamine
(ESI†). Poly(ethyleneimine) (PEI) of molecular weight 2.5 kDa
was used to introduce a single modification on the β-cyclodextrin 1° hydroxyl rim. Briefly, β-cyclodextrin was converted to
the monotosylated form27 and was further converted to CD-PEI
after isolation of the pure 6-monotosyl-β-cyclodextrin28 by
treatment with an excess of PEI2.5k. The CD-PEI product was
purified by precipitation in ether and exhaustive dialysis
against DMSO and water. The HA-Ad and CD-PEI components
(Fig. 2) were then used for assembly of the pDNA nanoparticle
complexes via bulk or flow mixing techniques. For bulk mixed
complexes, the CD-PEI and pDNA were mixed first and incubated for 1 h before the HA-Ad was added with vortex mixing
and further incubation for 1 h. At the same time, the pDNA,
CD-PEI and HA-Ad component solutions were assembled
under diﬀerent flow mixing conditions using the Chemtrix
microreactor as described below (Fig. 1).
The flow reactor (Fig. S1†) chosen provided suﬃcient length
and volume to enable eﬃcient mixing of the feed solutions.

Fig. 2

Chemical structures of (left) HA-Ad and (right) CD-PEI.
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This reactor is equipped with 2 input channels, 1 quench
channel, and 1 output channel with a total reactor volume of
10 μL and reactor length of 60 μm. CD-PEI and pDNA
( pAcGFP1, Clontech) were introduced in separate input channels while HA-Ad was added via the quench channel. This
setup replicates the stepwise assembly process used in bulk
mixing by allowing the pDNA and CD-PEI to first yield pDNA:
CD-PEI polyplexes before adding HA-Ad to consolidate the
initially formed condensed pDNA core to generate the final
transfection complexes. All the individual components were
diluted in sterile, filtered, nanopure water instead of buﬀer to
ensure that buﬀer counterions did not interfere with complex
formation. Transfection complexes were assembled at N/P
ratios of 10, 20 and 30, since these were the ratios shown to
have optimal activity for the bulk mixed complexes in initial
screening experiments. Flow mixing was carried out at pDNA
flow rates of 5, 10, and 20 μL min−1. CD-PEI and HA-Ad flow
rates were adjusted accordingly to aﬀord the required N/P
ratios.
Our studies revealed that higher flow rates resulted in
smaller complexes and lower PDIs than bulk mixed particles at
the same N/P ratios (Fig. 3A). Flow mixing also produced particles with lower ζ-potentials than the bulk mixed particles of
the same N/P ratio (Fig. 3B). AFM analysis of the complexes
showed that flow mixed complexes were smaller and more
monodisperse than the corresponding bulk mixed particles
(Fig. 3C–3F), with average diameters of 50 ± 10 nm for flow
mixed transfection complexes and 120 ± 20 nm for bulk mixed
complexes of the same composition (Fig. S3†).
The relative complexation ability and colloidal stability of
the transfection complexes were studied by gel retardation
(Fig. S4†) and PicoGreen competitive binding assays (Fig. 4),
respectively. PicoGreen is a highly sensitive dye that fluoresces
upon intercalation into dsDNA, but remains non-fluorescent
when the DNA is tightly condensed and inaccessible for dye
binding. The bulk mixed and flow mixed complexes were incubated for 30 min with increasing amounts of the negatively
charged polysaccharide heparin to promote polyion exchange
of CD-PEI:HA-Ad from the pDNA core. This was followed by
addition of the dye and fluorescence analysis. Interestingly,
while the gel shift assay indicated very similar complexation
profiles for the bulk mixed and flow mixed complexes, the
PicoGreen assay showed that the decomplexation characteristics of the various complexes were very diﬀerent.
The PicoGreen studies indicated that complexes formulated
by flow mixing, in general, were more susceptible to disassembly in the presence of polyanions than those prepared by bulk
mixing. Competitive binding assays also showed that the transfection complexes prepared by flow mixing at higher flow rates
were prone to disassemble more readily than those produced
at lower flow rates. These data indicate that the complexation
ability of all the pDNA:CD-PEI:HA-Ad ratios and flow rates are
nearly the same, however, disassembly is more facile in the
presence of a negatively charged polymer challenge when the
transfection complexes have been prepared by flow mixing.
This can be attributed to the shorter interaction time between
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Fig. 4 PicoGreen competitive binding assay showing colloidal stability of bulk
and ﬂow mixed pDNA:CD-PEI:HA-Ad complexes assembled at diﬀerent N/P
ratios and ﬂow rates in the presence of increasing amounts of heparin (0, 2, 10,
20, 40, and 80 times the mass of pDNA used for complex formation).

studies indicated that CD-PEI and the CD-PEI:HA-Ad complexes had negligible eﬀects on cell viability, even at concentrations as high as 1 mM, whereas bPEI had an LD50 of
∼0.15 mM (Fig. S5†). The relative transfection eﬃciencies and
cell viabilities of the bulk and flow mixed complexes were then
studied. Upon incubation with HeLa cells, flow mixed complexes demonstrated improved cell viability, but lower transfection eﬃciency, than the bulk mixed complexes (Fig. 5). We
infer from these data that the flow mixed complexes undergo
reduced cellular uptake due to their lower ζ-potential and
reduced stability in the presence of polyanions present in the
culture media. Cell viability was also evaluated using the 7AAD
viability stain during the transfection experiment. We found
that cells treated with flow mixed complexes had higher cell
viabilities (85–90%) than bulk mixed complexes (70–80%;
Fig. 5).

Fig. 3 (A) Diameter and polydispersity indices (PDI); (B) ζ-potentials; and AFM
images of transfection complexes produced at N/P = 20 by (C) bulk mixing and
ﬂow mixing at pDNA ﬂow rates of (D) 5, (E) 10 and (F) 20 μL min−1. Scale bar =
500 nm.

the individual components when they are flow mixed than
occurs for bulk mixed complexes. The longer interaction times
in the bulk mixed case enables multiple encounters with other
particles, leading to larger and more highly entangled ionomer
complexes with higher polydispersity. These findings suggest
that the flow mixing strategy demonstrated here gives us
control over properties such as diameter, PDI and ζ-potential,
as well as a less described characteristic, the disassembly propensity of the complexes.
The MTS cell viability assay was performed to compare the
HA-Ad and CD-PEI materials using bPEI as control. These

This journal is © The Royal Society of Chemistry 2013

Fig. 5 Quantiﬁcation of relative transfection eﬃciency and cytotoxicity of bulk
and ﬂow mixed pDNA:CD-PEI:HA-Ad complexes in HeLa cells with bPEI as a
control. Incubation for 4 h in 10% serum-supplemented medium was followed
by ﬂow cytometry analysis at 24 h.
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The presence of uncomplexed polycations in bulk mixed
complexes has been shown to be the reason for their higher
in vitro cellular uptake and transfection eﬃciency.29 These free
polycations are also responsible for increased in vitro cytotoxicity.30 Since no free CD-PEI was detected in our transfection complexes, the lower transfection eﬃciency and improved
cell viability of the flow mixed complexes may arise from the
absence of similarly uncomplexed polycations.
While a significant amount of research has been carried
out in the development of therapeutic genes and non-viral carriers, the absence of a robust operator-independent technique
for the production of nucleic acid complexes is still needed.
Unpackaging and escape of nucleic acids from transfection
complexes that have been internalized is regarded as a crucial
barrier to realizing more eﬃcient gene delivery. Traditionally,
transfection complex disassembly has relied on chemical
approaches, such as pH-31 or enzyme-32 responsive linkages, or
physical approaches such as temperature cycling.33 Herein, we
have demonstrated control over decomplexation properties
based solely on the formulation parameter of mixing rate
without making any changes to the carrier materials
themselves.

Conclusions
While control over diameter and PDI has been demonstrated
by use of microfluidics-assisted confinement, to our knowledge there exists no technique that has shown flow rate-dependent control over formulation of nucleic acid transfection
complexes. The high reproducibility of this technique allows
for more rigorous analysis of the dependence of transfection
eﬃciency on particle diameter, PDI, ζ-potential and disassembly rate.
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